The role of Orai inhibition in acute pancreatitis by Wen, Li
 
1 
 
 
 
 
 
The role of Orai inhibition in acute 
pancreatitis 
 
 
Thesis submitted in accordance with the requirements of the University of Liverpool 
for the degree of Doctor of Philosophy 
 
By 
 
Li Wen 
 
August 2015 
 
 
2 
 
 
 
 
 
 
 
 
 
 
Dedicated to my father, my mother & 
my husband 
 
 
 
 
 
 
 
 
3 
 
The work described in this thesis was carried out when I was doing the PhD study in 
the NIHR Liverpool Pancreas Biomedical Research Unit and Department of 
Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, 
University of Liverpool. All the work described in this thesis was done by me and the 
thesis was written entirely by me, except for the specific contributions listed below. 
Statement of originality 
 
Prof Robert Sutton supervised all aspects of experimental design and planning as 
well as advised on revision of all the chapters of this thesis. Dr Wei Huang taught me 
the techniques for the induction of experimental AP when I firstly started my PhD 
study. Dr Svetlana Voronina and Dr Michael Chvanov conducted the experiments for 
measuring [Ca2+]c in pancreatic acinar cells; Miss Diane Latawiec as one 
independent observer blindly scored pancreatic histopathological slides with me. Mr 
Muhammad Ahsan Javed and Dr Muhammad Awais assisted in the experiments for 
measuring necrotic cell death pathway activation. Dr John Barrett, GlaxoSmithKline 
(GSK) assisted to measure the levels of GSK-7975A and GSK-6288B in the blood 
and pancreas as well as protein binding of GSK-7975A in the blood and pancreas; 
Calcimedica assisted to measure the levels of CM_128 in the plasma, pancreas and 
lung. Dr Jane Amstrong helped to proof-read the English used in this thesis. I take 
full responsibility for any errors in the data within or compilation of this thesis, as well 
as any errors in the use of English.  
 
 
 
 
 
4 
 
Background and aims: Prolonged elevation of cytosolic Ca2+ concentration is the 
key trigger of pancreatic damage and acute pancreatitis (AP). Ca2+ release-activated 
Ca2+ modulator Orai1 channel is the most abundant store-operated Ca2+ entry 
(SOCE) channel in pancreatic acinar cells; it sustains calcium overload in mice 
exposed to toxins that induce AP. The studies in this thesis investigated the roles of 
Orai1channel in pancreatic acinar cell injury and the development of AP in mice.  
Abstract 
 
Methods: Freshly isolated mouse and human acinar cells were hyper-stimulated or 
incubated with human bile acid orthapsigargin to induce Ca2+ entry. Effects of GSK-
7975A or CM_128 on Ca2+ entry and necrotic cell death pathway activation were 
analysed by confocal and video microscopy. Experimental acute pancreatitis was 
induced in C57BL/6J mice by 1) ductal injections of taurolithocholic acid 3-sulphate 
(TLCS-AP); 2) intraperitoneal (IP) administration of caerulein (CER-AP) or 3) a 
combined IP administration of ethanol and palmitoleic acid (FAEE-AP). Two Orai1 
inhibitors were administrated at different time points and the disease severity was 
assessed by various local and systemic parameters, including pancreatic trypsin and 
myeloperoxidase (MPO) activity, serum interleukin (IL)-6 and lung MPO activityas 
well as blinded histopathology.  
 
Results: GSK-7975A and CM_128 each separately inhibited toxin-induced 
activation of SOCE via Orai1 channels in a concentration dependent manner, in 
mouse and human pancreatic acinar cells (inhibition >90% the levels observed in 
control cells). GSK-7975A and CM_128 each inhibited all local and systemic features 
of AP in all three representative models, in dose- and time-dependent manners. The 
agents were significantly more effective, in a range of parameters, when given early 
versus late after induction of AP.  
 
Conclusion: Cytosolic Ca2+ overload mediated via Orai1 plays a pivotal role in the 
pathogenesis of AP. Inhibition of Orai1 channel is a useful therapeutic approach for 
human acute pancreatitis.  
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1.1 Acute pancreatitis 
Acute pancreatitis (AP) is a worldwide common inflammatory disease with a 
substantial morbidity, mortality and financial burden on health care services (Peery 
et al., 2012). A recent publication from the United States evaluating the burden of 
gastrointestinal (GI) disorders revealed that AP is the commonest causes of GI-
related hospitalization with an estimated annual cost of $2.6 billion (Peery et al., 
2012). Gallstone and alcohol abuse account for 70-80% of cases of AP; other 
causes include drugs, viral infection, hyperlipidemia, hypercalcemia, trauma, 
etc.(Pandol et al., 2007). There are also genetic susceptibility, including mutations of 
human cationic trypsinogen (PRSS1), chymotrypsin C (CTRC), serine protease 
inhibitor, Kazal type1 (SPINK) and cystic fibrosis transmembrane conductance 
regulator (CFTR) for recurrent AP and chronic pancreatitis (Mounzer and Whitcomb, 
2013). Incidences vary from 10~100 per 100,000 annually with a geographical 
variation (about 50 per 100,000 in United Kingdom) and there has been a steadily 
rise worldwide, partly due to increased alcohol consumption (Goldacre and Roberts, 
2004, Roberts et al., 2008, Lowenfels et al., 2009). One out of five AP patients 
develops a severe form of the disease with significantly higher mortality, morbidity 
and prolonged hospital stay (Pandol et al., 2007). The overall mortality of AP is 
approximately 5% in patients with AP; higher mortality is seen in patients with 
necrotizing AP (~15%)(Pandol et al., 2007, van Santvoort et al., 2011). Despite such 
a major burden of the disease, there is no licensed drug therapy for AP, requiring the 
development of an effective therapy based on better understanding of the 
pathophysiology of AP.  
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The diagnosis of AP requires at least 2 of the following: typical upper abdominal pain, 
serum levels of amylase or lipase ≥3 times the upper limit of normal and confirmatory 
findings from cross-sectional imaging (Working Group, 2013, Wu and Banks, 2013). 
Better understanding of organ failure and necrosis and their outcomes, as well as the 
improvement of diagnostic imaging, have led to the expansion of disease categories 
from the original Atlanta Classification (mild and severe) into the revised Atlanta 
Classification (RAC) and Determinant-Based Classification (DBC) (Bradley, 1993, 
Banks et al., 2013, Dellinger et al., 2012). Patients with AP have been classified as 
mild, moderate and severe (three categories) in the RAC (Banks et al., 2013); and as 
mild, moderate, severe and critical (four categories) in the DBC (Dellinger et al., 
2012), see Table 1.1. Two main differences between these two new classification 
systems are 1) infected pancreatic necrosis is not considered severe in the RAC; 2) 
exacerbations of co-morbid disease are not considered to determine severity in the 
DBC (Windsor et al., 2015, Bakker et al., 2014, Gomatos et al., 2014).  
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Table 1.1 Severity classifications of acute pancreatitis 
Atlanta Classification 1992  
(Bradley, 1993) 
Mild 
No organ failure and 
No local complications 
Severe 
Ranson criteria ≥3 in first 48 hours: APACHE II ≥ 8 at any time and/or 
Local complications 
Revised Atlanta Classification 2012 (Banks 
et al., 2013) 
Mild 
No organ failure and 
No local and systemic complications 
Moderately 
severe 
Transient organ failure (˂48 h) and/or 
Local or systemic complications without persistent organ failure (˃48 h) 
and/or exacerbation of pre-existing co-morbidity 
Severe 
Persistent organ failure (˃48 h): single or multiple organ failure 
with/without Local complications 
with/without exacerbation of pre-existing comorbidity 
Determinant-Based Classification 2012 
(Dellinger et al., 2012) 
Mild 
No organ failure and 
No (peri)pancreatic necrosis  
Moderate 
Transient organ failure (˂48 h) and/or 
Sterile (peri)pancreatic necrosis 
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Severe 
Persistent organ failure (˃48 h) or  
Infected (peri)pancreatic necrosis 
Critical 
Persistent organ failure (˃48 h) and  
Infected (peri)pancreatic necrosis 
Note: In Atlanta Classification 1992, local complications were defined as necrosis (≥3 cm diameter or 30% volume), abscess (>4 weeks after 
onset) or pseudocyst (>4 weeks after onset); severe = three or more Ranson criteria in first 48 hours: 8 or more APACHE II at any time: systolic 
blood pressure <90 mm Hg; PaO2 ≤ 60 mm Hg; creatinine >177 µmol/L or 2 mg/dL after rehydration; >500 ml/24 h blood loss; platelets ≤
100,000 mm3; fibrinogen <1.0 g/L; fibrin split products >80 µg/mL; calcium ≤1.87 mmol/L (7.5 mg/dL). In revised Atlanta Classification 2012, 
local complications are defined as acute peripancreatic fluid collection, pancreatic pseudocyst, acute necrotic collection, walled-off necrosis, 
infected pancreatic (acute and wall-off) necrosis and other local complications including gastric outlet dysfunction, splenic or portal vein 
thrombosis and colonic necrosis; systemic complications are defined as transient or persistent organ failure and exacerbation of pre-existing 
co-morbidity and organ failure is assessed by ˃2 modified Marshall score (Marshall et al., 1995) for respiratory, cardiovascular and renal organ 
systems. In Determinant-based Classification 2012, organ failure is assessed by ˃2 sepsis-related organ failure assessment (SOFA) (Vincent 
et al., 1996).  
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1.2 Current understanding about the pathogenesis of AP 
Over last few decades, the basic research on AP has advanced our knowledge and 
provides the understanding of disease mechanism. The initial injury during AP starts 
within pancreatic acinar cells (PACs) and/or ductal cells, which make up the bulk of 
the organ (Sutton et al., 2003, Hegyi et al., 2011). Calcium toxicity characterized as 
the sustained elevation of cytosolic Ca2+ concentration ([Ca2+]C), is the earliest 
intracellular event (Ward et al., 1995) and contributes to almost all subsequent 
pathophysiological events, including premature enzyme activation, vacuolization and 
necrosis (Petersen and Sutton, 2006). Mitochondria supply cellular energy in the 
form of adenosine triphosphate (ATP) and are also critical determinants of cell death 
pathway activation. Cytosolic Ca2+ overload followed by mitochondrial Ca2+ overload 
results in uncoupled oxidative phosphorylation, mitochondrial membrane potential 
(∆ᴪM) depletion and impaired ATP production. Mitochondrial dysfunction has been 
found to play critical and central role in the pathogenesis of AP (Mukherjee et al., 
2008, Gerasimenko and Gerasimenko, 2012, Maleth et al., 2013). Intra-acinar 
trypsinogen activation has been shown to mediate early stage pancreatic injury, 
together with intra-acinar nuclear factor-kappa B (NF-κB) activation plays an 
important role in mediating the severity of AP (Rakonczay et al., 2008, Ji et al., 2009, 
Dawra et al., 2011).  
 
Patterns of cell death are the key determinants of disease severity in AP.  Necrosis 
is characterized by mitochondrial swelling, impaired ATP production, plasmalemmal 
disruption and spillage of cellular contents, which triggers acute inflammation and 
exacerbates pancreatitis. Apoptosis features chromatin condensation, nuclear 
fragmentation and the formation of plasma-membrane blebs without the leakage of 
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intracellular contents (Criddle et al., 2007, Hotchkiss et al., 2009). The severity of 
pancreatic damage correlates directly with the extent of necrosis and largely but not 
entirely inversely with apoptosis in distinct in vivo models of experimental AP (Kaiser 
et al., 1995, Criddle et al., 2007). Both forms of cell death (necrosis and apoptosis) 
can be triggered by cytosolic Ca2+ overload and mitochondrial dysfunction followed 
by Ca2+ overload (Criddle et al., 2007, Pandol et al., 2007, Mukherjee et al., 2008, 
Booth et al., 2011). Most recently, a form of programmed necrotic cell death termed 
necroptosis has been suggested to play a role in the pathogenesis of AP (He et al., 
2009). Autophagy, a multiple lysosome-driven process that degrades long-lived 
protein, lipids and cytoplasmic organelles, has been shown to be impaired during AP 
(Mareninova et al., 2009).  
 
On the other hand, injured PACs can act as inflammatory cells to produce, release 
and respond to cytokines, such as tumour necrosis factor (TNF)-α (Saluja et al., 
2007, Gukovskaya et al., 1997). Inflammatory mediators, such as TNF-α and 
interleukin (IL)-1, activate macrophages and neutrophils, resulting in a cascade of 
systemic inflammatory responses, followed by further excessive local and systemic 
damage (Raraty et al., 2005, Bhatia, 2005, Vonlaufen et al., 2007). Recently, 
damage-associated molecular patterns (DAMPs) have been implicated in mediating 
pancreatic and distant organ damage (Hoque et al., 2012). DAMPs, such as 
extracelluar ATP, high mobility group box 1 (HMGB1) and S100A can be 
endogenously released from dead or dying cells and bind to specific sensors on/in 
inflammatory cells, subsequently leading to sterile inflammation (Chen and Nunez, 
2010). Taken together, intra-acinar and immunological events are two independent, 
but synergic components that contribute to AP severity. 
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Figure 1.1 Pathogenesis of AP. Pancreatitis-associated toxins include 
supermaximal cholecystokinin (CCK), bile acids (BAs), fatty acid ethyl esters (FAEEs) 
and fatty acids (FAs). The initial site of injury is within pancreatic acinar and/or ductal 
cells after toxin stimulation. Cytosolic Ca2+ overload mediated by store-operated Ca2+ 
entry (SOCE) is the trigger of AP. Subsequent intra-cellular events including 
premature enzyme activation, mitochondrial dysfunction and cell death pathway 
activation are all Ca2+-dependent processes. Injured PACs release cytokines, 
chemokines and damage-associated molecular patterns (DAMPs) to activate 
inflammatory cells, resulting in a cascade of systemic inflammatory responses. All 
these events lead to further local damage and distant organ dysfunction. 
Abbreviations: ZG, zymogen granule; GA, golgi apparatus; ER, endoplasmic reticulum; 
MPTP, mitochondrial permeability transition pore; SIRS, systemic inflammatory response 
syndrome; MOF, multiple organ failure 
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1.3 Status of treatment development in AP 
Over last decade, substantial improvement of the management of AP has led to 
revised guidelines for patient management published in 2013 by the International 
Association of Pancreatology (IAP)/American Pancreatic Association (APA) (Working 
Group, 2013) and American College of Gastroenterology (ACG) (Tenner et al., 2013) 
separately. Therapeutic strategies at the early stage of the disease remain as basic 
supportive treatments including fluid resuscitation, pain management and nutritional 
support. Intensive care support including mechanical ventilation and renal 
replacement therapy are given to patients with severe AP if necessary. A well-
designed prospective randomized trial has demonstrated early fluid resuscitation 
with Ringer’s lactate, but not normal saline, significantly reduced systemic 
inflammation measured by levels of systemic inflammatory response syndrome 
(SIRS) and C-reactive protein (CRP) (Wu et al., 2011). Early aggressive fluid 
resuscitation is most beneficial during the first 12-24 h; aggressive fluid hydration is 
defined as 5-10 mL/kg/h in the IAP/APA guidelines and 250-500 mL/h in the ACG 
guidelines (Working Group, 2013, Tenner et al., 2013). Pain management is a 
priority in the management of patients with AP on admission. However, findings from 
a systemic review of eight RCTs showed that the randomised controlled trials 
comparing different analgesics were of low quality and did not favour clearly any 
particular analgesic for pain relief in AP (Meng et al., 2013). Nutritional support is 
accepted as therapeutic that provide energy suppliers, leading to the increased ATP 
production within PACs to better copy with cytosolic Ca2+ overload during AP. 
Findings from a systematic review including fifteen RCTs have shown either enteral 
or parenteral nutrition is associated with a lower risk of death compared with no 
supplementary nutrition (Petrov et al., 2008). A Cochrane systematic review and 
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meta-analysis has shown enteral nutrition significantly reduced mortality, multiple 
organ failure, systemic infection and the need for operative interventions in 
comparison with parenteral nutrition (Al-Omran et al., 2010), but there is insufficient 
evidence to support the use of any specific enteral nutrition formulation (Poropat et 
al., 2015) and the optimal delivery route for enteral nutrition is still a subject of 
investigation (Wu and Banks, 2013). An early initiation (within 48 h) of enteral 
nutrition is associated with significantly improved outcomes (Petrov et al., 2009, 
Bakker et al., 2014, Lankisch et al., 2015). Glutamine supplementation was found to 
significantly reduce the risk of mortality and total infective complications, but not 
length of hospital stay in patients receiving parenteral nutrition in a systematic review 
of twelve RCTs (Asrani et al., 2013). Several RCTs and meta-analyses have 
indicated that antioxidants are ineffective in improving the outcomes of AP 
(Siriwardena et al., 2007, Mohseni Salehi Monfared et al., 2009). In patients with 
gallstone AP, a Cochrane systematic review has indicated early endoscopic 
retrograde cholangiopancreatography (ERCP) significantly reduced mortality, local 
and systemic complications, but only in patient group with co-existing cholangitis or 
biliary obstruction (Tse and Yuan, 2012).  
 
Certainly, improvements of the surgical management of AP have emerged, resulting 
in the better management of patients with local complications such as infected 
necrosis at the later stage. Delayed intervention (performed after a median of ~4 
weeks after onset of symptom) is more beneficial than early intervention; a minimally 
invasive approach is superior to open necrosectomy (van Santvoort et al., 2011, Wu 
and Banks, 2013, Lankisch et al., 2015). A multicentre randomised clinical trial (RCT) 
has shown a step-up approach consisting of percutaneous drainage followed, if 
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necessary, by minimally invasive retroperitoneal necrosectomy reduced the rate of 
major complication or death by 29% compared with open necrosectomy (van 
Santvoort et al., 2010). Another RCT of 20 patients analyzed showed endoscopic 
transgastric necrosectomy reduced the proinflammatory response as well as a 
composite clinical end-point compared with surgical necrosectomy (Bakker et al., 
2012). Despite all these findings, there is still no specific drug treatment that targets 
the pathogenesis of AP to halt the progression of the disease. 
 
1.4  An ideal drug target for AP 
Several principal criteria are required for an ideal therapeutic target (Simmons, 2006, 
Gashaw et al., 2011). There are specific features in the pathophysiological 
processes of AP that should be exploited to yield good therapeutic targets. PACs are 
an initial site of pancreatic injury and ought to be the primary target to halt pancreatic 
damage during AP. PACs,  depend heavily on subtle, small changes in Ca2+ for 
pronounced changes in function(Petersen and Tepikin, 2008), making PACs among 
the most sensitive cells within the body to abnormal Ca2+ signalling. The strategies 
that prevent abnormal Ca2+ overload/signalling and enhance/preserve the ability of 
Ca2+ handling are potentially useful approaches to protect against pancreatic injury, 
which could ultimately lead to a cure for AP. Apart from targeting Ca2+ signals in 
PACs, there are several other potential therapeutic approaches for treating AP, 
including increasing ATP production, inhibition of trypsinogen activation and 
inhibition of intra-acinar NF-κB activation. Moreover, the critical roles of ductal cells 
in mediating AP severity have been noted (Hegyi and Petersen, 2013). Preservation 
of ductal cells function by preventing Ca2+ overload and increasing ATP production 
are useful tools and the approach that increase ductal cell secretion is also important. 
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In addition, modulation of inflammatory responses by deletion of certain types of 
inflammatory cells such as neutrophils or by inhibition the core functions of 
inflammatory cells, such as NADPH oxidase activity (Gukovskaya et al., 2002). In 
clinical cases of AP, pancreatic necrosis and organ failure are two major 
determinants of the severity and the outcome of AP (Petrov et al., 2010). Multiple 
organ failure is the leading cause of death in the first two weeks after symptom onset, 
whereas infected necrosis with multiple organ failure is the main reason for death 
after that time. Thus, all the therapies applied at the early stage of the disease 
should take these factors into account. Unlike myocardial infarction or cerebral 
ischemic stroke that are typically caused by a sudden arterial occlusion, pancreatic 
necrosis and organ failure may take days to develop. This offers a potentially wider 
therapeutic window to explore any possible treatments, see Figure 1.2.  
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Figure 1.2 Time course of the progression of AP. This plot shows a potential 
therapeutic window for therapies targeting the pathogenesis of pancreatitis. Most 
patients with AP present to a hospital emergency department within several hours of 
the onset of pain. A minority of patients develop severe AP, developing distant organ 
dysfunction 2 to 4 days later, although distant organ failure may be manifest at the 
time of admission. Such presentation allows for a therapeutic window during which 
time specific targeted treatment could be administered to attenuate/prevent the 
progression of AP. Adapted from (Norman, 1998) 
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1.5  Physiological Ca2+ signals, calcium overload and AP 
1.5.1 Physiological Ca2+ signals in PACs 
Cytosolic Ca2+ signals are critical for fluid and enzyme secretion from the exocrine 
pancreas. The highly polarized PACs have a sophisticated and complex Ca2+ 
signalling toolkit. In response to physiological stimulation of acetylcholine (ACh) or 
cholecystokinin (CCK), PACs generate the second messenger, inositol triphospate 
(IP3), cyclic ADP ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate 
(NAADP). These second messengers cause Ca2+ release from internal Ca2+ stores 
through binding to IP3 receptors (IP3Rs) and rynadine receptors (RyRs) on the 
endoplasmic reticulum (ER) and also from other intracellular Ca2+ stores, such as 
acidic Ca2+ stores (Petersen, 2005, Petersen and Tepikin, 2008, Petersen, 2012). 
Repetitive local Ca2+ spikes are produced in the apical region and buffered by peri-
apical mitochondria to elicit physiological functions of cells, such as secretion and 
protein synthesis. The normal basal cytosolic Ca2+ concentration is restored through 
two mechanisms, both of which are ATP-dependent processes, with the Na+-Ca2+ 
exchanger being of little quantitative importance in these cells (Petersen and Sutton, 
2006). The sarcoendoplasmic reticulum Ca2+-ATPase (SERCA) pump refills the ER 
Ca2+ stores while the plasma membrane Ca2+-ATPase (PMCA) pump extrudes Ca2+ 
to the outside of the cells. Ca2+ microdomains in PACs are responsible for regulating 
physiological Ca2+ spikes. In the functionally very important microdomain near the 
apical membrane, the opening of Ca2+ channels in the apical region would cause a 
rise in the local Ca2+ levels, whereas after channel closure, when the SERCA pump 
are working maximally, Ca2+ levels would deline (Petersen et al., 2006). Three 
distinct groups of mitochondria located in separate sub-cellular domains of PACs 
play specific roles: 1) peri-apical mitochondria act as a Ca2+ buffer barrier and the 
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uptake of Ca2+ into these mitochondria also stimulates mitochondrial ATP synthesis; 
2) sub-plasmalemmal mitochondria support both Ca2+ entry at the base and the 
refilling of the ER Ca2+ stores; 3) peri-nuclear mitochondria confine Ca2+ signals 
primarily generated inside the nucleus (Park et al., 2001, Petersen, 2012).    
 
1.5.2 Calcium overload and AP 
Almost twenty years ago, the hypothesis was proposed that prolonged elevation of 
[Ca2+]c is toxic and is the key trigger of auto-digestion of the pancreas and the onset 
of AP (Ward et al., 1995). Pancreatitis-associated toxins, including supramaximal 
CCK, BAs and non-oxidative alcohol metabolites, cause Ca2+ release through IR3Rs 
and RyRs, resulting in the depletion of internal Ca2+ stores including within the ER 
(Raraty et al., 2000, Criddle et al., 2006, Gerasimenko et al., 2006). Following ER 
store depletion, Ca2+ influx (into the ER) is activated through store-operated Ca2+ 
entry (SOCE) as a compensatory mechanism for Ca2+ loss from internal cellular 
stores (Petersen and Sutton, 2006), allowing further release from the ER and so 
sustaining cytosolic Ca2+ overload. Sustained cytosolic Ca2+ overload leads to 
mitochondrial Ca2+ overload, causing mitochondrial membrane potential depletion, 
mitochondrial permeability transition induction and impaired ATP production 
(Mukherjee et al., 2008). Ca2+ extrusion from PACs is largely dependent on PMCA 
pump activity (Petersen and Sutton, 2006). Mitochondrial dysfunction/failure as a 
consequence of cytosolic Ca2+ overload eventually results in cell death pathway 
activation and severe pancreatic acinar injury (Mukherjee et al., 2008, Odinokova et 
al., 2008, Gerasimenko and Gerasimenko, 2012, Maleth et al., 2013), see Figure 1.3.  
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Figure 1.3 Mechanism of Ca2+ overload and AP. Upon pancreatitis-associated 
toxin exposure of PACs, the second messengers IP3, cADPR and NAADP are 
generated or their receptors (IP3Rs and RyRs) activated, leading to Ca2+ release 
from these receptors on the ER membrane. Depletion of ER Ca2+ stores activates 
redistribution of  stromal interacting molecule 1 (STIM1) to form the puncta ER-
plasma membrane (ER-PM) junctions with Ca2+ release-activated Ca2+ entry 
channels (ORAI and TRPC). Subsequent Ca2+ influx via SOCE channels sustains 
cytosolic Ca2+ overload (typical trace showing Ca2+ plateau induced by 
hyperstimulation). Ca2+ extrusion is mainly through PMCA to pump Ca2+ outside 
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PACs. Meanwhile SERCA also acts to refill the ER Ca2+ store, the activity of which is 
largely dependent on the amount of ATP production; if mitochondria are impaired by 
Ca2+ overload, ATP supply is reduced and SERCA activity diminished, exacerbating 
cytosolic Ca2+ overload.  
Abreviations: SOCE, store-operated Ca2+ entry; TM, transmembrane; TPRC, transient 
potential receptor type C channel; CCK1R, cholecystokinin 1 receptor; PLC, phospholipase 
C; IP3,inositol-1,4,5-trisphosphate; DAG, diacyle glycerol; GPBAR1, G-protein couple bile 
acid receptor 1; PMCA, plasma membrane Ca2+ ATPase; PM, plasma membrane; ETC, 
electron transport chain; MCU, mitochondrial Ca2+ uniporter; MPTP, mitochondrial 
permeability transition pore; ADP, adenosine diphosphate; ATP, adenosine triphosphate; 
RyR, rynadine receptors; IP3R, inositol-1,4,5-trisphosphate receptor; STIM1, stromal 
interacting molecule 1; SERCA, sarcoendoplamic reticulum Ca2+ ATPase.  
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The Ca2+ release channels IP3Rs and RyRs are expressed in the pancreas and 
mediate intracellular Ca2+ release. IP3R type 2 and type 3 isoforms are widely 
expressed in various organs and play an essential role in regulating secretion and 
proliferation, whereas type 1 is more predominantly expressed in the nervous system 
(Futatsugi et al., 2005). RyRs are predominantly expressed in excitable cells, but 
also found in many other tissues; type 1 RyR is abundant in skeletal muscle, type 2 
RyR in the heart. RyR-deficient mice have perinatal death (Takeshima et al., 1994), 
suggesting its fundamental role. There is clear evidence demonstrating inhibition of 
IP3Rs and RyRs prevent PAC injury and AP in both in vitro and in vivo. PACs from 
IP3R2-deficient mice and IP3R2/IP3R3 double-knockout mice have significantly 
reduced Ca2+ release and trypsinogen activation, with more dramatic reduction in 
cells from double-knockout mice (Gerasimenko et al., 2009). IP3R2 knockout did not 
reduce the severity of caerulein-induced pancreatitis compared with wild-type mice 
(Orabi et al., 2012), but the effect of IP3R2/IP3R3 double-knockouts on AP severity 
remains to be investigated. RyR-mediated Ca2+ release modulates intra-acinar 
premature zymogen activation; inhibition of RyR by dantrolene reduces the severity 
of caerulein- and bile acid-induced pancreatitis (Husain et al., 2005, Orabi et al., 
2010, Husain et al., 2012). Nevertheless, preventing Ca2+ overload by inhibition of 
primary Ca2+ release through IP3Rs and RyRs is unlikely to be a safe therapeutic 
approach due to their ubiquitous expression and fundamentally important roles.   
 
ATP-dependent Ca2+ uptake into cell stores and extrusion outside cells is the main 
mechanism of Ca2+ clearance in PACs, which explains why Ca2+ overload is 
particularly dangerous in these cells (Petersen and Sutton, 2006). Two studies have 
shown insulin protected against Ca2+ overload and pancreatic damage by 
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maintaining cellular ATP and thus PMCA activity through switching acinar cell 
metabolism from oxidative phospholation to gylcolysis (Mankad et al., 2012, Samad 
et al., 2014). Ferdek et al have demonstrated that the antiapoptotic protein Bcl-2 
affects Ca2+ extrusion by regulating PMCA functions, thereby influencing cell fate 
(Ferdek et al., 2012). Apart from altering Ca2+ handling, preservation of mitochondrial 
function is potentially useful tool in order to maintain the ability of efficient Ca2+ 
handling of the cells. 
 
1.6  Mitochondrial dysfunction and AP 
Mitochondrial dysfunction as a consequence of cytosolic Ca2+ overload is a key 
determinant of the pattern of cell death and the severity of AP. Ca2+- and 
mitochondria-dependent necrotic cell death pathway activation is correlated with the 
more severe forms of pancreatitis (Criddle et al., 2007, Mukherjee et al., 2008, Booth 
et al., 2011, Gerasimenko and Gerasimenko, 2012, Odinokova et al., 2008, Maleth 
et al., 2013). Accumulating evidence suggests pancreatitis-associated toxins such as 
BAs or non-oxidative metabolites of ethanol and FAs cause mitochondrial membrane 
potential depletion, uncoupling of oxidative phosphorylation and impairment of ATP 
production through Ca2+ overload of mitochondria (Voronina et al., 2002, Criddle et 
al., 2004, Criddle et al., 2006, Mukherjee et al., 2008). FAEEs are non-oxidative 
alcohol metabolites that can bind to and accumulate within the inner mitochondrial 
membrane, where hydrolases act to release high concentrations of FAs locally 
(Criddle et al., 2006). FAs, relevant to hypertriglyceridemic AP, also have direct 
effects on the electron transport chain without depolarization of the inner 
mitochondria membrane (Petersen et al., 2009).  
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The mitochondrial permeability transition pore (MPTP) is a 40 nm, multi-protein 
channel that forms in the inner mitochondrial membrane (IMM) in response to 
mitochondrial Ca2+ overload and oxidative stress. This results in a sudden, sustained 
increase of IMM permeability, allowing solutes with a molecular mass up to 1.5 kDa 
to pass in and out. Induction of the MPTP is known as the point of ‘no return’ in the 
chain of cell death pathway activation (Kroemer et al., 2007, Gukovsky et al., 2011). 
Several proposed components of the MPTP include adenine nucleotide translocator 
(ANT), voltage-dependent anion channel (VDAC) and phosphate carrier (PiC). Over 
the past decades, studies using genetic manipulation clearly demonstrated that ANT 
is not a MPTP component, but could be a regulator of MPTP induction (Kokoszka et 
al., 2004) and VDAC did not contribute to MPTP formation (Baines et al., 2007). 
Most recently, a study using cardiac-specific deletion of PiC suggests PiC is not a 
pore-forming component, but is a regulator of its activation (Kwong et al., 2014). The 
most recent evidence is that dimers of F0F1 ATP synthase form the MPTP and the 
regulator cyclophilin (Cyp D) binds to the F0F1 ATP synthase in the oligomycin 
sensitivity-conferring protein (OSCP) subunit (Giorgio et al., 2013). A further study 
concluded that the c-subunit ring of F0 of F0F1 ATP synthase forms a voltage-
sensitive channel that is the MPTP (Alavian et al., 2014).  
 
Cyp D is a mitochondrial matrix protein with peptidylprolylcis-trans isomerase activity 
encoded by Ppif gene. Cyp D-deficient (Ppif-/-) mice are viable, fertile and have no 
obvious abnormalities. Cells from Ppif -/- mice are largely protected from necrosis 
induced by Ca2+ -overload and oxidative stress. Cyp D-deficient mice have been 
found to have decreased infarction sizes in cardiac and cerebral I/R injury in vivo 
(Baines et al., 2005, Nakagawa et al., 2005, Schinzel et al., 2005).  PACs from Ppif-/- 
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mice have less necrosis and Cyp D-deficient mice develop less severe forms of AP 
in response to the combined administration of ethanol and CCK (Shalbueva et al., 
2013). Most recent study demonstrated that genetic and pharmacological inhibition 
of Cyp D protect against pancreatic injury in mouse and human PAC and in four 
diverse experimental models of AP (Mukherjee et al., 2015). Preventing the opening 
of MPTP by specific Cyp D inhibition could be a useful therapeutic tool with 
significant therapeutic implications for other diseases.  
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Figure 1.4 Diagram of the MPTP formed by dimers of the F0F1 ATP synthase. (A) 
Opening of the MPTP is induced by mitochondrial Ca2+ overload and oxidative stress, 
allowing solutes with a molecular mass up to 1.5 kDa to pass through the inner 
mitochondrial membrane. Cyp D binds to the F0F1 ATP synthase on the oligomycin 
sensitivity-conferring protein (OSCP) subunit. (B) Inhibition of Cyp D prevents the 
interaction of Cyp D with the F0F1 ATP synthase, increasing the threshold of MPTP 
opening. The listed agents are cyclophilin inhibitors, although these lack specificity 
for cyclophilin D, being general cyclophilin inhibitors.  
Abbreviations: MPTP, mitochondrial permeability transition pore; ATP, adenosine 
triphosphate; Cyp D, cyclophilin D; IMM, inner mitochondrial membrane; MCU, mitochondrial 
Ca2+ uniporter 
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1.7  Store-operated Ca2+ entry channels are potential therapeutic 
targets 
Intracellular Ca2+ store depletion stimulates compensatory Ca2+ entry from outside 
the cell to refill the emptied Ca2+ stores, known as store-operated Ca2+ entry (SOCE). 
SOCE is the principal mechanism of maintaining physiological Ca2+ homeostasis and 
cell functions in non-excitable cells such as endothelial cells (Abdullaev et al., 2008), 
hepatocytes (Jones et al., 2008), platelets (Tolhurst et al., 2008), T cells (Barr et al., 
2008, Lioudyno et al., 2008) and PACs (Lur et al., 2009). Two key molecular 
components of this Ca2+ entry pathway have been identified a decade ago (Liou et 
al., 2005, Prakriya et al., 2006): firstly, the protein that senses Ca2+ store depletion 
on the endoplasmic reticulum referred as the STIM proteins, and secondly, the 
protein that forms the Ca2+ permeable ion channel on the plasma membrane referred 
to as Orai, see Figure 1.5. 
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Figure 1.5 STIM1/Orai1-mediated SOCE. (A) At the resting state or before ER Ca2+ 
store depletion, STIM1 bound to Ca2+ and is distributed uniformly as monomers in 
the ER membrane. Orai1 is four transmembrane domains with both N and C termini 
facing into the cytosol and it is Ca2+ selective pore-forming subunit of Ca2+ release-
activated Ca2+ channel located in the plasma membrane. Orai1 at resting state has 
been described as a dimer (Penna et al., 2008) or a tetramer (Ji et al., 2008). (B) 
Upon ER Ca2+ store depletion, Ca2+ dissociates with STIM1, enabling STIM1 
oligomerisaion and migration to the ER-PM junctions to form distinct STIM1 puncta. 
This allows STIM1 aggregates, interacts with and activates Orai1 channels, resulting 
in Ca2+ entry from the outside of the cells.  
Abbreviations: SOCE, store-operated Ca2+ entry; ER, endoplasmic reticulum; PM, plasma 
membrane.  
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1.7.1 STIM, a Ca2+ sensor of the level of Ca2+ in the ER 
STIM proteins are single-pass, type I transmembrane proteins with two mammalian 
homologues, STIM1 and STIM2. Two studies have demonstrated that STIM1, acting 
as Ca2+ sensor for the level of Ca2+ in the ER, plays an essential role in controlling 
and activating the Ca2+ release-activated Ca2+ entry (CRAC) channel (Roos et al., 
2005, Liou et al., 2005). The luminal N-terminal region of STIM1 including an EF-
hand motif near the amino terminus is the Ca2+ binding site. Upon the depletion of 
the ER Ca2+ store, STIM1 redistributes from the ER site to form a puncta at the ER-
plasma membrane (ER-PM) junctions, located 10-25 nm from the PM (Liou et al., 
2005, Zhang et al., 2005, Luik et al., 2006). The luminal Ca2+ –binding EF hand 
dissociated from Ca2+ loses interaction with a sterile α motif domain (SAM), leading 
to partial unfolding of STIM1 and the formation of STIM1 oligomers. Oligomerization 
of STIM1 alone is sufficient to cause STIM1 accumulation at ER-PM junctions, but 
this is not enough to activate the CRAC channel (Luik et al., 2006, Stathopulos et al., 
2008). A cytosolic region of STIM1, namely the 107-amino acid CRAC activation 
domain (CAD), is essential for CRAC activation and probably binds directly to both 
the N- and C-terminal of Orai1 to open the channels (Park et al., 2009), see Figure 
1.6.  
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Figure 1.6 Functional domains of STIM1. STIM1 is a single-pass membrane 
protein of 77 kDa with N-terminus facing ER lumen and C-terminus facing cytosol. Of 
the ER domains, EF-hand motif imparts the protein with ER Ca2+ sensing 
functionality; SAM regulates STIM oligomerization. The cytosolic C-terminus is 
organized into several distinct functionally important modules including CAD and 
STIM1 Orai1 activation region (SOAR). Among them, the most critical functional 
domain of a roughly 100 amino acid regions called CAD, which is necessary and 
sufficient to activate ICRAC. Adapted from (Shim et al., 2015). 
Abbreviations: SAM, sterile α motif domain; ER, endoplasmic reticulum; TM, 
transmembrane; CAD, CRAC activation domain; SOAR, STIM Orai1 activation region.  
 
 
 
 
 
 
 
 
 
 
48 
 
1.7.2 Orai1 is the component of the CRAC channel 
Orai are the keepers of the heaven gates in Greek mythology (Roberts-Thomson et 
al., 2010). Orai1 was firstly identified from patients with hereditary severe combined 
immune deficiency (SCID) syndrome, which is defective in SOCE and CRAC 
channel function. The defect of SCID is associated with replacement of a highly 
conserved arginine residue by tryptophan at R91 position (Feske et al., 2006). Two 
following studies have identified Orai1 as an essential pore subunit of the CRAC 
channel (Prakriya et al., 2006, Vig et al., 2006). Two conserved acidic residues, 
E106 and E190 in transmembrane helices 1 and 3, respectively determines the ion 
selectivity of CRAC channel (Prakriya et al., 2006). Orai1 is a four–transmembrane 
protein (TM1-TM4) expressed at the cell surface with its N- and C-terminal facing 
into the cytoplasm. The crystal structure of Orai was revealed in 2012 and shows a 
hexameric assembly of Orai subunits comprising the ion pore arranged around a 
central ion pore, which traverses the membrane and extends into the cytosol (Hou et 
al., 2012). Use of the crystal structure of Orai could facilitate the development of 
more selective Orai inhibitors. The selectivity of Orai is determined by glutamate 
residues on its extracellular side; the closed state is mediated by binding of anions to 
a basic region near the intracellular side (Yeromin et al., 2006, Hou et al., 2012). 
Orai1 interaction with the C-terminus of STIM induces Orai1 dimers to dimerize, 
forming tetramers that constitute the Ca2+–selective pore (Penna et al., 2008). 
Another study has suggested that Orai1 forms tetramers in resting cells and the 
activated CRAC channels remain as tetramers (Ji et al., 2008), see Figure 1.7.  
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Figure 1.7 Structure of Orai1. Each Orai1 monomer includes four transmembrane 
domains (TM1-TM4). Early studies identified several acidic residues in TM1 (E106) 
and TM3 (E190) whose mutation changed ion selectivity or permeation. Future study 
confirmed residue E106 forming critical molecular determinant of the high Ca2+ 
selectivity of the CRAC channel. STIM1 interacts with two sites in Orai1; CAD 
binding regions of intracellular C- and N-termini are highlighted in yellow. Adapted 
from (Shim et al., 2015).  
Abbreviations: TM, transmembrane; CAD, CRAC activation domain 
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Orai has three isoforms Orai1, Orai2 and Orai3. Orai proteins share no homology 
with any other known ion channel proteins (Roberts-Thomson et al., 2010). Orai1, 
Orai3 and STIM1 are almost ubiquitously expressed in the whole body while Orai2 is 
prominently expressed in the brain, lung, spleen and intestine (Gross et al., 2007). 
Orai1-deficient (Orai1-/-) mice exhibit some clinically relevant phenotypes, including 
immunodeficiency with defective T- and B-cell function and impaired mast cell 
function (Vig et al., 2008, Gwack et al., 2008). The important roles of Orai1 have 
been noted and studied in different diseases over recent few years, including allergic 
disease (Vig et al., 2008), breast cancer (Yang et al., 2009), myocardial infarction 
and stroke (Braun et al., 2009), allograft rejection(McCarl et al., 2010) and 
autoimmune disease (Kim et al., 2014). 
 
1.7.3 Development of Orai channel inhibitors  
There are currently no specific ICRAC inhibitors approved by the European Medicines 
Agency (EMA) or US Food and Drug Administration (FDA) for clinical use. 2-amino-
ethoxydiphenylborate (2-APB) is a blocker of ICRAC with multiple off-target effects, 
which has been used as a tool to study SOCE for many years (Bootman et al., 2002). 
DPB162-AE and 163-AE, chemical analogs of 2-APB, were identified by the 
Mikoshiba group with an IC50 of 27 nM and 42 nM respectively in DT-40 cells (Goto 
et al., 2010). Subsequent study indicated that the inhibitory effects of these two 
compounds target STIM1, though effects on the STIM1-Orai interaction are unknown 
(Jairaman and Prakriya, 2013). This prevents further development of these two 
compounds for clinical use since STIM1 plays such a fundamental role in 
maintaining physiological Ca2+ signals in the body. Bis(trifluoromethyl) pyrazole 
derivatives (BTPs) were first identified by Abbott Laboratories in a high-throughput 
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drug screen for inhibition of IL-2 production in Jurkat T cells (Djuric et al., 2000). YM-
58483 is the same as BTP2, but synthesized independently by Yamanouchi 
pharmaceuticals with an IC50 value of ~100 nM inhibiting SOCE in Jurkat T cells 
(Ishikawa et al., 2003). Apart from inhibition of CRAC channels, various studies have 
shown BTP2 inhibited other ion channels including TRM4, TRPC3 and TRPC5 
(Jairaman and Prakriya, 2013). The non-specific inhibitory effects of BTPs on several 
ion channels preclude their use in human diseases. 3-fluoropyridine-4-carboxylic 
acid (2’,5’-dimethoxybiphenyl-4-yl)amide (Synta 66) was developed by Synta 
pharmaceuticals with a similar structure to BTP2 and an IC50 of ~3 µM (Jairaman 
and Prakriya, 2013). Synta 66 showed selectivity for CRAC inhibition over inhibition 
of Kv1.3, hERG, TRPM4 or TRPM7 channels (Sweeney et al., 2009), but its 
relatively high IC50 value may prevent its use in clinical setting (Parekh, 2010).     
 
2,6-difluoro-N--benzamide (RO2959) is a potent SOCE inhibitor that completely 
inhibits SOCE, cytokine production and T cell proliferation in CD4+ T cells. RO2959 
has a 20-fold difference of IC50 between Orai1 and Orai2/3 (25 nM for Orai1 and 500 
nM for Orai3) and did not have a significant inhibitory effect on a number of ion 
channels screened including TRPC1, TRPM2, TRPM4, hERG, hCav1.2, hKv1.5. 
This makes RO2959 a fairly selective CRAC channel inhibitor (Chen et al., 2013, 
Jairaman and Prakriya, 2013). 2,6-difluoro-N-(1-(4-hydroxy-2-
(trifluoromethyl)benzyl)-1H-pyrazol-3-yl)benzamide (GSK-7975A) is a novel ICRAC 
inhibitor that blocks Orai1 and Orai3 channels with an IC50 of approximately 4.1 µM 
and 3.8 µM, respectively. Inhibitory profiles of GSK-7975A on sixteen ion channels 
revealed only a slight inhibitory effect on L-type (CaV1.2) Ca2+ channels (Derler et al., 
2013, Rice et al., 2013). CalciMedica (CM) has patented a series of compounds that 
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inhibit ICRAC and Orai channels. CM2489 has completed Phase I clinical trials for the 
treatment of moderate-to-severe plaque psoriasis, which is the first CRAC inhibitor to 
be tested in humans (Jairaman and Prakriya, 2013). The multiple-dose Phase I study 
of CM2489 has shown this to be safe, well-tolerated and well-behaved with some 
evidence of clinical improvement (www.calcimedica.com), see Table 1.3. 
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Table 1.2 Summary of Orai channel inhibitors  
Drug Company/Institute Drug class Mechanism of action Clinical phase 
BTP2 (YM58483) Abbott (Yamanouchi) SMWC Orai channel inhibitor, unknown selectivity Preclinical (discontinued) 
Synta 66 Synta SMWC Orai channel inhibitor, unknown selectivity Preclinical (discontinued) 
RO2959 Hoffmann-La Roche SMWC Orai1 channel inhibitor Preclinical (unknown) 
GSK-7975A GlaxoSmithKline SMWC Orai1/3 channel inhibitor Preclinical (discontinued) 
CM compounds CalciMedica SMWC Orai1/3 channel inhibitor Phase I 
Abbreviations: SMWC, small molecular weight chemical; CM, CalciMedica 
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1.7.4 SOCE and AP 
Pathophysiological events induced by pancreatitis-associated toxins in PACs are all 
dependent on Ca2+ entry through SOCE on the plasma membrane, including 
premature digestive enzyme activation, vacuole formation, altered trafficking and 
secretion, skeletal disruption, mitochondrial dysfunction and necrotic cell death 
activation. All these processes do not occur if there is removal of external Ca2+ or 
intracellular Ca2+ chelation (Raraty et al., 2000, Criddle et al., 2004, Kim et al., 2002, 
Voronina et al., 2002). Orai1 is the principal SOCE channel in PACs, opening of 
which is coordinated by STIM1, following decrease in ER Ca2+ store concentrations. 
PACs contain two pools of Orai1: an apical pool that co-localizes and interacts with 
IP3Rs and a basal pool that interacts with STIM1 following the Ca2+ store depletion 
(Lur et al., 2009). Previous studies have demonstrated that GSK-7975A inhibits 
SOCE induced by thapsigargin in isolated murine pancreatic acinar cells over the 
range of 1-50 µM (IC50 ~3.4 µM) (Gerasimenko et al., 2013). In addition, GSK-7975A 
inhibits endocytic vacuole formation (Voronina et al., 2015) and reduces necrosis 
induced by toxins that cause AP (Gerasimenko et al., 2013, Voronina et al., 2015). 
 
Transient receptor potential canonical (TRPC) channels are another class of 
functional SOCE channels present on PACs. They can be activated subsequent to 
the activation of different isoforms of phospholipase (PLC) and also can be activated 
whenever intracellular Ca2+ stores are depleted, acting as a non-selective Ca2+-
permeable cation, SOC channels (Nilius et al., 2007). Acinar cells expressed TRPC1, 
TRPC3 and TRPC6(Parekh and Putney, 2005). TRPC3-deficient mice (Trpc3-/-) are 
viable, fertile and have normal phenotype other than impaired synaptic transmission 
in Purkinje cells and motor coordination (Hartmann et al., 2008). Genetic depletion 
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and pharmacological inhibition of TRPC3 resulted in ~50% reduction Ca2+ influx in 
vitro and ~50% reduction of in vivo pancreatic damage induced by four injections of 
cerulein (Kim et al., 2009, Kim et al., 2011). 
 
1.8  Hypotheses and study aims 
Hypothesis 1: Cytosolic Ca2+ overload mediated via Orai1 channels has a 
pivotal role in the pathogenesis of AP.   
Study aims 1) to determine the effects of Orai1 inhibition by GSK-7975A and 
CM_128 on SOCE and necrotic cell death pathway activation in isolated murine 
pancreatic acinar cells; 2) to evaluate the effects of Orai1 inhibition by GSK-7975A 
and CM_128 on disease severity in at least two experimental AP models. 
 
Hypothesis 2: Prevention of Ca2+ overload by inhibition of Orai1 channel has 
translational potential as a treatment for human acute pancreatitis 
Study aims: to examine the effects of Orai1 inhibition by GSK-7975A and CM_128 
on SOCE and necrotic cell death pathway activation in isolated human pancreatic 
acinar cells. 
 
Hypothesis 3: Door-to-needle time is critical for AP treatment targeting the 
pathogenesis of pancreatic injury.   
Study aims: to compare the effects of early versus late administration of GSK-7975A 
and CM_128 on disease severity in two clinically representative models of AP. 
 
In vitro and in vivo mouse AP models were used in my study since the study in my 
thesis was mainly focusing on PACs and the cells from mouse pancreas have similar 
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characteristics as human PACs to better mimic the settings of human diseases. 
Hyperstimulation AP (CER-AP) was well-established, wildly used and reproducible 
experimental model. Biliary AP (TLCS-AP) and alcohol/fatty acid AP (FAEE-AP) 
were chosen to model the major etiology of human AP (Lerch and Gorelick, 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57 
 
 
 
 
 
 
 
 
 
 
 
Methods 
Chapter 2 
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2.1 Animals 
CD-1 and C57BL/6J mice were from Charles River UK Ltd. Pancreatic acinar cells 
were isolated from CD-1 mice. For in vivo experiments 10-12 week old male 
C57BL/6J mice were used. All animals were allowed to acclimatize for 1 week under 
temperature-controlled conditions with a 12-hour light/dark cycle, with free access to 
water and standard laboratory chow during this time. All efforts were made to 
minimize animal suffering and to reduce the number of animals used.  
 
2.2 Isolation of murine PACs 
Mice were humanely killed by dislocation of the neck following the Code of Practice 
for the Humane Killing of Animals under Schedule 1 of the Animals (Scientific 
Procedure) Act 1986. The pancreas was dissected immediately and washed twice 
with sodium 4-(2-hydroxyethyl)-1 piperazineethanesulfonic acid (HEPES) solution, 
containing in mM: 140 NaCl, 4.7 KCl, 1.13 MgCl2, 10 HEPES, 10 D-glucose and 1.2 
CaCl2; pH 7.35. The tissue was digested by injecting with 1 ml of collagenase (200 
units/ml, Worthington) dissolved in sodium HEPES solution and incubated in the 
collagenase solution, in a shaking water bath, at 37°C for 17 min. After incubation, 
the tissue was poured into 15 ml falcon tube and washed with sodium HEPES 
solution once to remove the collagenase solution. Then the tissue was disrupted by 
either shaking by hand or pipetting through an enlarged 1 ml pipette tip. The cloudy 
supernatant was transferred into fresh falcon tubes and this step repeated several 
times until the tubes were filled and centrifuged at 1,000 rpm for 1 minute. The 
supernatant was discarded and the cell pellet was re-suspended in sodium HEPES 
solution. The cell re-suspension was filtered through a 70 µm cell strainer (BD 
Falcon) and centrifuged at 1,000 rpm for 1 minute. The supernatant was discarded 
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carefully and the cell pellet was re-suspended in sodium HEPES solution for in vitro 
experiments. All isolated cells were used within 4-6 hours.   
 
2.3 Isolation of human PACs 
Human pancreas was sampled and cells isolated as described (Murphy et al., 2008). 
Briefly, specimen was taken from patients undergoing surgery for left-sided or small 
un-obstructing pancreatic tumours. During surgery, a small piece (~1 cm x 1 cm x 1 
mm) was cut with a fresh scalpel blade from the transaction margin of the pancreas 
in situ. The sample was washed immediately twice by sodium HEPES solution, then 
put straight into falcon tube containing sodium HEPES solution plus 5 µM trypsin 
inhibitor, 100 µM sodium pyruvate as well as protease inhibitor and taken into the 
laboratory. Pancreatic cell isolation in each case was started less than 10 minutes 
after sampling. Serial digestions of human tissue were required for high quantity and 
quality cell yields. For the first digestion, the tissue was injected with 1-2 ml of 
collagenase (200 units/ml, Worthington) and incubated in the collagenase solution in 
a shaking water bath at 37°C for 20-25 minute. After incubation, the tissue was 
poured into 15 ml falcon tube and washed with sodium HEPES solution once to 
remove the collagenase solution. Then the tissue was disrupted by either shaking by 
hand or pipetting through a 1 ml pipette tip. The cloudy supernatant was filtered with 
a 70 µm cell strainer (BD Falcon) before transfer into a fresh 50 ml falcon tube and 
this step was repeated several times until the 50 ml tube was filled and centrifuged at 
1,000 rpm for 1 minute. The supernatant was discarded and the cell pellet re-
suspended in sodium HEPES solution and stored at 4°C. The remaining tissue was 
subject to a second digestion by injecting with a stronger collagenase solution (4000 
units/ml, Worthington) and incubated in the collagenase solution in a shaking water 
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bath at 37°C for 10-15 minute. After incubation, the previously described steps were 
repeated and the cell pellet from the second digestion was re-suspended in sodium 
HEPES solution and stored at 4°C. Whether a third digestion was required depended 
on the cells yielded from first two digestions and the amount of remaining tissue. If 
the first two digestions have yielded big cell pellets and the remaining tissue was 
small and almost disrupted, the third digestion was not required. If cell pellets from 
the first two digestions were not big enough and the remaining tissue was still 
comparatively large, further digestion was required. After serial digestions of tissue, 
the cells from each digestion were checked separately under microscopy before 
mixing together for in vitro experiments. All isolated cells were used within 4-6 hours.    
 
2.4 Necrotic cell death pathway activation measurement 
Cells were treated with various concentrations of test compounds together with 500 
µM taurolithocholic acid 3-sulfate (TLCS) for 30 minutes, gently shaking at 1,000 rpm 
at room temperature. After washing with sodium HEPES solution once, cells were 
stained with propidium iodide (PI) and Hoechst 33342, placed onto a 96-well glass 
bottom plate (150 µl per well) and imaged using LSM710 systems. Hoechst 33342 
(50 µg/ml; excitation 364 nm, emission 405-450 nm) was used to stain the nucleus, 
to count the total number of cells. PI (1 µM; excitation 488 nm, emission 630-693 
nm) was used to assess plasma membrane rupture: the total number of cells 
displaying PI uptake was counted in 20 random fields of each isolate to give a 
percentage, averaged across fields as mean ± s.e.m. with ≥3 isolates/group. 
 
2.5 Induction of experimental AP  
2.5.1 Hyperstimulation AP 
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Hyperstimulation AP (CER-AP) was induced by seven hourly intraperitoneal 
injections of 50 µg/kg caerulein (Lerch and Gorelick, 2013), with humane killing 12 h 
after the first injection with no mortality. Analgesia was given by subcutaneous 
injection of 1 mg/kg buprenophine. The control mice were received seven hourly 
intraperitoneal injections of the same volume of saline.  
 
2.5.2 Biliary AP 
Biliary AP (TLCS-AP) was induced by retrograde pancreatic duct infusion of 3 mM 
TLCS at a speed of 5 μl/min over 10 min (50 µl TLCS in total) by infusion pump 
(Laukkarinen et al., 2007, Perides et al., 2010); humane killing 24 h later with no 
mortality. General anaesthesia was given using O2 and isoflurane. Prior to 
laparotomy, the mice were given 1 mg/kg buprenophine subcutaneously. Methylene 
blue with a final concentration of 100 mg/ml was used to indicate satisfactory 
pancreatic infusion (see Figure 2.1). After surgery, the mice were recovered in 37ºC 
mini-thermacage (Datasand Group) for 30 min, then move to the cage on a warm 
heat pad and monitored carefully for at least 2-3 h. The control mice were received 
sham operation.  
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Figure 2.1 A representative photo of TLCS-AP induction. Photo from TLCS-AP at 
the end of retrograde pancreatic duct infusion, indicating successful infusion of TLCS 
into the pancreas.  
 
2.5.3 Alcohol/fatty acid AP 
Alcohol/fatty acid AP (FAEE-AP) was induced by two hourly intraperitoneal injections 
of 150 mg/kg palmitoleic acid (POA) and 1.35 g/kg ethanol (Huang et al., 2014), with 
humane killing 24 h later for assessment of the severity of AP. In order to avoid local 
damage by ethanol and/or POA, 200 µl of sterile saline was injected intraperitoneally 
at the site before each injection. Analgesia was given by subcutaneous injection of 1 
mg/kg buprenophine every 12 h. The mice were kept on a warm heat pad during the 
procedure and monitored very carefully for the first 6 h after the first injection. During 
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the continuously monitoring, humane killing was applied to the mouse (1-2 out of 10 
mice) when the mouse was considered to suffer too much pain and stresses. The 
contol mice were received two hourly intraperitoneal injections of the same volume of 
saline.  
 
2.6 Drug delivery by mini-osmotic pump  
As experimental procedures were done with mice and the time course of 
experiments was up to 24 h, ALZET mini-osmotic pump (Model 2001D) with 8 µL/h 
delivery rate over 24 h periods was selected for subcutaneous implantation for some 
experiments in which a drug with a very short half-life (GSK-7975A given as 
phosphate prodrug GSK-6288B) was tested. ALZET mini-osmotic pump was filled-in, 
primed and implanted according to the manufacturer’s instructions. Good sterile 
technique was used during the filling, handling and surgical implantation of 
minipumps. During filling and implantation, minipumps were handled with surgical 
gloves because skin oils in large quantity may interfere with the performance of a 
pump if they accumulate on its surface.  
 
2.6.1 Working mechanism of mini-osmotic pump  
Minipumps operate because of an osmotic pressure difference between a 
compartment within the pump (called the salt sleeve) and the tissue environment in 
which the pump is implanted. The high osmolarity of the salt sleeve causes water to 
flux into the pump through a semipermeable membrane which forms the outer 
surface of the pump. As the water enters the salt sleeve, it compresses the flexible 
reservoir, displacing the test solution from the pump at a controlled, predetermined 
rate (see Figure 2.2).  
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Figure 2.2 A Schematic illustration of a minipump. Tested compound is dissolved 
in a compatible solvent and loaded into the impermeable reservoir. The semi-
permeable membrane allows water (from tissue fluid) to influx through the outer 
surface of the pump. The expanding layer in the salt sleeve compresses the flexible 
reservoir, pumping the tested solution at controlled rate through the flow moderator.  
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2.6.2 Selecting compatible solvent 
The minipumps are compatible with aqueous solutions, dilute acids and bases, dilute 
or low concentrations of DMSO and alcohol, and up to 100% propylene and 
polyethylene glycol. A phosphate prodrug GSK-6288B with higher solubility in 
aqueous solvent was used in some studies. It was dissolved in phosphate buffer, 
which is compatible with the minipump used.   
 
2.6.3 Filling mini-osmotic pumps 
Minipumps were carefully filled as below:  
1) The empty pump together with its flow moderator was weighed.  
2) Filling the pump was accomplished with a small syringe (1.0 ml) and the 
provided blunt-tipped, 27 gauge filling tube.  
3) With the flow moderator removed, the pump was held in an upright position 
and the filling tube was inserted through the opening at the top of the pump 
until it could go no further.  
4) The plunger of the syringe was pushed very slowly to avoid air bubbles. When 
the solution appeared at the outlet, the filling was stopped and the syringe 
was carefully removed.  
5) The excess solution was wiped off and the flow moderator was inserted until 
the white flange was flush with the top of the pump. The insertion of the flow 
moderator displaced some of the solution from the filled pump. To function 
properly, the flow moderator had to be fully inserted into the body of the 
pump.  
6)  The filled pump was weighed. The difference in the weights obtained in Step 
1) and 6) was the net weight of the solution loaded, with the weight in 
 
66 
 
milligrams approximately the same as the volume in microliters for dilute 
aqueous solutions.  
 
2.6.4 Priming mini-osmotic pumps 
Before implantation, the prefilled pumps were put in 0.9% saline for at least 3 hours 
at 37°C in order to reach a steady state pumping rate immediately after implantation.  
 
2.6.5 Implanting mini-osmotic pumps 
Minipumps were implanted subcutaneously in mice under general anesthesia of O2 
and isoflurane. A small incision was made in the skin between the scapulae, and a 
small pocket formed using scissors by spreading the subcutaneous connective 
tissues apart. Minipumps were inserted into the pocket with the flow moderator 
pointing away from the incision. The skin incision was closed with sutures (see 
Figure 2.3).   
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G 
Figure 2.3 Procedure of mini-pump implantation.  (A) Small pocket was made by 
spreading the subcutaneous connective tissues apart after a small incision was 
made (arrow showing towards the small pocket); (B) the pump was inserted into the 
pocket with flow moderator pointing away from the incision; (C) the incision was 
closed with sutures. 
 
2.6.6 Verifying the accuracy of mini-osmotic pump drug delivery  
The recommended method to verify the results from continuous administration is to 
measure the blood levels of drug at several points during the course of infusion. The 
levels of GSK-6288B and GSK-7975A in the blood and pancreas were measured at 
1, 2, 4, 10 and 22 h after minipump implantation in the study prior to drug efficacy 
assessment.  
 
2.7 Evaluation of experimental AP severity 
Whether experiment AP was successfully developed was confirmed by serum 
amylase and pancreatic histology. AP severity was evaluated by local biochemical 
parameters, including pancreatic trypsin and MPO activity, a marker of inflammatory 
infiltration (Dawra et al., 2008). Pancreatitis-associated distant organ damage was 
A B C 
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measured by IL-6 and lung MPO activity since respiratory failure is one of the 
commonest organ dysfunction in severe AP patients (Banks et al., 2013).  
 
2.7.1 Serum amylase and IL-6  
Blood was collected in a clean 2 ml tube, then centrifuged 1,500 ×g for 10 minutes. 
Serum amylase activity was determined by Roche automated clinical chemistry 
analyzers (Roche) and serum IL-6 was measured by Quantikine ELISA (R&D 
systems). 
 
2.7.2 Trypsin activity 
Pancreatic trypsin activity was measured by fluorogenic assay as previously 
described (Nathan et al., 2005), using Boc-Gln-Ala-Arg-MCA substrate (excitation 
380 nm, emission 440 nm) converted by trypsin to a fluorescent product.  Briefly, 
pancreatic tissue was homogenized in 5 mM 4-morpholinepropane sulfonic acid 
(MOPS) buffer, containing 250 mM sucrose and 1 mM magnesium sulphate, pH 6.5, 
centrifuged at 1,500 × g for 5 min at 4°C. The supernatant was added to each well of 
a 96-well plate containing pre-warmed pH 8.0 assay buffer, with 50 mM Tris, 150 
mM NaCl, 1 mM CaCl2 and 1% (w/v) bovine serum albumin and peptide substrate. 
Fluorescence was measured using a PLOARstar Omega microplate reader. 
Pancreatic trypsin activity was calculated as the difference of fluorescence intensity 
between 0 min and 5 min. 
 
2.7.3 Myeloperoxidase activity 
MPO activity was determined as described (Dawra et al., 2008). Briefly, pancreatic 
and lung tissue were homogenized in 100 mM phosphate buffer (pH 7.4) with 
 
69 
 
protease inhibitors, centrifuged at 16000 × g for 15 minutes at 4°C (twice for 
pancreas and three times for lung). The pellet was re-suspended in 100 mM 
phosphate buffer (pH 5.4), containing 0.5% hexadecyltrimethyl ammonium bromide, 
10 mM EDTA and protease inhibitors, then freeze-thawed three times, sonicated for 
30 sec and centrifuged at 16,000 × g for 15 minutes at 4°C. Myeloperoxidase activity 
was measured in the supernatants mixed with 3,3,5,5-tetramethylbenzidine as the 
substrate with freshly added 0.01% H2O2. Absorbance was measured at 655 nm and 
MPO activity calculated as the difference between the values at 0 and 3 min. 
 
2.7.4 Histology 
For morphological examination pancreatic tissues were fixed in 10% formalin, 
embedded in paraffin, and stained with hematoxylin and eosin (H&E). 
Histopathological evaluation was assessed blindly on 10 random fields (×10 high 
power fields) of each slide by two independent investigators, grading the degree and 
extent of oedema, inflammatory infiltration and necrosis from 0 to 3 (see Table 2.1 
for the details), calculating summated mean ± s.e.m, for ≥6 mice/group. The 
agreement of these scores between two indepedent investigators was evaluated and 
confirmed before assessing the slides from experimental groups.    
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Table 2.1 Pancreatic histopathological grading criteria (Wildi et al., 2007) 
Parameter Scores Indications 
1. Edema 0 Absent 
1 Focal increased between lobules  
2 Diffused increased 
3 Acini disrupted and separated 
2. Inflammatory 
inflitration 
0 Absent 
1 In ducts (around ductal margins ) 
2 In the parachyma (<50% of the lobules) 
3 In the parachyma (>50% of the lobules) 
3. Necrosis 0 Absent 
1 Periductal necrosis (<5)* 
2 Focal necrosis (5-20%) 
3 Diffused parachymal necrosis (>20%) 
*Approximate percentage of cells involved per field examined. 
 
2.8 Chemicals 
CCK-8 was from American Peptide; other fluorescent dyes from Molecular Probes; 
Boc-Gln-Ala-Arg-MCA from Peptide Instutite (Osaka, Japan); protease inhibitors 
from Roche GmbH (Mannheim, Germany); IL-6 Quantikine ELISA Kit from R&D 
Systems; ALZET® osmotic mini-pump (2001D) from Charles River UK Ltd. Other 
reagents were from Sigma (Dorset, United Kingdom). 2,6-difluoro-N-(1-(4-hydroxy-2-
(trifluoromethyl)benzyl)-1H-pyrazol-3-yl)benzamide (GSK-7975A) and pro-drug GSK-
6288B were gifted by GlaxoSmithKline (Stevenage, United Kingdom). CM_128 was 
gifted by CalciMedica (La Jolla, United States).   
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2.9 Statistical analysis 
Data were presented as mean + s.e.m. Statistical evaluation was performed using 
OriginPro 9 (OriginLab corporation, USA). Two-tailed Student’s t-test (two groups) 
and ANOVA (more than two groups) were performed for parametric data and χ2 test 
for non-parametric data; p values <0.05 were considered significant. 
 
2.10 Study Approval 
Human pancreatic samples were obtained with informed consent as approved by 
Liverpool Adult Local Research Ethics Committee (Ref: 03/12/242/A). All animal 
studies were ethically reviewed and conducted according to UK Animals (Scientific 
Procedures) Act 1986, approved by UK Home Office (PPL 40/3320, renewed as 
70/8109) and Prof Sutton (my supervisor) is the project license holder. 
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Effect of novel Orai inhibitors on store-
operated Ca2+ entry and cell fate in mouse 
and human pancreatic acinar cells 
Results: Chapter 3  
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3.1 Introduction 
Sustained elevation of the [Ca2+]c is a critical trigger for pancreatic acinar cell injury 
and necrosis that depends on SOCE. All subsequent cellular injury does not occur if 
sustained Ca2+ entry via SOCE channels is prevented, either by the removal Ca2+ 
from external solution or by blocking Ca2+ entry channels on the plasma membrane 
(Raraty et al., 2000, Petersen and Sutton, 2006, Gerasimenko et al., 2013, Lankisch 
et al., 2015). The molecular component of the CRAC channel named Orai1 has been 
identified by 1) genotyping and analyzing cells from patients with hereditary SCID 
syndrome; 2) genome-wide RNA intereference (RNAi) screens followed by a 
secondary patch-clamp screens (Feske et al., 2006, Vig et al., 2006). Orai1 is the 
principal SOCE channel in PACs (Lur et al., 2009), opening of which is coordinated 
by STIM1 and STIM2 following decreases in ER Ca2+ store concentrations 
(Gerasimenko et al., 2013, Lur et al., 2009, Muik et al., 2012, Derler et al., 2013). 
 
GSK-7975A and CM_128 were discovered independently as Orai channel inhibitors 
by GlaxoSmithKline (Derler et al., 2013, Rice et al., 2013) and CalciMedica, 
respectively. The inhibitory effects of GSK-7975A on SOCE have been evaluated in 
lung mast cells (Ashmole et al., 2012), platelets (van Kruchten et al., 2012) and 
glomerular mesangial cells (Chaudhari et al., 2014). Previous studies showed GSK-
7975A inhibits thapsigargin- and palmitoleic acid ethyl ester (POAEE)-induced 
SOCE in isolated murine PACs over the range of 1-50 µM (IC50 ~3.4 µM) 
(Gerasimenko et al., 2013), inhibits endocytic vacuole formation (Voronina et al., 
2015) and reduces necrosis induced by toxins that cause AP (Gerasimenko et al., 
2013, Voronina et al., 2015). But, the effects of GSK7975A on SOCE and cell fate in 
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human PACs remain unknown. Until now, there are no published data on the effects 
of CM_128, a new molecular entity of Orai inhibitor.  
 
The study described in this chapter was designed to evaluate the effects of GSK-
7975A on CCK- and TLCS-induced Ca2+ entry in isolated mouse PACs and 
thapsigargin-induced Ca2+ entry in isolated human PACs as well as the effects of 
GSK-7975A and CM_128 on bile acid-induced necrotic cell death pathway activation 
in isolated mouse and human PACs.  
 
3.2 Methods 
3.2.1 Measurement of cytosolic Ca2+ concentrations 
Cells isolated from mouse and human pancreata (details in 2.2 and 2.3) were loaded 
Fura-2 (5 µM; excitation 340 and 380, emission ˃490 nm ) for 30-45 mins and 
imaged using a Till Photonics System to assess [Ca2+]c ; ratio of fluorescence 
recorded from excitation at 340 and 380 nm were used for the analysis. Experiments 
were undertaken by Dr Svetlana Voronina and Dr Michael Chvanov.   
 
3.2.2 Measurement of necrotic cell death pathway activation 
Cells isolated from mouse and human pancreata (details in 2.2 and 2.3) were treated 
with 500 µM TLCS ± various concentrations of GSK-7975A and CM_128 for 30 min, 
shaking at 1,000 rpm, at room temperature. Control cells were treated with the same 
volume of dimethylsulfoxide (DMSO) used to dissolve GSK-7975A/CM_128, without 
TLCS, for 30 min under the same conditions. After washing, cells were stained with 
PI and Hoechst 33342, placed into a 96-well glass bottom plate (150 µl per well) and 
imaged using LSM710 systems. Hoechst 33342 (50 µg/ml; excitation 364 nm, 
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emission 405-450 nm) was used to stain the nucleus, to count the total number of 
cells. PI (1 µM; excitation 543 nm, emission 630-693 nm) was used to assess 
plasma membrane rupture: the total number of cells displaying PI uptake was 
counted in ≥ 3 wells and ≥ 12 random fields of each differently treated group of each 
isolate to give a percentage, averaged across fields as mean ± s.e.m. with ≥3 
isolates/group, except where stated.  
 
3.3 Results 
3.3.1 Effects of GSK-7975A on store-operated Ca2+ entry in mouse PACs 
Isolated mouse pancreatic acinar cells maintained in 5 mM external Ca2+ were 
perfused with supramaximal CCK (1 nM) or TLCS (500 µM) to induce sustained 
elevation of [Ca2+]c dependent on SOCE (Raraty et al., 2000, Gerasimenko et al., 
2013, Muik et al., 2012, Kim et al., 2009). Once a stable plateau in [Ca2+]c had 
formed, a range of fixed concentrations (0-100 µM) of GSK-7975A were applied (at 
700 s). Increasing concentrations of GSK-7975A lowered the [Ca2+]c plateau 
progressively and increasingly rapidly. With CCK, suppression of [Ca2+]c towards the 
initial baseline approached ˃95% using 15 µM GSK-7975A (see Figure 3.1), an 
effect also seen when cells were maintained in 1.8 mM external Ca2+ (see Figure 
3.2); with TLCS, suppression to baseline was ~80% using 30 µM GSK-7975A (see 
Figure 3.3). With CCK and TLCS, GSK-7975A at 100 µM but not 50 µM there was 
loss of effect (see Figure 3.1 and 3.3).  
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Figure 3.1 Effects of GSK-7975A on the CCK-induced Ca2+ plateau in mouse 
PACs. GSK-7975A concentration-dependently inhibited CRAC entry (Fura-2 340: 
380 normalised at 700 s). (A and B) Changes in mouse pancreatic acinar [Ca2+]c 
induced by 1 nM CCK, showing effects of GSK-7975A from 700 s, expanded. (C and 
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D) Mean (± s.e.m) [Ca2+]c at 700, 1200 and 2000 s from (A and B), showing 
progressive reduction with increasing concentration of GSK-7975A, but not 100 µM 
(≥38 cells/groups; *p<0.001, CCK vs CCK plus GSK-7975A at 1200 s; †p<0.001, at 
2000 s). Note: (A and B) were analysed by Dr Svetlana Voronina and (C and D) 
were suggested and calculated by myself according to the data from (A and B).  
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Figure 3.2 Effects of GSK-7975A on the CCK-induced Ca2+ plateau maintained 
in physiological Ca2+ concentration in mouse PACs. Changes in mouse 
pancreatic acinar [Ca2+]c induced by 1 nM CCK with external physiological [Ca2+] (1.8 
mM) applied, showing effect of 15 µM GSK-7975A from 700 s, expanded (≥79 
cells/group). Note: this was done by Dr Svetlana Voronina.  
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Figure 3.3 Effects of GSK-7975A on the TLCS-induced Ca2+ plateau in mouse 
PACs. GSK-7975A concentration-dependently inhibited CRAC entry (Fura-2 340: 
380 normalised at 700 s). (A and B) Changes in mouse pancreatic acinar [Ca2+]c 
induced by 500 µM TLCS, showing effects of GSK-7975A from 700 s, expanded. (C 
and D) Mean (± s.e.m) [Ca2+]c at 700, 1200 and 2000 s from (A and B), showing 
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progressive reduction with increasing concentration of GSK-7975A, but not 100 µM 
(≥19 cells/groups; *p<0.001, CCK vs CCK plus GSK-7975A at 1200 s; †p<0.001, at 
2000 s). Note: (A and B) were analysed by Dr Svetlana Voronina and (C and D) 
were suggested and calculated by myself according to the data from (A and B). 
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3.3.2 Effects of GSK-7975A on store-operated Ca2+ entry in human PACs 
Potential translation applications of SOCE inhibition as a treatment for clinical acute 
pancreatitis were evaluated by examination of the effects of GSK-7975A on isolated 
human pancreatic acinar cells (Murphy et al., 2008). Thapsigargin was used in zero 
external Ca2+ to empty Ca2+ stores, stimulate STIM-mediated Orai pore formation, 
and permit SOCE by the reintroduction of external Ca2+. GSK-7975A (10-50 µM) 
significantly inhibited SOCE in these cells (see Figure 3.4).  
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Figure 3.4 Effects of GSK-7975A on thapsigargin-induced Ca2+ entry in human 
PACs. (A) Typical trace showing inhibitory effect of GSK-7975A (50 µM) on 
thapsigargin-induced Ca2+ influx. (B) Mean (± s.e.m.) [Ca2+]c at 1200 s and 1400 s 
from thapsigargin and thapsigargin plus GSK-7975A traces, showing marked 
reduction with GSK-7975A (≥20 cells/group; *p<0.001, thapsigargin vs thapsigargin 
plus GSK-7975A at 1400 s). Note: (A) were analysed by Dr Svetlana Voronina and 
(B) were suggested and calculated by myself according to the data from (A). 
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3.3.3 Effects of GSK-7975A on necrotic cell death pathway activation in mouse 
and human PACs 
The percentage of PI uptake indicated necrotic cell death pathway activation; nuclei 
stained with Hoechst 33342 showed the total number of cells. GSK-7975A at 10 µM 
protected mouse PACs from necrotic cell death pathway activation induced by TLCS 
(500 µM), which induces acute pancreatitis in vivo (Laukkarinen et al., 2007, Lerch 
and Gorelick, 2013); GSK-7975A at 30 µM protected human PACs (See Figure 3.5).  
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Figure 3.5 Effects of GSK-7975A on necrotic cell death pathway activation in 
human PACs. The percentage of PI uptake indicated necrotic cell death pathway 
activation; nuclei stained with Hochest 3342 showed the total number of cells. 
Treatment of GSK-7975A protected both mouse and human PACs from necrotic cell 
death pathway activation induced by TLCS (500 µM) (mean± s.e.m., normalised to 
TLCS at 100; ≥3 experiments/group; *p<0.05, control vs TLCS; †p<0.05, TLCS vs 
TLCS plus GSK-7975A).  
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3.3.4 Effects of CM_128 on store-operated Ca2+ entry in mouse PACs 
To determine the effect of CM_128 on SOCE in isolated mouse PACs, thapsigargin 
was used to empty Ca2+ stores and initiate STIM-mediated Orai pore formation, 
while maintaining cells in zero external Ca2+ until Ca2+ was reintroduced to enable 
SOCE (Raraty et al., 2000, Gerasimenko et al., 2013). Application of this protocol 
demonstrated that CM_128 markedly reduced SOCE, at a lower dose (1 µM; see 
Figure 3.6).   
 
The effect of CM_128 on SOCE and its concentration-dependency was confirmed by 
a separate experimental protocol (Wen et al., 2015). Cyclopiazonic acid was used to 
empty Ca2+ stores within mouse PACs (Kim et al., 2009) (maintained in zero external 
Ca2+) to stimulate STIM-mediated Orai opening. Upon reintroduction of external Ca2+ 
(1.8 mM), the rate of Ca2+ entry demonstrated concentration-dependent log 
proportionality, with IC50 ~0.7 µM and a complete inhibition at 10 µM; there was no 
loss of effect at higher concentrations (Wen et al., 2015).  
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Figure 3.6 Effects of CM_128 on thapsigargin-induced Ca2+ entry in mouse 
PACs. (A) Changes in mouse pancreatic acinar [Ca2+]c induced by thapsigargin 
(Fura-2 340:380 normalised at 2000 s), showing effect of 1 µM CM_128. (B) Mean (± 
s.e.m) [Ca2+]c at 2000 s and 3000 s from (A), showing marked reduction with 1 µM 
CM_128 (≥62 cells/group; *p<0.001, thapsigargin vs thapsigargin plus CM_128 at 
3000 s). Note: (A) were analysed by Dr Michael Chvanov and (B) were suggested 
and calculated by myself according to the data from (A). 
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3.3.5 Effects of CM_128 on store-operated Ca2+ entry in human PACs 
Potential translation applications of SOCE inhibition as a treatment for clinical acute 
pancreatitis were evaluated by examination of the effects of CM_128 on isolated 
human PACs (Murphy et al., 2008). Thapsigargin was used in zero external Ca2+ to 
empty Ca2+, stimulate STIM-mediated Orai pore formation, and permit SOCE by the 
reintroduction of external Ca2+. CM_128 inhibited SOCE in human PACs at low 
concentrations (1 µM; see Figure 3.7).  
 
The inhibitory effect of CM_128 on human Orai1 was also verified using transfected 
HEK293 cells (Wen et al., 2015). HEK293 cells transfected with Orai1/STIM1 (Derler 
et al., 2013) were patched in zero extracelluar Ca2+ to measure ICRAC in response 
to extracellular addition of 10 mM Ca2+, and the effect of a range of concentrations of 
CM_128 tested. CM_128 inhibited ICRAC in a direct concentration-dependent manner, 
with IC50 ~0.1 µM and a complete inhibition at 1 µM; there was no loss of effect at 
higher concentrations (Wen et al., 2015).  
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Figure 3.7 Effects of CM_128 on thapsigargin-induced Ca2+ entry in human 
PACs. Changes in human pancreatic acinar [Ca2+]c induced by thapsigargin (Fura-2 
340:380 normalised at 2000 s), showing inhibitory effect of 1 µM CM_128 (68 cells). 
Dash line was drawing to indicate the [Ca2+]c in control human PACs as a reference 
line to compare with the inhibitory effects of CM_128.  
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3.3.6 Effects of CM_128 on necrotic cell death pathway activation in mouse 
and human PACs 
The percentage of PI uptake indicated necrotic cell death pathway activation, nuclei 
stained with Hoechst 3342 showed the total number of cells. CM_128 at 1 µM 
protected both mouse and human PACs from necrotic cell death pathway activation 
induced by TLCS (500 µM; see Figure 3.8).  
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Figure 3.8 Effects of CM_128 on necrotic cell death pathway activation in 
mouse and human PACs. CM_128 protected isolated (A) mouse and (B) human 
PACs from necrotic cell death pathway activation induced by TLCS (500 µM) (mean 
± s.e.m.; ≥3 experiments/group in mouse; 1 experiment/group (4 wells and 16 high 
power fields each, total 172 control cells, 97 TLCS, 110 TLCS and CM_128) in 
human; *p<0.05, TLCS vs TLCS plus CM_128).  
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3.4 Discussion 
GSK-7975A was found to inhibit CCK-, TLCS- and thapsigargin-induced SOCE in 
mouse PACs in a concentration-dependent manner, exceeding ˃90% block of 
relative control values in some protocols. These findings are consistent with 
published data, showing the effects of GSK-7975A on SOCE in mouse PACs 
(Gerasimenko et al., 2013, Voronina et al., 2015). The same inhibitory effect on the 
Ca2+ plateau was observed when PACs were maintained in physiological external 
Ca2+ concentrations, which mimics physiological conditions around PACs. GSK-
7975A at 100 µM showed a loss of inhibitory effect, resulting in an increase of [Ca2+]c 
by an unknown mechanism. CM_128 (0.1- 10 µM) was found to inhibit thapsigargin- 
and cyclopiazonic acid-induced SOCE in mouse PACs, showing higher potency with 
IC50 ~0.7 µM, and unlike GSK-7975A, no loss of efficacy at higher concentrations.    
 
Pancreatic necrosis is one determinant of severity in patients with AP (Petrov et al., 
2010). The extent of necrosis is related to severity in experimental AP (Kaiser et al., 
1995). The study reported in this chapter demonstrates GSK-7975A (10-30 µM) and 
CM_128 (1 µM) significantly reduce necrotic cell death pathway activation in mouse 
and human PACs exposed to TLCS, which induces AP in vivo (Laukkarinen et al., 
2007) and is related to clinical gallstone AP (Pandol et al., 2007, Lerch and Gorelick, 
2013). 
 
GSK-7975A at various concentrations (10-100 µM) and CM_128 at a lower 
concentration (1 µM) showed similarly critical effects on thapsigargin-induced SOCE 
and necrotic cell death pathway activation in human PACs. The data here suggest 
the translational potential of Orai inhibitors as the treatment of clinical AP. CM_128 
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with higher potency inhibited ICRAC in recombinant hOrai1/hSTIM1 HEK 293 cells in a 
concentration-dependent manner with an IC50 ~0.1 µM. Moreover, CM2489, a 
closely related analogue of CM_128 has been tested in a Phase I clinical trial for the 
treatment of moderate-to-severe plaque psoriasis and CM2489 has been shown to 
be safe and well-tolorated (www.calcimedica.com). All these data suggest further 
development of Orai inhibitors as a treatment for AP in man.  
 
3.5 Summary 
In this chapter, the data demonstrated that GSK-7975A significantly inhibited CCK- 
and TLCS-induced SOCE in mouse PACs in a concentration dependent manner. 
CM_128 significantly inhibited thapsigargin- and cyclopiazonic acid-induced Ca2+ 
influx in mouse pancreatic acinar cells in a concentration dependent manner. Both 
GSK-7975A and CM_128 inhibited thapsigargin-induced Ca2+ influx in human PACs 
and protected both mouse and human PACs from necrotic cell death pathway 
activation. Furthermore, CM_128 concentration-dependently inhibited ICRAC current in 
hOrai1/hSTIM1 HEK 293 cells; unlike GSK-7975A, no loss of efficacy at high 
concentration. There are no published data of both compounds evaluated in the in 
vivo setting of AP.  
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Effects of GSK-7975A given as prodrug 
GSK-6288B in experimental acute 
pancreatitis 
Results: Chapter 4  
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4.1 Introduction 
In the previous chapter (Chapter 3), we have demonstrated GSK-7975A inhibited 
TLCS-, CCK- and thapsigargin-induced SOCE and protested against TLCS-induced 
necrotic cell death pathway activation in mouse and human PACs. The inhibitory 
effects on SOCE was concentration-dependent over the range from 3-100 µM, with 
increasing concentrations of GSK-7975A showing increasing reduction of Ca2+ entry, 
but not at 100 µM, which showed a loss of effect. Others also demonstrated 
inhibition of Orai channels by GSK-7975A protected against CCK- and POAEE-
induced necrotic cell death pathway activation. However, the role of Orai channels in 
experimental AP in vivo has not yet been determined.   
 
Genetic knockout of TRPC3 channel (Kim et al., 2009), a non-selective cation 
channel regulated in part by STIM1 via TRPC1 (Lee et al., 2014), resulted in ~50% 
reduction of in vivo serum amylase elevation and oedema formation induced by four 
hourly injections of caerulein. These experiments supported some role for SOCE in 
AP, but in a single, mild AP model with few parameters evaluated of disease severity. 
 
The study described in this chapter was designed to investigate the effects of GSK-
7975A on experimental AP in vivo. Due to the modest aqueous solubility of GSK-
7975A, we used a phosphate pro-drug (GSK-6288B) that is rapidly cleaved in vivo to 
liberate GSK-7975A. As there are no preliminary pharmacokinetic data on GSK-
7975A and GSK-6288B, a pharmacokinetic study against a background of AP was 
conducted prior to the assessment of drug efficacy.  
 
4.2 Methods 
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4.2.1 Measurement of GSK-7975A in vivo 
Sampling was at 1, 2, 4, 10 and 22 h after subcutaneous osmotic minipump insertion 
from three mice/time point. Immediately following humane killing, blood was 
collected into a heparinised tube and diluted 1:1 with sterile water; the pancreas was 
removed and homogenized in 2 ml Covaris tubes containing ceramic beads. 
Standards and study samples (50 µl from blood and 100 µl from pancreas) were 
extracted by protein precipitation and centrifuged. Supernatants were dried under 
heated nitrogen (40°C). Levels of GSK-7975A and GSK-6288B were determined by 
liquid chromatography mass spectrometry (LC-MS/MS; API4000 with Jasco X-LC 
and Ascentis express C18 column). Samples were prepared by me and 
measurement by LC-MS/MS was undertaken by GSK.  
 
4.2.2 Protein binding of GSK-7975A  
The protein binding of GSK-7975A in the blood and pancreas was determined at 1 
μg/ml using a dialysis Teflon block with dialysis membrane strips and a rapid 
equilibrium dialysis (RED) device (Thermo Scientific) respectively. Blood was 
collected into a heparin pre-coated tube, diluted 1:1 with phosphate buffer saline 
(PBS, pH 7.4). Pancreas was homogenised in 500 μl PBS, diluted 1:10. Blood and 
pancreas homogenates were dialyzed against PBS in a buffer chamber, shaking 
gently at 37°C for 5 h (blood) and 4 h (pancreas homogenate). After equilibrium, 
samples from both sample chamber and buffer chamber were collected in a matrix-
match manner and analyzed by liquid chromatography mass spectrometry (LC-
MS/MS; AP14000, Applied Biosystems). Experiments were carried out in triplicate. 
The percentage of GSK-7975A bound was calculated by the equation: % bound= 
([GSK-7975A]a- [GSK-7975A]b)/ [GSK-7975A]a ×100%, where [GSK-7975A]a was 
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the concentration of GSK-7975A in the sample chamber and [GSK-7975A]b was the 
concentration of GSK-7975A in the buffer chamber. Samples were prepared by me 
and measurement by LC-MS/MS was undertaken by GSK. 
 
4.2.3 Induction of experimental AP 
Experimental AP (CER-AP, TLCS-AP and FAEE-AP) was induced as previously 
described in 2.5.  
 
4.2.4 Administration of GSK-7975A 
Low (L, 28 mg/kg/h) and high (H, 110 mg/kg/h) doses of GSK-7975A were given as 
prodrug GSK-6288B subcutaneously by osmotic mini-pump implantation after 
disease induction; this was undertaken at the third injection of caerulein, 30 min after 
TLCS-AP induction or 1 h after FAEE-AP induction. Minipump preparation and 
implantation was as described in 2.6.  
 
4.2.5 Assessment of experimental AP severity 
Standard biochemical parameters and blind histopathology were used, as previously 
described in 2.7.  
 
4.3 Results 
4.3.1 Pharmacokinetic study of GSK-7975A 
To ensure consistent delivery of GSK-7975A, levels of GSK-7975A in the blood and 
pancreas were measured at various time points after osmotic mini-pump insertion 
against a CER-AP background. Blood and pancreatic levels of GSK-7975A reached 
steady state within 4 h at all tested (see Figure 4.1). GSK-7975A at the low and high 
 
97 
 
doses achieved steady state blood concentrations of ~4.3 µM and ~13.3 µM and 
pancreatic concentrations of ~8.9 µM and 49.3 µM respectively, with no detectable 
prodrug GSK-6288B at all doses and time points.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Blood and pancreatic levels of GSK-7975A. GSK-7975A given as 
prodrug GSK-6288B administered subcutaneously by osmotic mini-pump was 
consistently delivered to each mouse and maintained throughout the experimental 
period. There was no detectable GSK-6288B in the blood or pancreas, suggesting 
complete conversion into GSK-7975A. (A) Blood and pancreas levels of GSK-7975A 
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following administration of 2 mg/kg/h GSK-6288B showed a steady state 4 h after 
minipump implantation, when the mean concentrations in blood and pancreas were 
~0.4 μM and ~0.6 μM respectively. (B) Blood and pancreas levels of GSK-7975A at 
the (lower) dose of 28 mg/kg/h GSK-6288B (L) reached a steady state 1 h after mini-
pump implantation, when the mean concentrations in blood and pancreas were ~5 
μM and ~10 μM respectively. (C) Blood and pancreas levels of GSK-7975A at the 
(higher) dose of 110 mg/kg/h GSK-6288B (H) reached a steady state 4 h after mini-
pump implantation, when the mean concentrations in blood and pancreas were ~15 
μM and ~50 μM respectively. Note: the raw data were provided by GSK and the 
calculation and graphs were made by me.  
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4.3.2 Protein binding of GSK-7975A in the blood and pancreas 
To better understand the relationship between in vivo drug levels and 
pharmacological effects, bound and free fractions of GSK-7975A were measured in 
the blood and pancreas. GSK-7975A showed high protein binding, with >95% bound 
fraction in the blood and pancreas across species.  
 
 Conc. 
(μg/ml) 
% Bound fraction % Free fraction  
 Blood Pancreas Blood Pancreas 
Murine Human Murine Murine Human Murine 
GSK-7975A 1 96.8 97.5 96.5 3.2 2.5 3.5 
 
Table 4.1 Binding fractions of GSK-7975A to murine/human blood and 
pancreas.  Note: the raw data were provided by GSK and the table was made by 
myself. 
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4.3.3 Effects of GSK-7975A on disease severity in CER-AP 
To evaluate the protective effects of GSK-7975A in vivo, hyperstimulation AP (CER-
AP) was studied first since it is the most widely used, well-established and is an 
easily reproducible experimental AP model (Lerch and Gorelick, 2013). GSK-7975A 
administered subcutaneously at the third injection of caerulein significantly reduced 
all local (see Figure 4.2) and systemic biochemical parameters (see Figure 4.3), 
with more pronounced reduction at the high dose (110 mg/kg/h) (p<0.05). Similar 
significant improvements were observed in pancreatic histopathology with the high 
dose approaching control levels (see Figure 4.4 and Figure 4.5).  
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Figure 4.2 Effects of GSK-7975A on pancreatic parameters in CER-AP. CER-AP 
resulted in substantial elevation of (A) serum amylase, (B) pancreatic trypsin activity 
and (C) pancreatic myeloperoxidase (MPO) activity. Subcutaneous administration of 
GSK-7975A given as prodrug GSK-6288B at the low (L) and high (H) doses 
significantly reduced all parameters, with more marked reduction of serum amylase 
and pancreatic trypsin activity at the high dose. Data were normalised to CER-AP at 
100, N suffix indicating normalisation applied for each parameter (mean ± s.e.m., ≥6 
mice/group; *p<0.05, control vs CER-AP; †p<0.05 CER-AP vs CER-AP plus GSK-
7975A).  
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Figure 4.3 Effects of GSK-7975A on systemic biochemical parameters. CER-AP 
resulted in substantial elevation of (A) IL-6 and (B) lung myeloperoxidase (MPO) 
activity. Subcutaneous administration of GSK-7975A given as prodrug GSK-6288B 
at the low (L) and high (H) doses significantly reduced IL-6 at the low dose, but not at 
the high dose and neither doses significantly reduced lung MPO activity. Data were 
normalised to CER-AP at 100, N suffix indicating normalisation applied for each 
parameter (mean ± s.e.m., ≥6 mice/group; *p<0.05, control vs CER-AP; †p<0.05 
CER-AP vs CER-AP plus GSK-7975A).   
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Figure 4.4 Typical histopathology from CER-AP. Representative histological 
images showing normal pancreatic histology, typical histopathology from CER-AP 
and typical histopathology from CER-AP after treatment with GSK-7975A at the low 
(L) and high (H) doses (H&E, Haematoxylin and Eosin; scale bar= 50 µM).  
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Figure 4.5 Histopathological scores from CER-AP. CER-AP results in substantial 
increase in (A) oedema, (B) inflammation and (C) necrosis.  Subcutaneous 
administration of GSK-7975A given as prodrug GSK-6288B at the high (H) dose 
significantly reduced pancreatic damage, approaching control levels (mean ± s.e.m., 
≥6 mice/group; *p<0.05, control vs CER-AP; †p<0.05 CER-AP vs CER-AP plus 
GSK-7975A).  
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4.3.4 Effects of GSK-7975A on disease severity in two clinical representative 
models.  
To fully investigate potential clinical significance using murine models, the effects of 
GSK-7975A were studied in TLCS-AP and FAEE-AP, which mimic biliary and 
alcoholic AP respectively. GSK-7975A administered subcutaneously 30 min after 
TLCS-AP induction and 1 h after FAEE-AP significantly reduced all pancreatic (see 
Figure 4.6) and systemic biochemical parameters (see Figure 4.7), with more 
pronounced reduction at the high dose in serum amylase, pancreatic trypsin activity 
and IL-6 (p<0.05). Similar significant improvements were observed in pancreatic 
histopathology, with the high dose showing more marked reduction (see Figure 4.8 
and Figure 4.9).  
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Figure 4.6 Effects of GSK-7975A on pancreatic parameters in TLCS-AP and 
FAEE-AP. Two models resulted in substantial elevation of (A) serum amylase, (B) 
pancreatic trypsin activity and (C) pancreatic myeloperoxidase (MPO) activity. 
Subcutaneous administration of GSK-7975A given as pro-drug GSK-6288B at either 
low (L) or high (H) doses significantly reduced all parameters, with more marked 
reduction of serum amylase and pancreatic trypsin activity at the high dose. Data 
were normalised to TLCS-AP or FAEE-AP at 100, N suffix indicating normalisation 
applied for each parameter (mean ± s.e.m., ≥6 mice/group; *p<0.05, control vs two 
models; †p<0.05, TLCS-AP vs TLCS-AP plus GSK-7975A; ‡p<0.05, FAEE-AP vs 
FAEE-AP plus GSK-7975A). 
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Figure 4.7 Effects of GSK-7975A on systemic biochemical parameters in TLCS-
AP and FAEE-AP. Two models resulted in substantial elevation of (A) IL-6 and (B) 
lung myeloperoxidase (MPO) activity. Subcutaneous administration of GSK-7975A 
given as pro-drug GSK-6288B at the low (L) and high (H) doses significantly reduced 
all parameters, with more marked reduction of lung MPO activity at the low dose. 
Data were normalised to TLCS-AP or FAEE-AP at 100, N suffix indicating 
normalisation applied for each parameter (mean ± s.e.m., ≥6 mice/group; *p<0.05, 
control vs two models; †p<0.05, TLCS-AP vs TLCS-AP plus GSK-7975A; ‡p<0.05, 
FAEE-AP vs FAEE-AP plus GSK-7975A).   
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Figure 4.8 Typical histopathology from TLCS-AP and FAEE-AP. Representative 
histological images showing normal pancreatic histology, typical histopathology from 
two models and typical histopathology from two models after treatment with GSK-
7975A at low (L) and high (H) doses (H&E, Haematoxylin and Eosin; scale bar= 50 
µM) 
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Figure 4.9 Histopathological scores from TLCS-AP and FAEE-AP. The two 
models resulted in substantial increases in (A) oedema, (B) inflammation and (C) 
necrosis scores. Subcutaneous administration of GSK-7975A given as pro-drug 
GSK-6288B at either low (L) or high (H) doses significantly reduced pancreatic 
damage, with more marked reduction at the high dose (mean ± s.e.m., ≥6 
mice/group; *p<0.05, control vs two models; †p<0.05, TLCS-AP vs TLCS-AP plus 
GSK-7975A; ‡p<0.05, FAEE-AP vs FAEE-AP plus GSK-7975A).  
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4.4 Discussion 
Subcutaneous administration of GSK-7975A at the low and high doses 30-60 min 
after disease induction was markedly effective across a representative range of local 
and systemic biochemical, immunological and histological disease responses in 
three diverse, clinically representative models of AP. In all models, GSK-7975A at 
the high dose showed more pronounced reduction in pancreatic injury biochemically 
and histologically. On the other hand, GSK-7975A at the low dose was generally as 
effective as the high dose in reducing IL-6, which contributes to lung injury and 
lethality (Zhang et al., 2013), and pancreatic and lung MPO. These data are 
consistent with the lower IC50 of GSK-7975A on Orai channel SOCE in leukocytes 
(~1 μM for T lymphocytes) (Derler et al., 2013, Rice et al., 2013) compared to that in 
PACs (3.4 μM) (Gerasimenko et al., 2013).  
 
Measurement of blood and tissue levels of GSK-7975A after induction of 
experimental AP established an appropriate dosing regimen (110 mg/kg/h via 
minipump) for maximum effect, at a steady state of 10-15 µM in the blood and ~50 
µM in the pancreas, with <10% free GSK-7975A. In vitro cell data indicated that at 
50 µM, GSK-7975A had no loss of effect, and the concentration of free compound in 
vivo was significantly lower. At this dose, however, GSK-7975A was highly effective 
in reducing all measures of disease response in three clinically representative 
models of AP (CER-AP, TLCS-AP and FAEE-AP), and more so than at a lower dose 
(28 mg/kg/h). These data provide robust confirmation of the hypothesis that cytosolic 
Ca2+ overload is a critical trigger for AP and inhibition of SOCE via Orai channels is a 
potential intervention for AP. 
 
111 
 
In clinical practice how soon after the onset of symptoms that patients with AP 
present to hospital varies from hours to days. Whether all patients can benefit from 
such treatment as tested here is uncertain, as the treatment was administered quite 
early (30-60 min) after disease induction in these preclinical evaluation settings. 
Whether there would be protective effects if the treatment were to be started late 
after disease induction remains to be determined.  
 
4.5 Summary 
The data described in this chapter demonstrate that the Orai inhibitor GSK-7975A is 
highly effective in protecting against experimental AP. Subcutaneous administration 
of GSK-7975A (as the prodrug GSK-6288B) at the low and high doses markedly 
reduced all local and systemic parameters, with more pronounced reduction at the 
high dose across three diverse, clinical representative experimental AP models 
(CER-AP, TLCS-AP and FAEE-AP). 
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Effects of GSK-7975A administered late in 
experimental acute pancreatitis  
Results: Chapter 5  
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5.1 Introduction 
Pancreatitis-toxins such as bile acids and ethanol metabolites cause PAC injury 
through aberrant intracellular calcium signalling, nuclear factor kappa B activation, 
trypsinogen activation, mitochondrial dysfunction, lysosomal dysfunction, impaired 
autophagy flux and endoplasmic reticulum stress (Petersen and Sutton, 2006, Sah et 
al., 2012, Lankisch et al., 2015). The timeline of these major cellular events is not 
fully understood. Cytosolic Ca2+ overload is the earliest intra-pancreatic acinar 
cellular event and is a critical trigger of AP (Ward et al., 1995, Sutton et al., 2003). 
Ca2+ entry through SOCE is the rate-limiting step in mediating pancreatic acinar cell 
injury during AP. In Chapter 4, GSK-7975A, an Orai inhibitor was shown to be highly 
effective when first administered early after disease induction, with a higher dose 
showing more marked efficacy. However, whether later administration of this or other 
compounds results in similar efficacy in experimental AP has not been extensively 
studied.  
 
Over the last three decades, several studies have investigated the effects of agents 
applied at different time points in murine experimental models. Table 5.1 shows a 
summary of agents administered prophylactically and therapeutically in mouse and 
rat experimental AP models. The modes of action of these agents are diverse, 
including anti-inflammatory, anti-oxidant, anti-secretory and microcirculatory effects. 
In 13 out of 21 studies, the beneficial effects were observed when the agents were 
given prophylactically, which would not be possible in the majority of patients 
developing AP as they present after the disease has begun. Among these 13 studies, 
5 studies only compared one parameter (mortality, single biochemical or single 
histological parameter) between groups. Interestingly, two agents, caffeic acid 
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phenethyl ester (CAPE) and propolis given prophylactically had less effects on 
reducing pancreatic damage in four hourly injections of caerulein model, compared 
to the agents administered 12 h after then last injections of caerulein.   
 
Moreover, only six studies (out of a total of over 300 studies) have compared the 
effects of agents applied therapeutically at different time points in murine 
experimental AP, Table 5.2 summarizes these studies. Except one study was in 
mouse model, all other studies were using AP models in rats with the majority being 
bile acid-induced AP. This simplex experimental AP models used in the previous 
publications did not fully represent different causes of human AP. 5 out of these 6 
studies showed the protective effects were observed when tested agents begun 
early after disease induction, with two studies only comparing a single outcome 
measure between groups. Also, the different efficacy between early versus late time 
points were generally not significant for most if not all parameters compared with the 
majority showing the trend that agents given early was better. Interestingly, one 
agent, caspase1/interleukin-1β-converting enzyme (ICE) inhibitor showed similar 
efficacy for reducing biochemical (amylase), immunological (peripheral white blood 
cell counts and myeloperoxidase activity) and histological (pancreatic necrosis and 
pulmonary structure and inflammation) parameters measured when given 6 h and 12 
h after disease induction. All these previous publications did not provide robust and 
valid evidence of the exact therapeutic time window for the therapies tested. 
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Table 5.1 Summary of agents applied prophylactically and therapeutically in murine experimental AP 
No. Agents Species EAP model Timing of therapeutical application Outcome Ref. 
1 PPAR-γ agonist Mouse Caerulein 3 h after the last injection of caerulein Equally effective* (Rollins et al., 2006) 
2 
Thalidomide analog, 
pomalidomide  Mouse Caerulein 1 h after the last injection of caerulein More effective when given prophylactically (Tsai et al., 2011) 
3 HO-1 metabolites Mouse Bile salt 4 h after the induction More effective when given prophylactically (Nuhn et al., 2013) 
4 PAR-2 inhibitor Mouse Bile salt 2 h or 5 h after the induction Effective when given prophylactically or 2 h after*  (Michael et al., 2013) 
5 
CCK receptor 
antagonist, CR 1392 Rat Caerulein 30 min after the last injection of caerulein More effective when given prophylactically (Otsuki et al., 1989) 
6 Octreotide Rat Bile salt 5 min after the induction Effective only when given prophylactically (Zhu et al., 1991) 
7 Antithrombin III Rat Bile salt 2 or 5 h after the induction Effective when given prophylactically or 2 h after† (Bleeker et al., 1992) 
8 Prostaglandin E1 Rat 
 Trypsin and 
Bile salt Immediately after the induction More effective when given prophylactically‡ (Sakai et al., 1992) 
9 
Protease inhibitor, 
E3123 Rat Caerulein 30 min after caerulein infusion More effective when give prophylactically* (Sata et al., 1994) 
10 Tetraprenylacetone Rat Caerulein 
Immediately after the last injection of 
caerulein More effective when given prophylactically  
(Tachibana et al., 
1995) 
11 MCl-727 Rat Caerulein 
Immediately after the last injection of 
caerulein More effective when given prophylactically 
(Tachibana et al., 
1996) 
12 IL-10 Rat Caerulein 2 h after caerulein infusion More effective when given prophylactically 
(Rongione et al., 
1997) 
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13 Octreotide Rat Bile salt 5 h after the induction 
Equally effective on reducing amylase, pancreatic 
damage and mortality (Chen et al., 1998) 
14 sPLA2 inhibitor Rat Bile salt 1 min or 1 h after the induction More effective when given prophylactically† (Tomita et al., 2004) 
15 AT receptor antagonist Rat Caerulein 30 min after the last injection of caerulein Equally effective (Tsang et al., 2004) 
16 Inosine Rat 
Bile salt plus 
caerulein 3 h after the induction More effective when given prophylactically 
(Schneider et al., 
2006) 
17 Relaxin Rat BPDOE-CDL 1 h or 4 h after the induction More effective when given prophylactically 
(Cosen-Binker et al., 
2006) 
18 
Polyamine analog, 
Me2Spm Rat Bile salt 4 h after the induction More effective when given prophylactically (Jin et al., 2008) 
19 Dexamethasone Rat Bile salt 1 h after the induction More effective when given prophylactically (Yubero et al., 2009) 
20 CAPE Rat Caerulein 12 h after the last injection of caerulein Less effective when given prophylactically 
(Buyukberber et al., 
2009a) 
21 Propolis Rat Caerulein 
 
12 h after the last injection of caerulein Less effective when given prophylactically 
(Buyukberber et al., 
2009b) 
Note: prophylactically- given before or at the time of disease induction; *only one (either biochemical or histological) parameter was compared between 
groups; †only mortality was compared between groups; ‡therapeutical administration only improved mortality, but not other parameters.  
Abbreviation: EAP, experimental AP; CER, caerulein; IL1R, interleukin-1 receptor; MCl-727, (Z)-2-(4-methylpiperazin-1-yl)-1-[4-(2-phenyl-ethyl)phenyl]-eth 
anone oxime hydrochloride monohydrate; IL-10, Interleukin-10; TNF receptor-bp, tumor necrosis factor receptor binding protein; PPAR, Peroxisome 
proliferator-activated receptor; CCK, Cholecystokinin; ICE, interleukin 1β-converting enzyme; HO-1, heme oxygenase-1; AT, angiotensin; sPLA2, secretory 
phospholipase A2; Me2Spm, bismethylspermine; PAR-2, proteinase-activated receptor-2; CAPE, caffeic acid phenethyl ester. 
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Table 5.2 Summary of agents administered therapeutically at early or late after disease induction in murine experimental AP 
No. Agents Species EAP model Timing of the treatment Outcome Ref. 
1 PAR-2 inhibitor Mouse Bile salt 
Early-2 h after the induction 
Late- 5 h after the induction 
Effective when given early in reducing pancreatic 
acinar injury (Michael et al., 2013) 
2 Antithrombin III Rat Bile salt 
Early-2 h after induction 
Late-5 h after induction Effective when given early in reducing mortality* (Bleeker et al., 1992) 
3 ICE inhibitor Rat Bile salt 
Early-6 h after the induction 
Late-12 h after the induction 
Equally effective in biochemical and histological 
parameters measured 
(Paszkowski et al., 
2002) 
4 Multiple antioxidant Rat L-arginine 
Early- 6 h after the induction 
Late-24 h after the induction 
Effective when given early in reducing biochemical 
and histological parameters measured† (Hardman et al., 2005) 
5 Relaxin Rat BPDOE-CDL 
Early-1 h after the induction 
Late- 4 h after the induction 
More Effective when given early in reducing 
biochemical and histological parameters measured 
(Cosen-Binker et al., 
2006) 
6 Octreotide Rat Bile salt 
Early-6 h after the induction 
Late-14 h after the induction 
Effective when given early in reducing biochemical 
and histological parameters measured (Wenger et al., 2007) 
Note: Multiple antioxidants contain selenium, ascorbate and N-acetylcystein. *only mortality was compared between early versus late group; †L-arginine 
started to damage the pancreas at least 24 h after the induction in rat (Hegyi et al., 2004); even after 48 h in mouse (Dawra et al., 2007) 
Abbreviation: EAP, experimental AP; PAR-2, proteinase-activated receptor-2; BPDOE-CDL, Bilio-pancreatic-duct-outlet-exclusion closed-duodenal-loops; 
ICE, interleukin 1β-converting enzyme. 
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The study described in this chapter was designed to determine the effects of delayed 
therapy using GSK-7975A in experimental AP, compared to earlier administration 
described in Chapter 4. This included assessment of control groups with AP at the 
time point when delayed administration of GSK-7975A would otherwise have been 
started. 
 
5.2 Methods 
5.2.1 Induction of experimental AP 
Experimental AP (TLCS-AP and FAEE-AP) was induced as previously described in 
2.6.  
 
5.2.2 Administration of GSK-7975A 
GSK-7975A was given subcutaneously as the pro-drug GSK-6288B at high dose 
(110 mg/kg/h) by minipump insertion, starting 6 h after TLCS-AP or FAEE-AP 
induction. 
 
5.2.3 Assessment of experimental AP severity 
Standard biochemical parameters and blinded histopathology were used, as 
previously described in 2.7.  
 
5.2.4 Statistical analysis 
Statistical evaluation was performed using OriginPro 9 (OriginLab corporation, USA), 
comparison was made by two-tailed Student’s t-test or χ2 test with p values <0.05 
considered significant. 
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5.3 Results 
5.3.1 Effects of GSK-7975A administered late on disease severity in TLCS-AP 
To examine the effects of GSK-7975A begun 6 h after disease induction (late), GSK-
7975A at high dose was tested in TLCS-AP, representative of gallstone AP. GSK-
7975A administered late after TLCS-AP induction was less protective on all tested 
parameters than when begun 30 min after disease induction (early); the data for the 
latter administration are the same as those presented in Chapter 4 and are included 
here to assist with comparisons. Treatment with GSK-7975A starting late still caused 
marked reduction of serum amylase (significantly less effective, although both 
p<0.05), but did not improve other local and systemic biochemical parameters (see 
Figure 5.1 and Figure 5.2). Similarly, GSK-7975A administered late was less 
protective on pancreatic histopathology, showing significantly less efficacy in 
reducing oedema, inflammatory infiltration and overall histopathology scores (see 
Figure 5.3 and Figure 5.4).  
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Figure 5.1 Effects of GSK-7975A administered late on pancreatic parameters in 
TLCS-AP. TLCS-AP resulted in substantial elevations of (A) serum amylase and (B) 
pancreatic myeloperoxidase (MPO) activity. Subcutaneous osmotic minipump 
administration of GSK-7975A given as the pro-drug GSK-6288B at high dose started 
at a late time point (6 h) was less protective than when begun early (30 min; mean ± 
s.e.m. ≥6 mice/group; *p<0.05, control vs TLCS-AP; †p<0.05 TLCS-AP vs TLCS-AP 
plus GSK-7975A; ‡p<0.05 GSK-7975A early vs late).  
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Figure 5.2 Effects of GSK-7975A administered late on systemic biochemical 
parameters in TLCS-AP. TLCS-AP resulted in substantial elevations of (A) IL-6 and 
(B) Lung MPO activity. Subcutaneous osmotic minipump administration of GSK-
7975A given as the pro-drug GSK-6288B at high dose from a late time point (6 h) 
was less protective than when begun early (30 min; mean ± s.e.m. ≥6 mice/group; 
*p<0.05, control vs TLCS-AP; †p<0.05 TLCS-AP vs TLCS-AP plus GSK-7975A; 
‡p<0.05 GSK-7975A early vs late). 
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Figure 5.3 Typical histopathology of TLCS-AP following late administration of 
GSK-7975A. Representative histological images showing normal pancreatic 
histology, typical histopathology from TLCS-AP and typical histopathology from 
TLCS-AP after treatment with GSK-7975A early (30 min) or late (6 h) after disease 
induction (Haematoxylin and Eosin, H&E; scale bar= 50 µM). 
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Figure 5.4 Histopathological scores of TLCS-AP comparing early versus late 
administration of GSK-7975A. TLCS-AP resulted in substantial increases in (A) 
oedema, (B) inflammation and (C) necrosis scores. Subcutaneous administration of 
GSK-7975A given as the pro-drug GSK-6288B at high dose administered from a late 
time point (6 h) was less effective that when begun early (30 min; mean ± s.e.m. ≥6 
mice/group; *p<0.05, control vs TLCS-AP; †p<0.05 TLCS-AP vs TLCS-AP plus 
GSK-7975A; ‡p<0.05 GSK-7975A early vs late).   
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5.3.2 Effects of GSK-7975A administered late on disease severity in FAEE-AP 
GSK-7975A applied 6 h after disease induction (late) was also tested in FAEE-AP, 
which mimics alcoholic acute pancreatitis. Consistent with the results in TLCS-AP, 
GSK-7975A administered late was less protective on all tested parameters than 
when begun early (1 h), showing significant less effect on reducing serum amylase 
(p<0.05) (see Figure 5.5 and Figure 5.6). Similarly, GSK-7975A administered late 
was less protective on pancreatic histopathology, showing significantly less efficacy 
on oedema and overall histopathology scores (see Figure 5.7 and Figure 5.8). 
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Figure 5.5 Effects of GSK-7975A administered late on pancreatic parameters in 
FAEE-AP. FAEE-AP resulted in substantial elevations of (A) serum amylase, (B) 
pancreatic trypsin and (C) pancreatic myeloperoxidase (MPO) activity. 
Subcutaneous administration of GSK-7975A given as pro-drug GSK-6288B at high 
dose from a late time point (6 h) less effective than when given early (1 h; mean ± 
s.e.m. ≥6 mice/group; *p<0.05, control vs FAEE-AP; †p<0.05 FAEE-AP vs FAEE-AP 
plus GSK-7975A; ‡p<0.05 GSK-7975A early vs late). 
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Figure 5.6 Effects of GSK-7975A administered late on systemic biochemical 
parameters in FAEE-AP. FAEE-AP resulted in substantial elevations of (A) IL-6 and 
(B) lung MPO activity. Subcutaneous administration of GSK-7975A given as the pro-
drug GSK-6288B at high dose from a later time point (6 h) was significantly less 
effective than when given early (1 h; mean ± s.e.m. ≥6 mice/group; *p<0.05, control 
vs FAEE-AP; †p<0.05 FAEE-AP vs FAEE-AP plus GSK-7975A; ‡p<0.05 GSK-
7975A early vs late).  
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Figure 5.7 Typical histopathology of FAEE-AP following late administration of 
GSK-7975A. Representative histological images showing normal pancreatic 
histology, typical histopathology from FAEE-AP and typical histopathology from 
FAEE-AP after treatment with GSK-7975A early (1 h) and late (6 h) after disease 
induction (Haematoxylin and Eosin, H&E; scale bar= 50 µM). 
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Figure 5.8 Histological scores of FAEE-AP comparing early versus late 
administration of GSK-7975A. FAEE-AP results in substantial increases in (A) 
oedema, (B) inflammation and (C) necrosis scores. Subcutaneous administration of 
GSK-7975A given as the pro-drug GSK-6288B at high dose from a later time point (6 
h) was significantly less effective that when begun early (1 h; mean ± s.e.m. ≥6 
mice/group; *p<0.05, control vs FAEE-AP; †p<0.05 FAEE-AP vs FAEE-AP plus 
GSK-7975A; ‡p<0.05 GSK-7975A early vs late). 
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5.3.3 The extent of experimental AP when late administration of GSK-7975A 
was begun 
To determine the extent of experimental AP established by the time that late 
administration of GSK-7975A was begun (6 h after the start of disease induction) 
acute pancreatitis was induced in control mice for assessment at 6 h after the start of 
disease induction, using standard biochemical parameters and histopathology. The 
data already presented earlier in this Chapter on the effects of late administration of 
GSK-7975A are also given below in the figures for ease of comparison, especially 
comparison with disease severity at 6 h after the start of disease induction. 
Pancreatic parameters from TLCS-AP and FAEE-AP at 6 h markedly increased 
compared to control without disease induction (p<0.05); the values further increased 
at 24 h, with pancreatic MPO being significant (p<0.05) (see Figure 5.9). Systemic 
biochemical parameters from these two models at 6 h were markedly elevated 
compared to control without disease induction (p<0.05), with significantly higher 
levels of IL-6 and lung MPO in FAEE-AP at 6 h compared with the values at 24 h 
(see Figure 5.10). GSK-7975A started 6 h after disease induction did not reduce 
biochemical parameters compared to the scores at 6 h, except for amylase (TLCS-
AP), IL-6 (FAEE-AP) and lung MPO (FAEE-AP) being significantly reduced.  
 
 Pancreatic injury at 6 h and 24 h evaluated by histopathology progressively 
increased, with significant progression of inflammation, necrosis and overall 
histopathology scores at 24 h (p<0.05). GSK-7975A started 6 h after disease 
induction did not reduce pancreatic histopathology scores compared to the scores at 
6 h (see Figure 5.11 and Figure 5.12).   
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Figure 5.9 Pancreatic parameters at 6 h and 24 h in TLCS-AP and FAEE-AP. 
The two models at 6 h and 24 h resulted in substantial elevations of (A) serum 
amylase, (B) pancreatic trypsin and (C) myeloperoxidase (MPO) activity, with more 
markedly elevation of pancreatic trypsin and MPO activity at 24 h. Subcutaneous 
administration of GSK-7975A at the high dose begun at 6 h after the start of disease 
induction (late) significantly reduced serum amylase from levels at 6 h, but not other 
parameters (mean ± s.e.m. ≥6 mice/group;  *p<0.05, control vs two models at 6 h; 
†p<0.05, two models at 6 h vs 24 h; ‡p<0.05, TLCS-AP at 6 h vs TLCS-AP plus 
GSK-7976A; §p<0.05, FAEE-AP at 6 h vs FAEE-AP plus GSK-7975A).  
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Figure 5.10 Systemic biochemical parameters at 6 h and 24 h in TLCS-AP and 
FAEE-AP. The two models at 6 h and 24 h resulted in substantial elevation of (A) 
serum amylase and (B) lung myeloperoxidase (MPO) activity, with more marked 
elevation of both at 6 h. Subcutaneous administration of GSK-7975A at high dose 
administered late (6 h) significantly reduced both IL-6 and Lung MPO from levels at 6 
h in TLCS-AP, but not in FAEE-AP (mean ± s.e.m. ≥6 mice/group; *p<0.05, control 
vs two models at 6 h; †p<0.05, two models at 6 h vs 24 h; §p<0.05, FAEE-AP at 6 h 
vs FAEE-AP plus GSK-7975A).  
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Figure 5.11 Typical histopathology at 6 h and 24 h from TLCS-AP and FAEE-AP 
including effects of late administration of GSK-7975A. Representative 
histological images showing normal pancreatic histology, typical histopathology from 
two models at 6 h and 24 h and typical histopathology from two models after 
treatment with GSK-7975A begun 6 h after disease induction (late) (H&E; scale bar= 
50 µM). 
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Figure 5.12 Histopathological scores at 6 h and 24 h in TLCS-AP and FAEE-AP, 
including effects of late administration of GSK-7975A. The two models at 6 h 
and 24 h resulted in progressive increases in (A) oedema, (B) inflammation and (C) 
necrosis scores, with more marked elevation of all scores at 24 h. Subcutaneous 
administration of GSK-7975A begun 6 h after disease induction (late) did not reduce 
any score significantly from levels at 6 h (mean ± s.e.m. ≥6 mice/group;  *p<0.05, 
control vs two models at 6 h; †p<0.05, two models at 6 h vs 24 h).  
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5.4 Discussion  
Subcutaneous administration of GSK-7975A at high dose from a late time point (6 h) 
after disease induction was significantly less protective across a broad range of 
pancreatic and systemic parameters in two clinically representative models of acute 
pancreatitis, significantly so for amylase (TLCS-AP and FAEE-AP), IL-6 (TLCS-AP), 
oedema (TLCS-AP and FAEE-AP), inflammatory infiltrate (TLCS-AP) and total 
histolopathology score (TLCS-AP and FAEE-AP). It is notable that the same dose 
administered early after disease induction was found to be highly effective in three 
representative models of acute pancreatitis (see Chapter 4).  
 
GSK-7975A was administered after disease induction to model the potential 
treatment of clinical acute pancreatitis, but the delay in administration of GSK-7975A 
to six hours after disease induction resulted in diminished efficacy. Biological time 
courses including that of acute pancreatitis are longer in humans than mice, with 
pancreatic necrosis typically detected within days rather than hours. Nevertheless 
human pancreatic acinar necrotic cell death pathway activation may begin in clinical 
AP at an early stage after disease onset, shown here in mouse models within six 
hours of onset.  
 
Door-to-needle times of less than 60 minutes are established in guidelines for 
patients with acute myocardial infarction (30 min)(O'Gara et al., 2013) and acute 
ischaemic stroke (60 min)(Jauch et al., 2013), making every second count, with 
national and international quality improvement initiatives underway towards fully 
achieving these (Fonarow et al., 2014). Although pancreatic necrosis has a less 
rapid time course and is not the result of major arterial occlusion (Lankisch et al., 
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2015), the translational implication from here is that door-to-needle time is an 
important issue in administration of any treatment for acute pancreatitis that targets 
the pathogenesis of pancreatic injury, which drives the disease.  
 
5.5 Summary 
In this chapter the data demonstrated that delayed administration of GSK-7975A 
resulted in diminished efficacy in two clinical representative models of AP. 
Subcutaneous administration of GSK-7975A from a late time point (6 h after disease 
induction) was significantly less protective across a broad range of parameters, 
suggesting the timing of treatment that targets pancreatic injury is an important issue 
in future endeavour to gain optimal benefits from any drug treatment.  
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 Effects of CM_128, a novel Orai inhibitor, 
in experimental acute pancreatitis 
Results: Chapter 6 
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6.1 Introduction 
CM_128 is a new molecular entity that has been shown to inhibit Orai1, discovered 
and patented by CalciMedica. Confidential unpublished data from CalciMedica 
demonstrate that Orai channels are the targets of CM_128, not STIM1; CM_128 has 
10-20 fold greater potency on Orai1 compared to Orai2. CM_128 inhibits 
thapsigargin-induced SOCE in both mouse and human PACs (Chapter 3). CM_128 
concentration-dependently inhibited cyclopiazonic acid-induced Ca2+ entry in mouse 
PACs, with IC50 of ~0.7 µM (Wen et al., 2015). Moreover, confidential unpublished 
data from CalciMedica showed CM_128 also blocks CCK and TLCS-induced SOCE 
in mouse PACs, with complete inhibition at 10 µM for CCK and at 1 or 3 µM for 
TLCS. Patch clamp recordings demonstrated that CM_128 concentration-
dependently inhibited ICRAC in HEK 293 cells transfected with human Orai1 and 
human STIM1, with IC50 of ~0.1 µM and a complete inhibition at 1 µM (Wen et al., 
2015). CM_128 protected against necrotic cell death pathway activation in mouse 
and human PACs (Chapter 3). Furthermore, intraperitoneal administration of 
CM_128 significantly reduced serum amylase and lipase, pancreatic weight and 
pancreatic damage in a dose-dependent manner, showing maximal efficacy at 20 
mg/kg in mouse CER-AP model (confidential unpublished data from CalciMedica).   
 
CM2489 is a closely related analogue of CM_128 that has been tested in a Phase I 
clinical trial for the treatment of moderate-to-severe plaque psoriasis; CM2489 is the 
first CRAC inhibitor to be tested in human (Jairaman and Prakriya, 2013). In the 
multiple ascending dose Phase I study of CM2489 this drug was shown to be safe, 
well-tolerated and well-behaved with evidence of clinical improvement 
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(www.calcimedica.com), suggesting the potential for clinical application of CRAC 
inhibitors.  
 
The study described in this chapter was designed to investigate the effects of 
CM_128 begun one and six hours after disease induction in two clinically 
representative models of experimental AP. The work included assessment of 
CM_128 administration at both early and late time points (as in Chapters 4 and 5 for 
GSK-7975A) as well as comparison with the severity of AP at 6 h after disease 
induction. 
 
6.2 Methods 
6.2.1 Measurement of CM_128 in vivo 
Sampling of CM_128 from three mice was made at the same time point when drug 
efficacy was assessed. Immediately following humane killing, 0.5 µL of blood was 
collected in a heparinised tube containing 10 U of heparin; centrifuged at 7,600 rpm 
for 7 min to obtain the plasma; the pancreas and lung were removed, processed in a 
Mini-Beadbeater (Biospec) containing glass beads and mixed with plasma matrix 
(1:4). Levels of CM_128 were determined by liquid chromatography mass 
spectrometry (LC-MS/MS; Varian 500-MS with Varian 212 LC and Phenomenex C8 
column).  
 
6.2.2 Protein binding of CM_128 
The protein binding of CM_128 in plasma (from Bioreclamation, Inc.,Westbury, NY) 
was determined at 30 µM and 50 µM by equilibrium dialysis using a high throughput 
dialysis Teflon block (HTDialysis, LLC, Gales Ferry, CT) and dialysis membrane 
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strips. Plasma was dialyzed against phosphate buffered saline (PBS, pH 7.4 from 
Invitrogen/Gibco, Carlsbad, CA) in a buffer chamber, shaking gently at 37ºC 
overnight. After equilibrium, samples from both sample chamber and buffer chamber 
were collected in a matrix-match manner and analyzed by LC-MS/MS (Varian 500-
MS with Varian 212 LC and Phenomenex C8 column). Experiments were carried out 
in triplicate. The percentage of CM_128 bound was calculated by the equation: % 
bound= ([CM_128]a- [CM_128]b)/ [CM_128]a ×100%, where [CM_128]a was the 
concentration of CM_128 in the sample chamber and [CM_128]b was the 
concentration of CM_128 in the buffer chamber. 
 
6.2.3 Induction of experimental AP 
Experimental AP (TLCS-AP and FAEE-AP) was induced as previously described in 
2.5.  
 
6.2.4 Administration of CM_128 
Preliminary in vivo experiments indicated CM_128 has a significantly longer half-life 
than GSK-7975A, suitable for intraperitoneal dosing every 12 hours to achieve 
sustained blood levels. 20 mg/kg CM_128 was administered intraperitoneally every 
12 hours in TLCS-AP and FAEE-AP; treatment of CM_128 was begun either one or 
six hours after disease induction.    
 
6.2.5 Assessment of experimental AP severity  
Standard biochemical parameters and blinded histopathology scoring systems were 
used, as previously described in 2.6.  
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6.2.6 Statistical analysis 
Statistical evaluation was performed using OriginPro 9 (OriginLab corporation, USA); 
comparison was made by two-tailed Student’s t-test or χ2 test with p values <0.05 
considered significant. 
 
6.3 Results 
6.3.1 Effects of CM_128 administered 1 h or 6 h after disease induction on 
disease severity in TLCS-AP and FAEE-AP 
Preliminary in vivo experiments undertaken by Calcimedica indicated that CM_128 
has a long half-life, suitable for intraperitoneal dosing every 12 hours to achieve 
sustained blood levels with >99% bound (free fraction in murine plasma 0.33%; 
when added to human plasma 0.16%). Levels of CM_128 in the plasma, pancreas 
and lung were measured (see Figure 6.1), showing ~7.5 µM in blood, ~50 µM in the 
pancreas and ~30 µM in the lung.   
 
Since high dose GSK-7975A demonstrated greater efficacy in vivo than with low 
dose GSK-7975A (Chapter 4), and in vitro data obtained with CM_128 did not 
suggest loss of efficacy at high concentrations (Wen et al., 2015) and also that 
CM_128 at 20 mg/kg previously showed to have maximal efficacy in CER-AP, 20 
mg/kg CM_128 was administered every 12 hours to test efficacy of this agent in 
TLCS-AP and FAEE-AP. High dose GSK-7975A administered 6 h after disease 
induction resulted in diminished protective effects, compared with treatment starting 
early after disease induction (Chapter 5). Therefore the relative efficacy of CM_128 
administered either 1 h or 6 h after disease induction was determined in both models.   
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CM_128 started 1 h after disease induction significantly reduced all pancreatic and 
systemic biochemical parameters in TLCS-AP and FAEE-AP (see Figure 6.2 and 
Figure 6.3). Similar effects on pancreatic histopathology were observed, showing 
significant reduction of oedema, inflammation, necrosis and total histopathological 
scores (see Figure 6.4 and Figure 6.5). CM_128 begun 6 h after disease induction 
was less effective across a broad range of biochemical parameters (see Figure 6.2 
and Figure 6.3), significantly so for pancreatic MPO (FAEE-AP), lung MPO (TLCS-
AP) and IL-6 (TLCS-AP), although significant reductions were still seen in amylase 
(TLCS-AP and FAEE-AP) and lung MPO (TLCS-AP). CM_128 begun 6 h after 
disease induction was less protective on pancreatic histopathology (see Figure 6.4 
and Figure 6.5), although significant reductions were still observed in oedema 
(TLCS-AP and FAEE-AP), inflammation (FAEE-AP), necrosis (FAEE-AP) and total 
histological scores (FAEE-AP).  
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Figure 6.1 Levels of CM_128 in the plasma, pancreas and lung. Mean (± s.e.m) 
plasma, pancreas and lung levels following administration of CM_128 at 20 mg/kg, 
sampling at the time point when drug efficacy was assessed; these were ~10 μM, 
~50 μM and ~ 30 µM respectively. 
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Figure 6.2 Effects of CM_128 administered early or late on pancreatic 
parameters in TLCS-AP and FAEE-AP. The two models resulted in substantial 
elevations of (A) serum amylase, (B) pancreatic trypsin activity and (C) pancreatic 
myeloperoxidase (MPO) activity. Intraperitoneal administration of CM_128 at 20 
mg/kg given at 1 h after disease induction (early) or 6 h after (late) significantly 
reduced all parameters, with more marked reduction of pancreatic MPO activity 
when CM_128 was administered early (mean ± s.e.m., ≥6 mice/group; *p<0.05, 
control vs TLCS-AP; †p<0.05 TLCS-AP vs TLCS-AP plus CM_128; ‡p<0.05 FAEE-
AP vs FAEE-AP plus CM_128; §P<0.05 CM_128 early vs late). 
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Figure 6.3 Effects of CM_128 administered early or late on systemic 
biochemical parameters in TLCS-AP and FAEE-AP. The two models resulted in 
substantial elevation of (A) IL-6 and (B) lung myeloperoxidase (MPO) activity. 
Intraperitoneal administration of CM_128 at 20 mg/kg given at 1 h after disease 
induction (early) or 6 h after (late) significantly reduced all parameters, with more 
marked reduction when CM_128 was administered early (mean ± s.e.m., ≥6 
mice/group; *p<0.05, control vs TLCS-AP; †p<0.05 TLCS-AP vs TLCS-AP plus 
CM_128; ‡p<0.05 FAEE-AP vs FAEE-AP plus CM_128; §P<0.05 CM_128 early vs 
late). 
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Figure 6.4 Typical histopathology from TLCS-AP and FAEE-AP following early 
or late administration of CM_128. Representative histological images showing 
normal pancreatic histology, typical histopathology from two models and typical 
histopathology from two models after treatment with CM_128 early or late after 
disease induction (Haematoxylin and Eosin, H&E; scale bar= 50 µM). 
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Figure 6.5 Histopathological scores of CM_128 administered early or late in 
TLCS-AP and FAEE-AP. Both models resulted in substantial increases in (A) 
oedema, (B) inflammation, (C) necrosis and (D) total histology score. Intraperitoneal 
administration of CM_128 at 20 mg/kg given at 1 h after disease induction (early) or 
6 h after (late) significantly reduced all parameters, with more marked reduction 
when CM_128 was administered early (mean ± s.e.m. ≥6 mice/group;  *p<0.05, 
control vs TLCS-AP; †p<0.05 TLCS-AP vs TLCS-AP plus CM_128; ‡p<0.05 FAEE-
AP vs FAEE-AP plus CM_128; §P<0.05 CM_128 early vs late). 
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6.3.2 The extent of experimental AP when late administration of CM_128 was 
begun 
To determine the extent to which disease was established at 6 h after disease 
induction, and the effect of CM_128 begun then, all parameters were assessed at 6 
h and compared with values at 24 hours. The data already presented earlier in this 
Chapter on the effects of late administration of CM_128 are also given below in the 
figures for ease of comparison, especially comparison with disease severity at 6 h 
after the start of disease induction. Pancreatic parameters from TLCS-AP and FAEE-
AP at 6 h markedly increased compared to control without disease induction 
(p<0.05); the values further increased at 24 h, with pancreatic MPO being significant 
(p<0.05) (See Figure 6.6). Systemic biochemical parameters from the two models at 
6 h were markedly elevated compared to controls without disease induction (p<0.05); 
there were significantly higher levels of IL-6 and lung MPO in FAEE-AP at 6 h 
compared with the values at 24 h (See Figure 6.7). Pancreatic injury at 6 h and 24 h 
evaluated by histopathology progressively increased, with significant progression of 
inflammation, necrosis and overall histopathology scores at 24 h (p<0.05) (See 
Figure 6.8 and Figure 6.9). These data demonstrated that by 24 h there was no 
significant improvement of parameters as measured at six hours as a result of 
CM_128 administration begun at six hours, confirming delay in therapy to be 
disadvantageous, although CM_128 appeared to prevent these parameters from 
increasing.  
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Figure 6.6 Pancreatic parameters at 6 h and 24 h in TLCS-AP and FAEE-AP.  
The two models at 6 h and 24 h resulted in substantial elevations of (A) serum 
amylase, (B) pancreatic trypsin activity and (C) pancreatic myeloperoxidase (MPO) 
activity, with more marked elevation of pancreatic trypsin and MPO activity at 24 h. 
Intraperitoneal administration of CM_128 at 20 mg/kg late significantly reduced all 
parameters from levels at 6 h (mean ± s.e.m., ≥6 mice/group; *p<0.05, control vs two 
models at 6 h; †p<0.05 two models at 6 h vs at 24 h; ‡p<0.05 TLCS-AP at 6 h vs 
TLCS-AP plus CM_128; §P<0.05 FAEE-AP at 6 h vs FAEE-AP plus CM_128). 
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Figure 6.7 Systemic biochemical parameters at 6 h and 24 h in TLCS-AP and 
FAEE-AP. The two models at 6 h and 24 h resulted in substantial elevations of (A) 
IL-6 and (B) lung myeloperoxidase (MPO) activity, with more elevation at 6 h. 
Intraperitoneal administration of CM_128 at 20 mg/kg late significantly reduced all 
parameters from levels at 6 h (mean ± s.e.m. ≥6 mice/group; *p<0.05, control vs two 
models at 6 h; †p<0.05 two models at 6 h vs at 24 h; ‡p<0.05 TLCS-APO at 6 h vs 
TLCS-AP plus CM_128; §P<0.05 FAEE-AP at 6 h vs FAEE-AP plus CM_128). 
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Figure 6.8 Typical histopathology from TLCS-AP and FAEE-AP showing extent 
of injury at 6 h and following late administration of CM_128. Representative 
histological images showing normal pancreatic histology, typical histopathology from 
two models at 6 h and 24 h and typical histopathology from two models after 
treatment with CM_128 late after disease induction (Haematoxylin and Eosin, H&E; 
scale bar= 50 µM). 
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Figure 6.9 Histopathological scores of TLCS-AP and FAEE-AP showing extent 
of injury at 6 h and following late administration of CM_128. The two models at 6 
h and 24 h resulted in substantially progressive increases in (A) oedema, (B) 
inflammation and (C) necrosis scores, with more marked elevation of all scores at 24 
h. Intraperitoneal administration of CM_128 at 20 mg/kg from 6 h after disease 
induction significantly reduced oedema, but not inflammation, necrosis and total 
histopathology scores at 6 h (mean ± s.e.m., ≥6 mice/group; *p<0.05, control vs two 
models at 6 h; †p<0.05 two models at 6 h vs at 24 h; ‡p<0.05 TLCS-AP at 6 h vs 
TLCS-AP plus CM_128; §P<0.05 FAEE-AP at 6 h vs FAEE-AP plus CM_128). 
 
0.0
0.5
1.0
1.5
2.0
2.5
O
ed
em
a
24 h 6 
Late
-
-+ 
-
- -
-
- - +
CM_128
FAEE-AP
TLCS-AP -
Late
24 h 6 
- - --
0.0
0.5
1.0
1.5
2.0
2.5
In
fla
m
m
at
io
n
 24 h 6 
Late
-
-+
-
- -
-
- - +
CM_128
FAEE-AP
TLCS-AP -
Late
24 h 6 
- - --
0.0
0.5
1.0
1.5
2.0
2.5
N
ec
ro
si
s
24 h 6 
Late
-
-+ 
-
- -
-
- - +
CM_128
FAEE-AP
TLCS-AP -
Late
24 h 6 
- - --
A B 
C 
* 
* * 
* 
* 
* 
† 
† 
‡ 
§ 
 
152 
 
6.4 Discussion 
Intraperitoneal administration of CM_128 at 20 mg/kg significantly reduced a broad 
range of biochemical, immunological and histopathological disease parameters in 
TLCS-AP and FAEE-AP, which are representative models of gallstone and alcoholic 
acute pancreatitis (Lerch and Gorelick, 2013, Huang et al., 2014). These findings are 
consistent with previously findings in vitro (Chapter 3, data from CalciMedica and 
(Wen et al., 2015)), in CER-AP (data from CalciMedica) and with GSK-7975A in 
three models of experimental acute pancreatitis (Chapter 4 and 5). CM_128 is highly 
potent but with high levels of plasma and tissue binding; the pharmacokinetic study 
indicated that CM_128 levels are ~10 µM in blood, ~50 µM in the pancreas and ~30 
µM in the lung 11 h after the last dose, levels which were highly effective in reducing 
all disease parameters. These data provide robust preclinical validation of SOCE 
inhibition by CM_128 as a therapeutic approach for treating AP.  
 
Treatment of CM_128 begun late was less protective in both models, although it did 
prevent parameters from increasing. Consistently with the findings from experiments 
with GSK-7975A, both compounds were administered after disease induction to 
model treatment of clinical acute pancreatitis, but delay in administration of either 
compound to 6 h after disease induction resulted in diminished efficacy. As 
concluded in Chapter 5, these data also strongly suggest that door-to-needle time is 
an important issue in administration of any treatment for acute pancreatitis that 
targets the pathogenesis of pancreatic injury. To minimise the initiation of a 
treatment, a quicker approach to recruit patient is required for trials of any therapy, 
such as that offered here with Orai inhibition by CM_128, a novel molecular entity 
currently undergoing preclinical toxicological evaluation prior to Phase I trials. 
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6.5 Summary 
The data presented in this Chapter demonstrate that intraperitoneal administration of 
CM_128, a novel Orai inhibitor, at 20 mg/kg 1 h (early) and 6 h (late) after disease 
induction significantly reduced disease severity in two clinically representative 
models of acute pancreatitis. Treatment with CM_128 begun early showed more 
marked reduction of all parameters than that begun late. These data confirm the 
hypothesis that cytosolic Ca2+ overload is a critical trigger of AP and indicate that 
door-to-needle time is an important issue. Since an analogue of CM_128 has been 
tested in humans and been found to be safe, CM_128 would appear to have 
significant potential as a treatment for human acute pancreatitis.  
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Chapter 7  
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7.1 Targeting Ca2+ signalling to treat AP 
Intracellular Ca2+ overload plays a central role in a variety of diseases, such as 
myocardial infarction (Garcia-Dorado et al., 2012), cardiac hypertrophy and vascular 
proliferative disease (Lompre et al., 2013), acute ischemic stroke (Tuttolomondo et 
al., 2009), Alzheimer disease (Demuro et al., 2010), atherosclerosis (Prendergast et 
al., 2014) and AP (Lankisch et al., 2015). Cautions should be taken as cells from 
different systems have their unique set of components from the Ca2+-signalling 
toolkit to regulate cytosolic Ca2+ overload in response to toxins and to mediate 
subsequent pathophysiological processes (Berridge et al., 2003). Better 
understanding of the unique pathogenesis of each disease is required to search 
suitable therapeutic targets for preventing Ca2+ overload in the cytosol. For instance, 
targeting neuronal voltage-gated cation channels, particularly blockers of calcium 
and sodium channels may be beneficial following ischemic stroke in vitro and in vivo, 
but have yet yielded a significant clinical benefit (Tuttolomondo et al., 2009). 
Targeting the late sodium current (INa) could reduce Ca2+ overload after myocardial 
ischemia with a successful translation into clinical as an anti-ischemic agent 
(Madonna et al., 2013). Targeting SOCE via Orai1 channels as described in this 
thesis could prevent cytosolic Ca2+ overload induced by toxins in PACs and protect 
against AP.  
 
Mounting evidence suggests that cytosolic Ca2+ overload is the key trigger and early 
common mechanism for PAC injury in most if not all forms of AP (Ward et al., 1995, 
Lankisch et al., 2015). It has been noted for many years that SOCE is the rate-
limiting step for abnormal Ca2+ signal generation in PACs induced by pancreatitis 
toxins (Petersen and Sutton, 2006). Molecular components (Orai1 and STIM1) of this 
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Ca2+ entry pathway have been identified (Liou et al., 2005, Prakriya et al., 2006) and 
pharmacological Orai channel inhibitors have emerged during recent years 
(Sweeney et al., 2009, Parekh, 2010, Jairaman and Prakriya, 2013). These 
advances make it possible to investigate the roles of SOCE in AP and various other 
diseases. The studies described in this thesis have successfully demonstrated 
SOCE via Orai channels plays a pivotal role in the pathogenesis of AP and 
confirmed the hypothesis that prolonged elevation of [Ca2+]c is toxic and is the key 
trigger of AP (Ward et al., 1995), providing a valid therapeutic tool for treating human 
AP.  
 
SOCE is the principle mechanism of Ca2+ influx in non-excitable cells (Abdullaev et 
al., 2008). The critical role of Orai channels in the pathogenesis of several other 
diseases has been noted. For instance, McCarl et al demonstrated the important in 
vitro and in vivo role of Orai1 channel for T cell-mediated autoimmunity and allograft 
rejection using T cells from SCID patients and mice expressing non-functional Orai-
R91W protein, respectively (McCarl et al., 2010). Vig et al showed Orai1 deficient 
mice exhibited defective mast cell effector function and the inhibition of allergic 
reaction elicited (Vig et al., 2008). Braun et al showed Orai1 is strongly expressed in 
human and mouse platelets and Orai1 deficiency in mice resulted in resistance to 
pulmonary thromboembolism, arterial thrombosis and ischemic brain infarction with 
only mild bleeding time prolongation (Braun et al., 2009). Yang et al demonstrated 
SOCE mediated via Orai1 and STIM1 is essential for breast tumor cell migration in 
vitro and tumor metastasis in vivo (Yang et al., 2009). SOCE via Orai1 channel was 
the predominant mechanism that mediates neutrophil recruitment in response to 
acute inflammation (Schaff et al., 2010). Moreover, the protective effects of Orai1 
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inhibition by 2-APB or GSK-7975A/Synta-66 have also been observed in vitro and in 
vivo models of the diseases, such as allergic rhinitis (Lin et al., 2011), stroke (van 
Kruchten et al., 2012) and asthma (Ashmole et al., 2012). Together with the 
observations in this thesis, all these investigations indicate much broader potential 
applications of Orai1 inhibitors with significant clinical impact.  
 
Orai1 was firstly discovered from the patients with hereditary SCID syndrome, who 
presented as infants with a marked propensity for fungal and viral infections and had 
the defect in SOCE and CRAC channel function (Feske et al., 2006). Orai1 knockout 
(Orai1-/-) mice were smaller in size and exhibited clinical relevant phenotypes about 
immunodeficiency with defective T- and B-cell function, impaired mast cell function 
(Vig et al., 2008, Gwack et al., 2008). Gwack et al found Orai1-/- mice with the inbred 
C57BL/6 background were perinatal lethality, which could overcome by crossing 
them to outbred ICR mice and had eyelid irritation and sporadic hair loss (Gwack et 
al., 2008). Since immunological events are known to be one critical component in the 
development and progression of AP, targeting Orai1 channels could be an attractive 
strategy for treating AP on the one hand. There are clear evidences indicating the 
inflammatory cells and their functions are critical determinants of AP severity. 
Depletion of neutrophil markedly reduced the severity of caerulein-, CDE diet-
induced AP (Sandoval et al., 1996, Frossard et al., 1999, Gukovskaya et al., 2002). 
Demols et al showed AP severity significantly decreased in nude mice and CD4+ 
(but not CD8+)-depleted mice, suggesting T cells-predominantly CD4+ T cells play a 
pivotal role in the development of experimental AP (Demols et al., 2000). Moreover, 
platelet activation significantly enhanced in AP patients and was associated with AP 
severity with a more pronounced increase in more severe form of the disease 
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(Mimidis et al., 2004, Beyazit et al., 2012, Osada et al., 2012). Depletion of platelet 
protected against caerulein- and L-arginine-induced experimental AP with decreased 
neutrophil infiltration (Abdulla et al., 2011) . The functions of neutrophils, T-cells and 
platelets all can possibly be altered by inhibition of Orai1, which was expected to 
ameliorate disease severity to some extent during AP. On the other hand, 
phenotypic data from SCID patient and Orai1-deficient mice highlights the 
importance of CRAC channel function for immune defence, especially for lymphocyte 
activation. Moreover, the normal function of immune defence at the late stage of AP 
is certainly important in mediating the morbidity and mortality since the death at the 
late stage of AP is mainly caused by infected necrosis (Raraty et al., 2004, Petrov et 
al., 2010).  
 
Apart from inhibition of SOCE via Orai1 channels to prevent Ca2+ overload, inhibition 
of primary Ca2+ release through IP3Rs and RyRs has been shown to be protective in 
vitro and in vivo models of AP (Husain et al., 2005, Gerasimenko et al., 2009, Orabi 
et al., 2012, Husain et al., 2012), but ubiquitous expression of IP3Rs and RyRs and 
their physiological important roles preclude them to be translated as a safe 
therapeutic tool. Ca2+ extrusion from PACs is largely dependent on PMCA pump 
activity since Na+-Ca2+ exchanger is of little quantitative importance (Petersen and 
Sutton, 2006). Highly ATP-dependent PAC Ca2+ extrusion highlights mitochondrial 
protection as a potentially useful approach for efficient Ca2+ handling in the 
development of AP.  
 
Pancreatitis toxins caused mitochondrial Ca2+ overload as a result of cytosolic Ca2+ 
overload, leading to ∆ᴪM depletion, uncoupling of oxidative phosphorylation and 
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impairment of ATP production (Voronina et al., 2002, Criddle et al., 2004, Criddle et 
al., 2006, Mukherjee et al., 2008). Cyp D a mitochondrial matrix protein encoded by 
Ppif gene, is the key regulator of MPTP opening. Compared with Orai1 knockout 
phenotypes, Cyp D-deficient (Ppif-/-) mice are viable, fertile and have no obvious 
abnormalities. Accumulative evidences showed Cyp D-dependent MPTP plays 
critical role in acute cellular injuries such as cardiac and cerebral I/R injury (Baines et 
al., 2005, Nakagawa et al., 2005). Two studies demonstrated genetic deletion and 
pharmacological inhibition of Cyp D markedly reduced AP severity in vitro and in vivo 
(Shalbueva et al., 2013, Mukherjee et al., 2015). Development of specific Cyp D 
inhibitors has much wider clinical applications. The agents currently in the market are 
all general cyclophilin inhibitors with specificity lack for Cyp D. Moreover, 
preservation of mitochondrial function may have a much broader therapeutic window 
and also have more potential for preserving other vital organ function (not only the 
pancreas) than targeting Ca2+ overload. Experimental evidence suggested 
mitochondrial respiration rates are affected at different time points after the onset of 
AP; 6 h after in the pancreas, 24 h after in the kidney and 48 h after in the lung, 
respectively (Trumbeckaite et al., 2013). The duration of mitochondrial function stays 
intact after disease onset offers good opportunity for the drug that preserves 
mitochondrial function to exert its roles.  
 
7.2 Other strategies to treat AP 
The exocrine pancreas is the organ within the whole body that has the highest level 
of protein synthesis and secretion. Maintaining ER homeostasis is of particularly 
importance for pancreatic physiology and unfolded protein responses (UPRs) as a 
copying mechanism of ER stress play a critical role in the disease status (Logsdon 
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and Ji, 2013). UPRs are mediated by three distinct ER-transmembrane protein 
sensors, namely double strand RNA-activated protein kinase-like ER kinase (PERK), 
inositol-requiring kinase 1 alpha (IRE1α) and activating transcription factor (ATF) 6. 
ER chaperones BiP (immunoglobulin heavy chain binding protein, also known as 
GRP78) dissociates from these sensors and binds to unfolded/misfolded polypeptide 
in the ER lumen(Austin, 2009, Kim et al., 2008, Zhang and Kaufman, 2008). ER 
stress-induced cell death (apoptosis mainly) is mediated largely by C/EBP 
homologous protein (CHOP), which is a critical downstream component of ER-stress 
pathways at the convergence of PERK-eIF2α-ATF4, IRE1α and ATF6 pathways 
(Kim et al., 2008). Early massive dilatation of rough ER has been observed in 
experimental models of AP (Aho and Nevalainen, 1980, Lerch et al., 1992), 
indicating ER stress is an early event in the pathogenesis of AP. ER-stress related 
processes, including PERK phosphorylation, eIF2α phosphorylastion, BiP 
upregulation, X box binding protein (XBP1) splicing, CHOP expression and caspase 
12 activation, have been detected during hyperstimulation in vitro and L-arginine-
induced in vivo models of AP (Kubisch et al., 2006, Kubisch and Logsdon, 2007). 
Emerging evidences suggest alteration of some components such as BiP, XBP1 and 
CHOP in the UPR pathway can affect the severity of AP (Suyama et al., 2008, Ye et 
al., 2010, Lugea et al., 2011). Thus, the strategies that enhance the efficacy or 
sustain the ability of UPR could be potential approach for overcoming the disease 
induced by defective ER stress.  
 
The hallmark of AP is premature digestive enzyme activation and loss-of-function 
mutation in PRSS1 was associated with hereditary pancreatitis (Whitcomb et al., 
1996), providing further confirmation.  Mice lacking trypsinogen isoform 7 (T7) gene 
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exhibited a 50% reduction in acinar necrosis during AP (Dawra et al., 2011), 
suggesting inhibition of trypsinogen activation could be beneficial. Early NF-κB 
activation was detectable and most previous studies indicated the blockage of NF-κB 
activation is beneficial in several experimental AP models (Rakonczay et al., 2008). 
On the other hand, Algul et al showed constitutive deletion of pancreas-specific RelA 
lead to more severe pancreatic damage and systemic complications (Algul et al., 
2007); Huang et al recently demostrated co-expression of IKKβ and p65 results in 
more severe form of caerulein-induced panceatitis (Huang et al., 2013). All these 
observation implied NF-κB activation paly multideimensional roles in the 
pathogenesis of AP, suggesting cautions should be taken into account for targeting 
NF-κB activation. Pancreatic ductal cells also as the initial site of injury could be 
another potential target for preventing AP (Hegyi and Petersen, 2013).    
 
Immune responses are one independent, but synergic determinant of AP severity. 
Tissue injuries caused by toxins use the same set of the immune sensors and 
initiators, such as toll-like receptors (TLRs), nucleotide-binding domain (NOD)-like 
receptors (NLRs) and receptor for advanced glycation end-products (RAGE), to 
initiate sterile inflammation (Chen and Nunez, 2010). There are emerging evidences 
indicated targeting these inflammatory sensors, such as TLR4 and TLR9 to prevent 
inflammation initiation could be protective in AP (Sharif et al., 2009, Hoque et al., 
2011). On the other hand, cell death (RCD) in parenchymal cells can promote 
inflammation by the release of pro-inflammatory cytokines and/or DAMPs. Following 
an initial event, cell death and inflammation can induce and amplify each other to 
exaggerate the disease (Linkermann et al., 2014). Necroptosis is activated by death 
receptor, including tumor necrosis factor receptor 1 (TNFR1) and is dependent on 
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receptor-interacting protein kinase (RIP) and mixed lineage kinase domain-like 
protein (MLKL)(Sun et al., 2012, Vandenabeele et al., 2010, Linkermann and Green, 
2014). Genetic deletion of TNFR1 and RIP3 protected from experimental AP 
(Denham et al., 1997, He et al., 2009), suggesting some role of necroptosis in the 
pathogenesis of AP, though further investigations are required. Thus, targeting the 
upstream sensor of inflammation and/or the key components from RCD pathway can 
be potential therapeutic strategies for modulating the inflammation to prevent the 
progression of AP.  
 
There are several potentially useful approaches that can be investigated from either 
intra-acinar pathways or immunological pathways, leading to search a cure for 
human AP. The studies presented in this thesis confirmed that inhibition of Orai1 
channels to prevent Ca2+ overload is a valid therapeutic strategy for human AP. The 
experiments designed here have addressed several critical aspects concerning the 
development of clinically applicable Orai channel inhibitors, which will be discussed 
in this chapter. 
 
7.3 SOCE mediated via Orai1 is a valid drug target for protecting 
against AP 
The Orai1 channel fulfils several key criteria required of an ideal drug target, such as 
it is the principal channel for SOCE in PACs (Gerasimenko et al., 2013, Lur et al., 
2009); it is proximal to the initiation of AP; it plays a pivotal role and acts as the key 
regulator in aberrant intracellular Ca2+ signalling during AP; possibly potential side 
effects can be favourably predicted according to its phenotype data. Well-established, 
diverse, in vitro and in vivo models of experimental AP were used in the studies 
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described in this thesis to validate the capability of Orai1 channel as a potential 
target for the treatment of AP.  
 
Firstly, the effects of Orai inhibition was investigated in freshly isolated PACs, 
comprising the bulk of the pancreas and, together with ductal cells, the initial site of 
injury during AP (Sutton et al., 2003, Hegyi and Rakonczay, 2015). Clearly, GSK-
7975A and the new molecular entity CM_128 markedly inhibit toxin-induced SOCE in 
murine and human PACs in a concentration-dependent manner, exceeding >90% 
block of relative control values in some protocols. It has been known for a long time 
that the severity of pancreatic damage correlates directly with the extent of necrosis 
in vitro as well as in distinct in vivo models of experimental AP (Kaiser et al., 1995, 
Criddle et al., 2007). In the studies here, GSK-7975A and CM_128 significantly 
reduced necrotic cell death pathway activation in murine and human PACs exposed 
to TLCS, which induces acute pancreatitis in vivo (Laukkarinen et al., 2007). The 
effects of GSK-7975A have been described on thapsigargin- and POAEE-induced 
SOCE as well as necrotic cell death pathway activation in murine PACs 
(Gerasimenko et al., 2013, Voronina et al., 2015). Here, GSK-7975A had a similarly 
critical effects on TLCS- and CCK-induced SOCE in murine PACs, as well as 
thapsigargin-induced SOCE and TLCS-induced necrotic cell death pathway 
activation in human PACs. CM_128 showed higher potency (IC50 ~0.1 µM from 
Orai1/STIM1-transfected HEK 293 cell patch clamp data) (Wen et al., 2015) and 
unlike GSK-7975A, no loss of efficacy at high doses. Administration of either 
compound within one hour following disease induction was markedly effective across 
a representative range of local and systemic biochemical, immunological and 
histopathological disease responses.   
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Orai channels also contribute to inflammatory cell responses, including neutrophil 
migration and activation (Bergmeier et al., 2013); inhibition of innate immune 
responses significantly reduces the severity of experimental AP (Gukovskaya et al., 
2002), thus there may be a contribution here from Orai inhibition of immune cells. 
Nevertheless while knockout of Orai1/STIM1 SOCE inhibits neutrophils functions, it 
does not prevent all (Bergmeier et al., 2013); also data obtained in the NIHR 
Pancreas Biomedical Research Unit (not shown in this thesis) show that 
polymorphonuclear leukocyte reactive oxygen species (ROS) production is 
significantly reduced, but not abrogated, by Orai blockade with GSK-7975A. So the 
primary contribution of Orai blockade in this study is likely to have been in the 
pancreas. Orai blockade has less effect on other cell types in which Orai channels 
have less prominent roles, such as electrically excitable cells in which other ion 
channels, e.g. non-selective cation channels, have a larger role in Ca2+ entry (Choi 
et al., 2014). Non-selective cation channels permit limited SOCE into PACs 
(Gerasimenko et al., 2013, Kim et al., 2009) that could sustain essential Ca2+ entry.  
 
7.4 Inhibitors of Orai1 have translational potential as a treatment for 
human AP 
Previous work in Liverpool demonstrated that CCK-8 can directly act on murine and 
human PACs by activation of the CCK receptor (Murphy et al., 2008, Criddle et al., 
2009), providing explannation for the use of CCK-8 in vitro and caerulein in vivo 
hyperstimulation models in this study. The hyperstimulation model also draws a 
parallel with human pancreatitis following scorpion bites from Tityus trinitatis 
(Bartholomew, 1970). TLCS-AP and FAEE-AP have been used in this study, 
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paralleling with two major causes - gallstone and alcohol abuse of AP, respectively. 
The reflux of bile plays a crucial role in the pathogenesis of human AP, which was 
firstly suggested by Opie (Opie, 1901). Subsequent study indicated it may not be bile 
acid alone, but ductal pressure or a combination that causes actual damage in  
human AP (Lerch and Gorelick, 2013). Effects of TLCS in vitro (Voronina et al., 2002) 
and in vivo (Laukkarinen et al., 2007, Perides et al., 2010) are stable, well-
characterised and well-established. Non-oxidative metabolites of ethanol are key 
toxic components in alcohol-induced pancreatic damage in vitro (Criddle et al., 2004, 
Criddle et al., 2006). A combined application of ethanol and fatty acids, providing the 
fuel to form fatty acid ethyl esters within the pancreas, causes pancreatitis in vivo 
(Huang et al., 2014). 
 
Both GSK-7975A and CM_128 blocked SOCE promptly, shown to result in complete 
block of human Orai1 by CM_128 at 1 µM (Wen et al., 2015). Both compounds 
protected against necrotic cell death pathway activation induced by TLCS, showing 
the same effects on murine and human PACs. Moreover, CM_128 at 1 µM 
significantly inhibited thapsigargin-induce SOCE, showing the same effects on 
murine and human PACs. These novel human data support the potential applicability 
of Orai1 inhibition as a treatment for clinical AP. Either compound has been 
administered after disease induction, showing pronounced protection in experimental 
models of AP. 
 
7.5 Door-to-needle time is critical for the treatment of AP 
Here both compounds were administered after disease induction to model treatment 
of clinical AP, but delay in administration of either compound to six hours after 
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disease induction resulted in diminished efficacy, dependent on the endpoint 
measured and the model employed. While biological time courses including that of 
AP are longer in humans than mice, with pancreatic necrosis typically detected 
within days rather than hours, human pancreatic acinar necrotic cell death pathway 
activation may begin in clinical pancreatitis at the early stage after disease onset, 
shown here in mouse models within six hours of onset.  
 
Door-to-needle times of less than 60 minutes are established in guidelines for 
patients with acute myocardial infarction (30 min)(O'Gara et al., 2013) and acute 
ischaemic stroke (60 min) (Jauch et al., 2013), making every second count, with 
national and international quality improvement initiatives underway towards fully 
achieving these (Fonarow et al., 2014). Although pancreatic necrosis has a less 
rapid time course and is not the result of major arterial occlusion (Lankisch et al., 
2015), the translational implication of the work presented here is that door-to-needle 
time is an important issue in administration of any treatment for acute pancreatitis. 
Previously clinical trials of treatments for acute pancreatitis have ‘enriched’ 
recruitment with patients predicted to have severe disease (often with recruitment up 
to 72 h after admission) (Lankisch et al., 2015, Villatoro et al., 2010), which delays 
initiation of therapy. Furthermore, the expansion of disease categories from the 
original Atlanta Classification (mild and severe)(Bradley, 1993) into the RAC (mild, 
moderate and severe)(Banks et al., 2013) and DBC (mild, moderate, severe, 
critical)(Dellinger et al., 2012), further complicates patient selection from among 
these potentially overlapping sub-groups.  
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Numerous compounds have been assessed in Phase II or Phase III clinical trials, but 
with rather disappointing outcomes. None of these compounds have become 
licensed drugs for treating AP. Understanding causes of failure could inform and 
guide us to improve trial design in the future. Implications of the work described in 
this thesis for clinical trial design is that the timing to initiate the treatment would be 
the key to gain the maximal therapeutic benefits, see Figure 7.1.  
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Figure 7.1. Optimal therapeutic window for the drug that targets the 
pathogenesis of AP. This plot indicates a potential therapeutic window for therapies 
targeting the pathogenesis of pancreatitis. The duration from emergency 
presentation to the established organ dysfunction allows for specific targeted 
treatment to be administered. Implications of the work in this thesis suggested 
initiation of certain treatment within the time that yellow bar indicated could gain the 
better therapeutic benefits than within the time that grew bar indicated. Adapted from 
(Norman, 1998) 
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7.6 Conclusion 
Significant progresses have made for understanding the molecular mechanisms of 
AP and identifying the molecular components/regulators of each pathway. Novel 
insights into intracellular and immunological pathways, including the understanding 
of Ca2+ overload, mitochondrial dysfunction, ER stress and inflammation provide 
opportunities to identify/select promising therapeutic approaches. These potential 
strategies can be explored, confirmed and translated for human AP. The studies in 
this thesis firstly validate the hypothesis that cytosolic Ca2+ overload plays a pivotal 
role in the pathogenesis of AP; secondly provide a comprehensive preclinical 
validation of Orai1 channel inhibition as the treatment using in vitro and three diverse, 
clinically representative in vivo models of AP. Novel human data strongly suggested 
the translational potential of Orai channel inhibitors. The comparison of drug efficacy 
between early versus late time point indicated the door-to-needle time is an 
important issue for such treatment.  
 
Implications from the work here are 1) the precise understanding of the mechanism 
is critically important for successfully identifying the therapeutic target; 2) the optimal 
therapeutic window time is much earlier than it is accepted for treatment that targets 
the pathogenesis of AP. Efforts should be made to minimise any delay of the 
initiation of the treatment in order to gain therapeutic benefit. Continuing basic 
research into the mechanism of AP will never end, continuously serving to exploit 
novel therapeutic strategies in the future. Ideas from other diseases that share 
similar pathophysiological processes could broad the exploration of novel drug 
targets for treating AP. The hope will be that a new specific targeted therapy for 
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treating AP will soon be translated into clinical usage, bringing benefits to our 
patients. Inhibition of Orai as described here could be such a treatment. 
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ASBACKGROUND & AIMS: Sustained activation of the cytosolic
calcium concentration induces injury to pancreatic acinar cells
and necrosis. The calcium release–activated calcium modulator
ORAI1 is the most abundant Ca2þ entry channel in pancreatic
acinar cells; it sustains calcium overload in mice exposed to
toxins that induce pancreatitis. We investigated the roles of
ORAI1 in pancreatic acinar cell injury and the development of
acute pancreatitis in mice. METHODS: Mouse and human
acinar cells, as well as HEK 293 cells transfected to express
human ORAI1 with human stromal interaction molecule 1,
were hyperstimulated or incubated with human bile acid,
thapsigargin, or cyclopiazonic acid to induce calcium entry.
GSK-7975A or CM_128 were added to some cells, which were
analyzed by confocal and video microscopy and patch clamp
recordings. Acute pancreatitis was induced in C57BL/6J mice
by ductal injection of taurolithocholic acid 3-sulfate or intra-
venous’ administration of cerulein or ethanol and palmitoleic
acid. Some mice then were given GSK-7975A or CM_128,
which inhibit ORAI1, at different time points to assess local
and systemic effects. RESULTS: GSK-7975A and CM_128
each separately inhibited toxin-induced activation of ORAI1
and/or activation of Ca2þ currents after Ca2þ release, in a
concentration-dependent manner, in mouse and human
pancreatic acinar cells (inhibition >90% of the levels observed
in control cells). The ORAI1 inhibitors also prevented activation
of the necrotic cell death pathway in mouse and human
pancreatic acinar cells. GSK-7975A and CM_128 each inhibited
all local and systemic features of acute pancreatitis in all 3
models, in dose- and time-dependent manners. The agents were
signiﬁcantly more effective, in a range of parameters, when
given at 1 vs 6 hours after induction of pancreatitis.
CONCLUSIONS: Cytosolic calcium overload, mediated via
ORAI1, contributes to the pathogenesis of acute pancreatitis.
ORAI1 inhibitors might be developed for the treatment of
patients with pancreatitis.Ca2D release-activated Ca2D currents; IL, interleukin; MPO, myeloperox-
idase; PI, propidium iodide; SOCE, store-operated calcium entry; STIM,
stromal interaction molecule; TLCS, taurolithocholate acid sulfate.
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http://dx.doi.org/10.1053/j.gastro.2015.04.015Keywords: STIM1; SOCE; Calcium Entry Inhibition; Drug
Development; Experimental Pancreatitis.ustained increase of the cytosolic calcium concen-
2þStration ([Ca ]C) is a critical trigger for pancreatic
acinar cell injury and necrosis, which depends on store-
operated calcium entry (SOCE).1–4 ORAI1 is the principal
SOCE channel in the pancreatic acinar cell,5 the opening of
which is coordinated by stromal interaction molecule
(STIM)1 and STIM2, after decreases in endoplasmic reticu-
lum calcium store concentrations.3,5–7 GSK-7975A and
CM_128 were developed independently by GlaxoSmithKline
(Stevenage, United Kingdom)3,7,8 and CalciMedica (La Jolla,
CA), respectively, to block ORAI1 channels, although only
CM_128 continues toward clinical development. GSK-7975A
inhibits SOCE induced by thapsigargin in isolated murine
pancreatic acinar cells over the range of 1–50 mmol/L (half-
maximal inhibitory concentration [IC50], w3.4 mmol/L),
3
inhibits endocytic vacuole formation9 and reduces necrosis
induced by toxins that cause acute pancreatitis.3,9 CM_128 is
a new molecular entity. ORAI1 inhibition could inhibit SOCE
and necrosis in human pancreatic acinar cells and amelio-
rate acute pancreatitis.
Genetic knockout of the transient receptor potential ca-
nonical 3 channel,10 a nonselective cation channel regulated
in part by STIM1 via transient receptor potential canonical
1,11 resulted in an approximately 50% reduction of in vivo
serum amylase increase and edema formation induced by 4
injections of cerulein.10 These experiments supported some
role for SOCE in acute pancreatitis, but in a single mild
model with few parameters of response.
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AND
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PANCREASHere, we deﬁned the concentration-dependent inhibi-
tory effects of GSK-7975A and CM_128 on SOCE and ne-
crosis in murine and human pancreatic acinar cells induced
by taurolithocholic acid 3-sulfate (TLCS)2,12 or cholecysto-
kinin (CCK) 8.1,10 The effects of CM_128 on ORAI1 were
substantiated by examination of its effect on Ca2þ release-
activated Ca2þ currents (ICRAC)
3,6,7 in ORAI1/STIM1-
transfected HEK 293 cells.7 Our in vitro work informed
in vivo pharmacokinetic analysis. GSK-7975A was given at
selected doses after induction of acute pancreatitis (AP)
with TLCS (TLCS-AP),13 7 injections of cerulein (CER-AP)14
or ethanol and palmitoleic acid (FAEE-AP).15 Because GSK-
7975A markedly reduced all parameters of pathobiologic
response in a dose-dependent manner, a high dose of GSK-
7975A and separately CM_128 was begun at 2 different time
points after disease induction to determine the effect of
early vs late drug administration. Drug administration that
was begun 1 hour after disease induction was highly
effective in reducing parameters of pathobiologic response,
signiﬁcantly more so than when begun 6 hours after disease
induction, in all models. These data provide thorough pre-
clinical validation for ORAI channel inhibition as a potential
early treatment for acute pancreatitis.
Materials and Methods
Human Specimen Sampling
Human pancreas was sampled and cells were isolated as
described.16 The time from sampling to the start of cell isola-
tion was fewer than 10 minutes.
Cell Culture and Transfection
HEK 293 cells were cultured and transfected as described.7
HEK 293 cells stably transfected with complementary DNAs
encoding human ORAI1 and STIM1 were used in patch-clamp
recording.
Animals
CD-1 and C57BL/6J mice were from Charles River UK, Ltd
(Margate, Kent, UK). Pancreatic acinar cells were isolated from
CD-1 mice as described.1,3,12,15 For in vivo experiments, 10-
week-old male C57BL/6J mice (25 g) were used.
Confocal Fluorescence Microscopy and
Video Imaging
Isolated pancreatic acinar cells were imaged using a Till
Photonics System (Munich, Germany) to assess [Ca2þ]C with
Fura-2 (5 mmol/L; excitation, 340 and 380 nm; emission, >490
nm; ratio of ﬂuorescence recorded from excitation, 340 and 380
nm) and using LSM710 systems (Carl Zeiss, Jena GmbH) to assess
necrotic cell death pathway activation with propidium iodide
(PI) (1 mmol/L; excitation, 488 nm; emission, 630–693 nm).
Necrotic Cell Death Pathway Activation
Measurement
Cells were treated with GSK-7975A or CM_128 together
with TLCS (500 mmol/L) for 30 minutes, gently shaking at 1000
rpm at room temperature. After washing, cells were stainedwith PI and Hoechst 33342, distributed into 96-well glass
bottom plates (150 mL/well), and imaged using LSM710 sys-
tems. Hoechst 33342 (50 mg/mL; excitation, 364 nm; emission,
405–450 nm) was used to stain nuclei and count the total
number of cells. PI was used to assess plasma membrane
rupture: the total number of cells showing PI uptake was
counted in 3 or more wells and in 12 or more random ﬁelds of
each differently treated group of each isolate to provide a
percentage, averaged across ﬁelds, as the mean ± SEM ﬁeld
percentage PI uptake with 3 or more isolates per group, except
where stated.Patch-Clamp Current Recording
The whole-cell conﬁguration was used to record ICRAC from
hORAI1/hSTIM1 HEK 293 cells.7 Patch pipettes were pulled
from borosilicate glass capillaries (Sutter Instruments) with a
resistance of 2–5 MU when ﬁlled with an extracellular solution
of 120 mmol/L NaCl; 10 mmol/L TEA-Cl; 10 mmol/L HEPES;
10 or 0 mmol/L CaCl2; 2 or 12 mmol/L MgCl2, and 10 mmol/L
glucose, pH 7.2. ICRAC was activated by passive depletion of
intracellular Ca2þ stores using the intracellular solution of 105
mmol/L Cs-glutamate; 10 mmol/L HEPES; 20 mmol/L
1,2-bis(o-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid; 8
mmol/L MgCl2, pH 7.2. Patched cells were exposed to Ca
2þ-free
buffer to establish stable baseline (for 5 min), then 10 mmol/L
CaCl2 to develop ICRAC (for 10 min), and then CM_128 (0.001,
0.01, 0.1, and 1 mmol/L for 10 min). External recording saline
with no Ca2þ then was perfused for 2 minutes to determine the
background current in the absence of ICRAC. Whole-cell currents
were sampled at 10 KHz and ﬁltered at 2 KHz (Multiclamp
700B ampliﬁer and PClamp software; Axon Instruments). The
voltage clamp protocol included a cycle of steps to 0 mV (for
10 ms to evaluate zero current), then -100 mV (for 10 ms to
measure ICRAC), and a ramp from -100 mV to þ100 mV over
50 ms for I-V relationship followed by step to þ50 mV (for
10 ms to estimate leak current). The voltage between sweeps
was þ30 mV (for 12 s). Whole-cell capacitive compensation
was used. Data analysis was performed using Clampﬁt soft-
ware. ICRAC was measured at -100 mV and current was
measured at approximately 6 minutes and was used as the
baseline control. The current measured after a 10-minute
application of test compound was normalized to the baseline
current (expressed as the percentage of control). The current
measured in zero Ca2þ buffer was used to subtract the back-
ground leak current. Data points were ﬁtted by nonlinear
regression analysis with variable slope (SigmaPlot software) to
determine the IC50 and Hill slope. The IC50 was taken as the
point on the nonlinear regression halfway between the
extrapolated baseline (control) and maximum inhibition pro-
duced by the compound.Experimental Acute Pancreatitis
TLCS-AP was induced by retrograde pancreatic ductal in-
jection with 3 mmol/L TLCS (5 mL/min over 10 minutes by
infusion pump)13; humane killing was 6 or 24 hours later. CER-
AP was induced by 7 hourly intraperitoneal cerulein injections
(50 mg/kg)14; humane killing was 12 hours after the ﬁrst.
FAEE-AP was induced by 2 hourly intraperitoneal injections of
150 mg/kg palmitoleic acid and 1.35 g/kg ethanol15; humane
killing was 6 or 24 hours later. GSK-6288B, the prodrug of
August 2015 ORAI1 Inhibition in Acute Pancreatitis 483GSK-7975A, was administered by minipump; CM_128 was
administered by intraperitoneal injection (6 mice/group).Enzyme Activity and Interleukin 6 Measurement
Trypsin activity was measured as described17 in homoge-
nized tissue (Boc-Gln-Ala-Arg-MCA substrate; excitation, 380
nm; emission, 440 nm). Responses without treatment were
normalized to 100 with SEM to compare different doses of
either drug at different time points across models. Serum
amylase was determined by a Roche Analyzer (Roche); inter-
leukin (IL)6 was determined by enzyme-linked immunosorbent
assay (R&D Systems).Myeloperoxidase Activity
Myeloperoxidase (MPO) activity was determined as
described.18 Pancreatic or lung tissue was homogenized,
resuspended in 100 mmol/L phosphate buffer (pH 5.4) con-
taining 0.5% hexadecyltrimethyl ammonium bromide, 10
mmol/L EDTA and protease inhibitors, freeze-thawed 3 times,
sonicated for 30 seconds, and centrifuged for 15 minutes at
16,000  g. MPO activity was measured in supernatants
(3,3,5,5-tetramethylbenzidine substrate with 0.01% H2O2).
Absorbance was measured at 655 nm and MPO was calculated
as the difference between absorbance at 0 and 3 minutes.Histology
Pancreatic tissue was ﬁxed in 10% formalin, embedded in
parafﬁn, and stained (H&E). Evaluation was performed on 10
random ﬁelds (200) by 2 blinded independent investigators
grading (scale, 0–3) edema, inﬂammatory cell inﬁltration, and
acinar necrosis, calculating the means ± SEM (6 mice/group).BA
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CCK-8 was from American Peptide; ﬂuorescent dyes were
from Molecular Probes; Boc-Gln-Ala-Arg-MCA was from the
Peptide Institute (Osaka, Japan); protease inhibitors were from
Roche GmbH (Mannheim, Germany); IL6 quantikine enzyme-
linked immunosorbent assay kit was from R&D Systems; and
other reagents were from Sigma (Dorset, United Kingdom). 2,6-
diﬂuoro-N-(1-(4-hydroxy-2-(triﬂuoromethyl)benzyl)-1H-pyr-
azol-3-yl)benzamide (GSK-7975A) and pro-drug GSK-6288B
were a gift from GlaxoSmithKline. CM_128 was a gift from
CalciMedica. ALZET osmotic mini-pumps (2001D) were from
Charles River UK, Ltd.Statistical Analysis
Data are presented as means ± SEM. Comparisons were
performed by the 2-tailed Student t test or chi-squared test, and
P values less than .05 were considered signiﬁcant.Study Approval
Human pancreatic samples were obtained with informed
consent as approved by the Liverpool Adult Local Research
Ethics Committee (ref: 03/12/242/A). All animal studies were
ethically reviewed and conducted according to UK Animals
(Scientiﬁc Procedures) Act of 1986, approved by the UK Home
Ofﬁce (PPL 40/3320, renewed as 70/8109).Results
Effects of GSK-7975A and CM_128 on Human
Pancreatic Acinar Cells
Potential translational applications of SOCE inhibition as
a treatment for clinical acute pancreatitis were evaluated by
examination of the effects of GSK-7975A or CM_128 on
isolated human pancreatic acinar cells.16 Thapsigargin was
used in zero external Ca2þ to empty Ca2þ stores, stimulate
STIM-mediated Orai pore formation, and permit SOCE by
the re-introduction of external Ca2þ. GSK-7975A (10–50
mmol/L) inhibited SOCE in these cells (Figure 1A and B).
CM_128 also was found to inhibit SOCE in human pancreatic
acinar cells at lower concentrations (Figure 1C). Both GSK-
7975A (30 mmol/L) and CM_128 (1 mmol/L) inhibited
necrotic cell death pathway activation in these cells
(Figure 1D). To verify that CM_128 inhibits human ORAI1,
HEK 293 cells transfected with ORAI1/STIM17 were
patched in zero extracellular Ca2þ to measure ICRAC in
response to extracellular addition of 10 mmol/L Ca2þ, and
the effect of a range of concentrations of CM_128 tested.
CM_128 was found to inhibit ICRAC in a direct concentration-
dependent manner, with IC50 at approximately 0.1 mmol/L
and no loss of effect at high concentrations (10 mmol/L)
(Figure 1E and F). These ﬁndings were conﬁrmed over the
same concentration range with FLIPR technology (data not
shown).
Effects of GSK-7975A on Murine Pancreatic
Acinar Cells
Isolated murine pancreatic acinar cells maintained in 5
mmol/L external Ca2þ were perfused with TLCS (500 mmol/
L) or supramaximal CCK (1 nmol/L) to induce sustained
increases of [Ca2þ]C dependent on SOCE.
1,3,6,10 Once a stable
plateau in [Ca2þ]C had formed, a range of ﬁxed concentra-
tions (0–100 mmol/L) of GSK-7975A were added. Increasing
concentrations of GSK-7975A decreased the [Ca2þ]C plateau
progressively and increasingly rapidly (Figure 2A–D). With
TLCS, suppression of [Ca2þ]C toward the initial baseline
approached 80% using 30 mmol/L GSK-7975A; with CCK,
more than 95% using 15 mmol/L GSK-7975A, an effect also
seen when cells were maintained in 1.8 mmol/L external
Ca2þ (Supplementary Figure 1A). At 100 mmol/L GSK-
7975A, but not at 50 mmol/L GSK-7975A, there was a loss
of effect through an unknown mechanism (Supplementary
Figure 1B–E). Necrotic cell death pathway activation was
reduced markedly in murine pancreatic acinar cells by GSK-
7975A (Figure 2E).
Effects of CM_128 on Murine Pancreatic
Acinar Cells
To determine the effect of CM_128 on SOCE into isolated
murine pancreatic acinar cells, thapsigargin was used to
empty Ca2þ stores and initiate STIM-mediated ORAI pore
formation, while maintaining cells in zero external Ca2þ
until Ca2þ was re-introduced to enable SOCE.1,3 Application
of this protocol showed that CM_128 reduced SOCE mark-
edly, at a lower dose than that of GSK-7975A (1 mmol/L)
Figure 1.GSK-7975A and CM_128 inhibit CRAC entry (Fura-2 340:380 normalized at 1200 or 2000 s) and necrosis (PI uptake)
in human pancreatic acinar cells and CM_128 concentration-dependently inhibits ICRAC in hORAI1/hSTIM1 HEK 293 cells. (A)
Typical trace showing the inhibitory effect of GSK-7975A (50 mmol/L) on thapsigargin-induced Ca2þ inﬂux. (B) Mean (±SEM)
[Ca2þ]C at 1200 and 1400 s from thapsigargin and thapsigargin plus GSK-7975A traces, showing a marked reduction with
GSK-7975A (20 cells/group; *P < .001; thapsigargin vs thapsigargin plus GSK-7975A at 1400 s). (C) Changes in human
pancreatic acinar [Ca2þ]C induced by thapsigargin (Fura-2 340:380 normalized at 2000 s), showing the inhibitory effect of 1
mmol/L CM_128. (D) GSK-7975A and CM_128 protected isolated human pancreatic acinar cells from necrotic cell death
pathway activation induced by TLCS (500 mmol/L) (mean ± SEM; 3 experiments/group for GSK-7975A; *P < .05, TLCS vs
TLCS plus GSK-7975A and 1 experiment/group [4 wells and 16 high-power ﬁelds each; total. 172 control cells, 97 TLCS, 110
TLCS, and CM_128] for CM_128; *P < .05, TLCS vs TLCS plus CM_128). (E) Typical trace showing ICRAC current in response
to Ca2þ-depletion protocol with 1 mmol/L CM_128 in hORAI1/hSTIM1 HEK 293 cells. (F) Concentration-dependent inhibitory
effects of CM_128 on ICRAC current.
484 Wen et al Gastroenterology Vol. 149, No. 2
BASIC
AND
TRANSLATIONAL
PANCREAS(Figure 3A and B); this same dose also was effective in
signiﬁcantly reducing necrotic cell death pathway activation
by TLCS in these cells (Figure 3C). To conﬁrm the effect of
CM_128 on SOCE and to determine dose-dependency,cyclopiazonic acid was used to empty Ca2þ stores within
murine pancreatic acinar cells10 (maintained in zero
external Ca2þ) to stimulate STIM-mediated ORAI opening.
Upon reintroduction of external Ca2þ (1.8 mmol/L), the rate
Figure 2.GSK-7975A
concentration-dependently
inhibits CRAC entry (Fura-2
340:380 normalized at
700 s) and necrosis (PI up-
take). Changes in mouse
pancreatic acinar [Ca2þ]C
induced by (A) TLCS (500
mmol/L) and (B) CCK (1
nmol/L) showing effects of
GSK-7975A from 700 s,
expanded. (C and D) Mean
(±SEM) [Ca2þ]C at 700,
1200, and 2000 s from
panels A and B, showing
progressive reduction with
increasing GSK-7975A
(19 cells/group; *P <
.001, toxin vs toxin plus
GSK-7975A at 1200 s; †P<
.001 at 2000 s). (E) GSK-
7975A protected isolated
murine pancreatic acinar
cells from necrotic cell
death pathway activation
induced by TLCS (500
mmol/L) (mean ± SEM,
normalized to TLCS at 100;
3 experiments/group;
*P < .001, control vs TLCS;
†P < .001, TLCS vs TLCS
plus GSK-7975A).
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portionality, with the IC50 at approximately 0.7 mmol/L and
no loss of effect at high concentrations (10 mmol/L)
(Figure 3D and E).
Effects of GSK-7975A on Experimental
Acute Pancreatitis
To ensure consistent delivery of GSK-7975A in vivo we
tested subcutaneous minipump administration of GSK-
7975A against a background of CER-AP. Because of the
modest aqueous solubility of GSK-7975A, we used a phos-
phate prodrug (GSK-6288B) that is cleaved rapidly in vivo
to liberate GSK-7975A. Blood and pancreatic levels of GSK-
7975A reached a steady state within 4 hours at all doses
tested (Supplementary Figure 2). GSK-7975A at 28 (low)
and 110 (high) mg/kg/h achieved steady-state blood con-
centrations of approximately 4.3 mmol/L and approximately
13.3 mmol/L, and pancreatic concentrations of approxi-
mately 8.9 mmol/L and approximately 49.3 mmol/L,
respectively, with no detectable prodrug at all doses and
time points.
GSK-7975A was tested in 3 clinically representative
mouse models of acute pancreatitis. TLCS-AP, which is
representative of acute biliary pancreatitis from ampullary
gallstone obstruction, was induced by pancreatic ductalinfusion of TLCS13 and minipumps inserted 30 minutes
later. At both doses GSK-7975A signiﬁcantly reduced in-
creases in serum amylase, IL6, and pancreatic MPO levels;
lung MPO was reduced signiﬁcantly by low dose only
(Figure 4). There were consistent reductions in pancreatic
edema, inﬂammatory cell inﬁltration, and acinar cell ne-
crosis, with a marked reduction in overall histopathology
score in the GSK-7975A–treated groups; inﬂammatory cell
inﬁltration and histopathology score were reduced signiﬁ-
cantly more by the higher dose (Figure 5).
CER-AP is the most widely used model that is repre-
sentative of acute pancreatitis induced by hyperstimula-
tion,14 such as from anticholinesterase insecticides or Tityus
species scorpion stings.19 In CER-AP, minipumps were
inserted with the third of 7 cerulein injections. At both
doses GSK-7975A signiﬁcantly reduced the increases in
serum amylase, pancreatic trypsin, and MPO levels, with the
low dose resulting in signiﬁcant reductions in IL6 and lung
MPO levels (Figure 4). Pancreatic histopathology showed a
trend toward a reduction in the low-dose group; at the high
dose, there were signiﬁcant marked reductions in all mea-
sures of pancreatic histopathology, approaching control
levels (Figure 5).
FAEE-AP parallels acute alcoholic pancreatitis through
in vivo formation of toxic ethanol metabolites.15 Minipumps
Figure 3. CM_128 concentration-dependently inhibits CRAC entry and necrosis (PI uptake). (A) Changes in mouse pancreatic
acinar [Ca2þ]C induced by thapsigargin (Fura-2 340:380 normalized at 2000 s), showing effect of 1 mmol/L CM_128. (B) Mean
(±SEM) [Ca2þ]C at 2000 and 3000 s from panel A, showing a marked reduction with 1 mmol/L CM_128 (62 cells/group; *P <
.001, thapsigargin vs thapsigargin plus CM_128 at 3000 s). (C) CM_128 protected isolated murine pancreatic acinar cells from
necrotic cell death pathway activation induced by TLCS (500 mmol/L) (mean ± SEM; 3 experiments/group; *P < .001, TLCS
vs control; †P < .05, TLCS vs TLCS plus CM_128). (D) Concentration-dependent inhibitory effects of CM_128 on cyclopiazonic
acid–induced Ca2þ inﬂux, showing a progressive reduction of the initial rate of Ca2þ entry and plateau with increasing
CM_128, with complete inhibition of Ca2þ entry at 10 mmol/L (17 cells/group). (E) Concentration-dependent inhibitory effects
of CM_128 on the initial rate of Ca2þ entry.
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intraperitoneal injections of ethanol and palmitoleic acid.
GSK-7975A reduced the increases in all parameters, with
pancreatic and lung MPO levels signiﬁcantly reduced at the
low dose; serum amylase level, IL6 level, pancreatic trypsin
level, and histopathology were reduced signiﬁcantly at the
high dose (Figures 4 and 5). There were signiﬁcantly greater
reductions in edema, inﬂammation, and the overall histo-
pathology score at the high dose, with levels of necrosis
approaching control levels (Figure 5). In all models, low-
dose GSK-7975A was generally as effective as the high
dose in reducing IL6, which contributes to lung injury and
lethality,20 and MPO. These data are consistent with the
lower IC50 of GSK-7975A on ORAI channel SOCE in leuko-
cytes (w1 mmol/L for T lymphocytes)7,8 than in pancreatic
acinar cells (3.4 mmol/L).3Effects of CM_128 on Experimental
Acute Pancreatitis
Preliminary in vivo experiments indicated that CM_128
has a signiﬁcantly longer half-life than GSK-7975A, and is
suitable for intraperitoneal dosing every 12 hours to achieve
sustained blood levels with more than 99% bound (free
fraction in murine plasma, 0.33%; when added to human
plasma, 0.16%). Because our work with high-dose GSK-
7975A showed greater efﬁcacy in vivo than with low-doseGSK-7975A, and in vitro data obtained with CM_128
did not suggest loss of efﬁcacy at high concentrations
(10 mmol/L), we administered 20 mg/kg CM_128 every 12
hours to test the efﬁcacy of this agent in TLCS-AP and FAEE-
AP. We also determined the relative efﬁcacy of CM_128
administered either 1 or 6 hours after induction of either
model of acute pancreatitis. CM_128 begun 1 hour after
disease induction signiﬁcantly reduced all parameters of
both TLCS-AP and FAEE-AP, including all local and systemic
biochemical, immunologic, and histopathologic measures
(Figures 6 and 7). CM_128 begun 6 hours after disease in-
duction was less effective across a broad range of parame-
ters (Figures 6 and 7), signiﬁcantly so for IL6 (TLCS-AP),
pancreatic MPO (FAEE-AP), and lung MPO (TLCS-AP),
although signiﬁcant reductions still were seen in amylase
(TLCS-AP and FAEE-AP), lung MPO (TLCS-AP), edema
(TLCS-AP and FAEE-AP), inﬂammation (FAEE-AP), necrosis
(FAEE-AP), and total histopathology score (FAEE-AP). To
determine the extent to which disease was established at 6
hours after disease induction, and the effect of CM_128
begun at that time, all parameters were assessed at 6 hours
and compared with values at 24 hours. These data showed
that by 24 hours there was no signiﬁcant improvement of
parameters as measured at 6 hours as a result of CM_128
administration begun at 6 hours (Supplementary Figures 3
and 4), conﬁrming delay in therapy to be disadvanta-
geous; although CM_128 appeared to prevent these
Figure 4.GSK-7975A
markedly reduces all
biochemical responses of
TLCS-AP, CER-AP, and
FAEE-AP. All models resul-
ted in substantial increases
of (A) serum amylase, (B)
IL6, (C) pancreatic trypsin
activity, (D) pancreatic
activity, and (E) lung MPO
activity. Subcutaneous os-
motic minipump adminis-
tration of GSK-7975A given
as prodrug GSK-6288B at
low (L) or high (H) doses
signiﬁcantly reduced all
parameters, with a more
marked reduction of serum
amylase and IL6, pancre-
atic trypsin at the high dose
(mean ± SEM 6 mice/
group; *P< .05, control vs 3
models; †P < .05 TLCS-AP
vs TLCS-AP plus GSK-
7975A; ‡P < .05, CER-AP
vs CER-AP plus GSK-
7975A; and §P < .05,
FAEE-AP vs FAEE-AP plus
GSK-7975A).
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delay in dosing, the effect of high-dose GSK-7975A on dis-
ease responses also was tested at 1 and 6 hours after in-
duction. Similar to CM_128, GSK-7975A begun 6 hours after
disease induction was less effective across a broad range of
parameters (Supplementary Figures 5 and 6), signiﬁcantly
so for amylase (TLCS-AP and FAEE-AP), IL6 (TLCS-AP),
edema (TLCS-AP and FAEE-AP), inﬂammatory inﬁltrate
(TLCS-AP), and total histopathology score (TLCS-AP and
FAEE-AP).Discussion
We found GSK-7975A and the new molecular entity
CM_128 to inhibit toxin-induced SOCE into murine and hu-
man pancreatic acinar cells in a concentration-dependent
manner, exceeding more than 90% block of relative con-
trol values in some protocols. We also found both GSK-
7975A and CM_128 to reduce signiﬁcantly the necrotic
cell death pathway activation in murine and human
pancreatic acinar cells exposed to TLCS, which inducesacute pancreatitis in vivo.13,14 Although effects of GSK-
7975A have been described on thapsigargin- and palmito-
leic acid ethyl ester–induced murine pancreatic acinar
SOCE,3 our study found GSK-7975A to have a similarly
critical effect on TLCS- and CCK-induced murine pancreatic
acinar SOCE, as well as thapsigargin-induced human
pancreatic acinar SOCE and TLCS-induced human pancreatic
acinar necrotic cell death pathway activation. CM_128
showed a higher potency (IC50 w0.1 mmol/L from ORAI1/
STIM1-transfected HEK 293 cell patch-clamp data), and
unlike GSK-7975A, no loss of efﬁcacy at high doses.
Comprehensive in vivo evaluation using 3 diverse, clinically
representative models of acute pancreatitis14 with prior
pharmacokinetic assessment showed the validity of SOCE
inhibition as a therapeutic approach. Thus, administration of
either compound within 1 hour after disease induction was
markedly effective across a representative range of local
and systemic biochemical, immunologic, and histologic dis-
ease responses.
Our novel human data support the potential applicability
of SOCE inhibition as a treatment for clinical acute
Figure 5.GSK-7975A markedly reduces pancreatic histopathology in TLCS-AP, CER-AP, and FAEE-AP. All models resulted in
substantial increases in (A) edema, (B) inﬂammation, (C) necrosis, and (D) total histology score. Subcutaneous osmotic
minipump administration of GSK-7975A given as prodrug GSK-6288B at low (L) or high (H) doses markedly reduced
pancreatic damage, with more marked reduction at high dose (mean ± SEM 6 mice/group; *P < .05 control vs 3 models;
†P < .05, TLCS-AP vs TLCS-AP plus GSK-7975A; ‡P < .05, CER-AP vs CER-AP plus GSK-7975A; and §P < .05, FAEE-AP vs
FAEE-AP plus GSK-7975A). (E) Representative images showing normal pancreatic histology, typical histopathology from all 3
models, and typical histopathology from all 3 models after treatment with GSK-7975A at low (L) or high (H) doses (H&E; scale
bar: 50 mm).
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promptly, shown here to result in complete block of human
ORAI1 by CM_128. Although an action on other ORAI
channels cannot be excluded and could be desirable, ORAI1is the primary channel for SOCE into pancreatic acinar
cells,3,5 blocked by both compounds. ORAI channels also
contribute to inﬂammatory cell responses, including
neutrophil migration and activation21; inhibition of innate
Figure 6. CM_128 mark-
edly reduces all biochem-
ical responses of TLCS-AP
and FAEE-AP. Two
models resulted in sub-
stantial increases of (A)
serum amylase, (B) IL6, (C)
pancreatic trypsin activity,
(D) pancreatic activity, and
(E) lung MPO activity.
Intraperitoneal administra-
tion of CM_128 at 20 mg/
kg given at 1 hour after
disease induction (early)
and 6 hours after (late)
signiﬁcantly reduced all
parameters, with more
marked reduction of IL6,
pancreatic activity, and
lung MPO activity when
CM_128 was administered
early (mean ± SEM 6
mice/group; *P < .05,
control vs 2 models; †P <
.05 TLCS-AP vs TLCS-AP
plus CM_128; ‡P < .05,
FAEE-AP vs FAEE-AP plus
CM_128; and §P < .05,
CM_128 early vs late).
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experimental acute pancreatitis,22 thus there may be a
contribution here from ORAI inhibition of immune cells.
Nevertheless, although knockout of ORAI1/STIM1 SOCE
inhibits neutrophil functions, it does not prevent all func-
tions,21 so the primary contribution of ORAI blockade in our
experiments is likely to have been in the pancreas.
Furthermore, because SOCE inhibition for clinical acute
pancreatitis would necessarily be short term, inhibition of
the adaptive immune system21 also would be short term.
ORAI blockade has less effect on other cell types in which
ORAI channels have a less prominent role, such as electri-
cally excitable cells in which other ion channels (eg,
nonselective cation channels) have a larger role in Ca2þ
entry.23 Nonselective cation channels, however, permit
limited SOCE into pancreatic acinar cells3,10 that could
sustain essential Ca2þ entry.23 Without such Ca2þ entry,continued activation of the plasma membrane Ca2þ-adeno-
sine triphosphatase pump upon secretagogue- or toxin-
mediated release of Ca2þ from intracellular stores could
deplete these stores to deleterious levels, inducing or
exacerbating endoplasmic reticulum stress.24
Measurement of blood and tissue levels of GSK-7975A
after induction of experimental acute pancreatitis estab-
lished an appropriate dosing regimen (110 mg/kg/h via
minipump) for maximum effect, at a steady state of 10–15
mmol/L in blood and approximately 50 mmol/L in the
pancreas, with less than 10% free GSK-7975A. Our cell data
indicated that at 50 mmol/L, GSK-7975A had no loss of ef-
fect, and the concentration of free compound in vivo was
signiﬁcantly lower. At this dose, however, GSK-7975A was
highly effective in reducing all measures of disease response
in 3 clinically representative models of acute pancreatitis
(TLCS-AP, CER-AP, and FAEE-AP), and more so than at a
Figure 7. CM_128 markedly reduces pancreatic histopathology in TLCS-AP and FAEE-AP. Both models resulted in substantial
increases in (A) edema, (B) inﬂammation, (C) necrosis, and (D) total histology score. Intraperitoneal administration of CM_128 at
20 mg/kg given at 1 hour after disease induction (early) and 6 hours after (late) signiﬁcantly reduced all parameters, with a more
marked reduction when CM_128 was administered early (mean ± SEM 6 mice/group; *P < .05, control vs 2 models; †P < .05
TLCS-AP vs TLCS-AP plus CM_128; ‡P < .05, FAEE-AP vs FAEE-AP plus CM_128; and §P < .05, CM_128 early vs late). (E)
Representative images showing normal pancreatic histology, typical histopathology from 2 models, and typical histopathology
from 2 models after treatment with CM_128 early and late after disease induction (H&E; scale bar: 50 mm).
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than GSK-7975A but higher levels of plasma and tissue
binding, was tested at 20 mg/kg given every 12 hours via
intraperitoneal injection in TLCS-AP and FAEE-AP, repre-
sentative of gallstone and alcoholic acute pancreatitis,14,15
the most common forms of the disease.4 This resulted in
CM_128 levels greater than 7 mmol/L in blood and
approximately 50 mmol/L in the pancreas 11 hours after the
last dose, levels that were highly effective in reducing all
disease parameters. These data provide robust conﬁrmation
of the hypothesis that cytosolic Ca2þ overload is a critical
trigger of acute pancreatitis.25
Both compounds were administered after disease in-
duction to model treatment of clinical acute pancreatitis,
but a delay in administration of either compound to 6
hours after disease induction resulted in diminished efﬁ-
cacy, dependent on the end point measured and the model
used. Although biological time courses including that of
acute pancreatitis are longer in human beings than in
mice,4,14,26 with pancreatic necrosis typically detected
within days rather than hours,4,27 human pancreatic acinar
necrotic cell death pathway activation may begin in
clinical acute pancreatitis at an early stage after disease
onset, shown here in mouse models within 6 hours of
onset. Door-to-needle times of less than 60 minutes are
established guidelines for patients with acute myocardial
infarction (30 min)28 and acute ischemic stroke (60
min),29 making every second count, with national and in-
ternational quality-improvement initiatives underway to-
ward fully achieving these.30 Although pancreatic necrosis
has a less rapid time course and is not the result of major
arterial occlusion,4 the translational implication of our
work is that door-to-needle time is an important issue in
administration of any treatment for acute pancreatitis that
targets the pathogenesis of pancreatic injury, which drives
the disease. Previously, clinical trials of treatments for
acute pancreatitis “enriched” recruitment with patients
predicted to have severe disease (often with recruitment
up to 72 h after admission),4,31 which delays the initiation
of therapy. Furthermore, the expansion of disease cate-
gories from the original Atlanta Classiﬁcation (mild and
severe)32 into the revised Atlanta (mild, moderate, and
severe)33 and Determinants-Based (mild, moderate, se-
vere, and critical)34 classiﬁcation, further complicates pa-
tient selection from among these potentially overlapping
subgroups. To minimize door-to-needle time, a quicker
and more accurate approach to the selection of patients is
required for trials of any therapy, such as that offered here
with ORAI inhibition by CM_128, a novel molecular entity
currently undergoing preclinical toxicologic evaluation
before phase I trials.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2015.04.015.References
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Supplementary Materials and Methods
Measurements of GSK-7975A and CM_128
In Vivo
Sampling of GSK-7975A was at 1, 2, 4, 10, and 22 hours
after osmotic minipump insertion from 3 mice/time point.
Immediately after humane killing, blood was collected into a
heparinized tube, diluted 1:1 with sterile water, and the
pancreas was removed and homogenized in 2 mL Covaris
tubes containing ceramic beads. Standards and study sam-
ples (50 mL from blood and 100 mL from pancreas) were
extracted by protein precipitation and centrifuged. Super-
natants were dried under heated nitrogen (40C). Levels of
GSK-7975A and GSK-6288B were determined by LC-MS/MS
(API4000 with Jasco X-LC and Ascentis express C18 col-
umn), as were levels of CM_128 in plasma and pancreas
(Varian 500-MS with Varian 212 LC and Phenomenex C8
column), sampling from 3 mice at the same time point when
drug efﬁcacy was assessed.
Protein Binding of GSK-7975A and CM_128
The protein binding of GSK-7975A in the blood and
pancreas was determined at 1 mg/mL using a dialysis Teﬂon
block (HTDialysis, LLC, Gales Ferry, CT) with dialysis
membrane strips and a rapid equilibrium dialysis device
(Thermo Scientiﬁc), respectively. The protein binding of
CM_128 in plasma (from Bioreclamation, Inc, Westbury, NY)
was determined at 30 mmol/L or 50 mmol/L by equilibrium
dialysis using a high-throughput dialysis Teﬂon block
(HTDialysis, LLC) and dialysis membrane strips. Blood was
collected into a heparin precoated tube and diluted 1:1 with
phosphate-buffered saline (pH 7.4). Pancreas was homoge-
nized in 500 mL phosphate-buffered saline, diluted 1:10.
Blood, pancreas, homogenate, and plasma were dialyzed
against phosphate-buffered saline in a buffer chamber,
shaking gently at 37C for 5 hours (blood), 4 hours
(pancreas homogenate), and overnight (plasma). After
equilibrium, samples from both the sample chamber and the
buffer chamber of the rapid equilibrium dialysis plate were
collected in a matrix-match manner and analyzed by liquid
chromatography–mass spectrometry (AP14000; Applied
Biosystems; or Varian 500-MS with Varian 212 LC and
Phenomenex C8 column). Experiments were performed in
triplicate. The percentage of GSK-7975A bound was calcu-
lated by the following equation: % bound¼ ([GSK-7975A]a -
[GSK-7975A]b)/[GSK-7975A]a 100%, where [GSK-7975A]a
was the concentration of GSK-7975A in the sample chamber
and [GSK-7975A]b was the concentration of GSK-7975A in
the buffer chamber. The same equation was applied to
calculate CM_128 binding.
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Supplementary Figure 1.GSK-7975A inhibits CRAC entry (Fura-2 340:380 normalized at 700 s). (A) Changes in mouse
pancreatic acinar [Ca2þ]C induced by CCK (1 nmol/L) with external physiological [Ca
2þ] (1.8 mmol/L) applied, showing the
effect of 15 mmol/L GSK-7975A from 700 seconds, expanded (79 cells/group). Changes in mouse pancreatic acinar [Ca2þ]C
induced by (B) TLCS (500 mmol/L) and (C) CCK (1 nmol/L), showing effects of 50 and 100 mmol/L GSK-7975A from 700
seconds, expanded. (D and E) Mean (±SEM) [Ca2þ]C at 700, 1200, and 2000 seconds from panels B and C, showing a marked
reduction with 50 mmol/L GSK-7975A, but not 100 mmol/L GSK-7975A (27 cells/group; *P < .001, toxin vs toxin plus GSK-
7975A at 1200 s; †P < .001, at 2000 s).
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Supplementary Figure 2.GSK-7975A given as prodrug GSK-6288B administered by a subcutaneous osmotic minipump can
be delivered consistently to each mouse and maintained throughout the experimental period. There was no detectable GSK-
6288B in the blood or pancreas, suggesting complete conversion into GSK-7975A. (A) Blood and pancreas levels of GSK-
7975A after administration of 2 mg/kg/h GSK-6288B showing a steady state 4 hours after minipump implantation, when the
mean concentrations in blood and pancreas were approximately 0.4 and approximately 0.6 mmol/L respectively. (B) Blood and
pancreas levels of GSK-7975A at the (lower) dose of 28 mg/kg/h GSK 6288B (L) reached a steady state 1 hour after minipump
implantation, when the mean concentrations in blood and pancreas were approximately 5 and approximately 10 mmol/L,
respectively. (C) Blood and pancreas levels of GSK-7975A at the (higher) dose of 110 mg/kg/h GSK-6288B (H) reached a steady
state 4 hours after minipump implantation, when the mean concentrations in blood and pancreas were approximately 15 and
approximately 50 mmol/L, respectively. (D) Mean (±SEM) plasma and pancreas levels of CM_128 at 20 mg/kg sampling at the
time point when drug efﬁcacy was assessed, were approximately 10 and approximately 50 mmol/L, respectively.
August 2015 ORAI1 Inhibition in Acute Pancreatitis 492.e3
Supplementary Figure 3. CM_128 administered from 6 hours after disease induction (late) markedly reduced biochemical
responses in TLCS-AP and FAEE-AP. Two models at 6 and 24 hours resulted in substantial increase of (A) serum amylase, (B)
IL6, (C) pancreatic trypsin activity, (D) pancreatic activity, and (E) lung MPO activity, with more marked increase of IL6 and lung
MPO activity at 6 hours, but of pancreatic trypsin and MPO activity at 24 hours. Intraperitoneal administration of CM_128 at
20 mg/kg late signiﬁcantly reduced all parameters from levels at 6 hours (mean ± SEM 6 mice/group; *P < .05, control vs 2
models at 6 h; †P < .05 2 models at 6 vs 24 h; ‡P< .05, TLCS-AP at 6 h vs TLCS-AP plus CM_128; §P < .05, FAEE-AP at 6 h vs
FAEE-AP plus CM_128).
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Supplementary Figure 4. CM_128 administered from 6 hours after disease induction (late) markedly reduced pancreatic
histopathology in TLCS-AP and FAEE-AP. Two models at 6 and 24 hours resulted in substantially progressive increases in (A)
edema, (B) inﬂammation, (C) necrosis, and (D) total histology score, with more marked increase of all scores at 24 hours.
Intraperitoneal administration of CM_128 at 20 mg/kg from 6 hours after disease induction signiﬁcantly reduced edema, but
not inﬂammation, necrosis, or total histology scores at 6 hours (mean ± SEM 6 mice/group; *P < .05, control vs 2 models at 6
hours; †P < .05 2 models at 6 vs 24 hours; ‡P < .05, TLCS-AP at 6 h vs TLCS-AP plus CM_128; §P < .05, FAEE-AP at 6 h vs
FAEE-AP plus CM_128). (E) Representative images showing normal pancreatic histology, typical histopathology from 2
models at 6 and 24 hours, and typical histopathology from 2 models after treatment with CM_128 administered late after
disease induction (H&E; scale bar: 50 mm).
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Supplementary Figure 5.GSK-7975A administered from 6 hours after disease induction (late) less effectively reduced
biochemical responses of TLCS-AP and FAEE-AP. Two models resulted in substantial increases of (A) serum amylase, (B) IL6,
(C) pancreatic trypsin activity, (D) pancreatic activity, and (E) lung MPO activity. Subcutaneous osmotic minipump adminis-
tration of GSK-7975A given as prodrug GSK-6288B at high dose administered from a late time point was less protective than
when given early (mean ± SEM 6 mice/group; *P < .05, control vs 2 models; †P < .05 TLCS-AP vs TLCS-AP plus GSK-
7975A; ‡P < .05, FAEE-AP vs FAEE-AP plus GSK-7975A; and §P < .05, GSK-7975A early vs GSK-7975A late).
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Supplementary Figure 6.GSK-7975A administered from 6 hours after disease induction (late) less effectively reduced
pancreatic histopathology in TLCS-AP and FAEE-AP. Two models resulted in substantial increases in (A) edema, (B)
inﬂammation, (C) necrosis, and (D) total histology score. Subcutaneous osmotic minipump administration of GSK-7975A given
as prodrug GSK-6288B at high dose administered from a late time point was less effective that when begun early (mean ±
SEM 6 mice/group; *P < .05, control vs 2 models; †P < .05 TLCS-AP vs TLCS-AP plus GSK-7975A; ‡P < .05, FAEE-AP vs
FAEE-AP plus GSK-7975A, and §P < .05, GSK-7975A early vs GSK-7975A late). (E) Representative images showing normal
pancreatic histology, typical histopathology from 2 models, and typical histopathology from 2 models after treatment with
GSK-7975A administered early and late after disease induction (H&E; scale bar: 50 mm).
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